

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C07K 14/00</b>		<b>A2</b>	(11) International Publication Number: <b>WO 98/02455</b>
			(43) International Publication Date: 22 January 1998 (22.01.98)
(21) International Application Number: <b>PCT/US97/12100</b>		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 11 July 1997 (11.07.97)		<b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i> <i>With an indication in relation to a deposited microorganism furnished under Rule 13bis separately from the description.</i> <i>Date of receipt by the International Bureau:</i> 05 August 1997 (05.08.97)	
(30) Priority Data: 60/021,247 12 July 1996 (12.07.96) US			
(71) Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE [FR/FR]; 101, rue de Tolbiac, F-75654 Paris Cedex 13 (FR). CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE [FR/FR]; 3, rue Michel Ange, F-75794 Paris Cedex 16 (FR). UNIVERSITE LOUIS PASTEUR [FR/FR]; 4, rue Blaise Pascal, Boite postale 1032F, F-67070 Strasbourg Cedex (FR). BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 & Provinceline Road, Princeton, NJ 08543-4000 (US).			
(72) Inventors: CHAMBON, Pierre; 4, rue A. Schweitzer, F-67113 Blaesheim (FR). GRONEMEYER, Hinrich; Uhlandstrasse 1A, D-77704 Oberkirch (DE). VOGEL, Johannes; 2, rue du Cheval, F-67100 Strasbourg (FR). LUTZ, Yves; 12, rue d'Ypres, F-67000 Strasbourg (FR).			
(74) Agents: STEFFE, Eric, K. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).			

(54) Title: TRANSCRIPTIONAL INTERMEDIARY FACTOR-2

(57) Abstract

The present invention concerns a nuclear receptor (NR) transcriptional mediator. More specifically, isolated nucleic acid molecules are provided encoding transcriptional intermediary factor-2 (TIF2). Recombinant methods for making TIF2 polypeptides are also provided as are TIF2 antibodies. Screening methods are also provided for identifying agonists and antagonists of the activation function AF-2 of nuclear receptors, for identifying agonists and antagonists of the AD1 activation domain activity of TIF2, and for identifying agonists and antagonists of the AD2 activation domain activity of TIF2.



# Transcriptional Intermediary Factor-2

## *Field of the Invention*

5 The present invention relates to a nuclear receptor (NR) transcriptional mediator. More specifically, isolated nucleic acid molecules are provided encoding transcriptional intermediary factor-2 (TIF2). Recombinant methods for making TIF2 polypeptides are also provided as are screening methods for identifying agonists and antagonists of the activation function AF-2 of nuclear receptors, as well as TIF2 antibodies. Also provided are screening methods for identifying agonists and antagonists of TIF2 AD1 activation domain activity, as are provided screening methods for identifying agonists and antagonists of TIF2 AD2 activation domain activity.

## *Background of the Invention*

15 Activators that enhance the initiation of transcription by RNA polymerase B (II) are composed of at least two functional domains: a DNA binding domain and an activating domain (M. Ptashne, *Nature* 335:683-689 (1988); P.J. Mitchell *et al.*, *Science* 245:371-378 (1989)). These two domains are generally separable functional units and each can actually be interchanged with the complementary region of an unrelated activator, thereby creating functional chimeric activators (S. Green *et al.*, *Nature* 325:75-78 (1987)).

20 A number of structure-function analyses of eukaryotic transcriptional have been performed, focussing primarily on the yeast GAL4 and GCN4 proteins and on members of the nuclear receptor family. GAL4 and GCN4 proteins activate transcription by binding to specific upstream activation sequence, which have many of the characteristics of higher eukaryotic enhancer elements (K. Struhl, *Cell* 49:295-297 (1987)). The herpes simplex activator VP16 represents  
25 another type of activator, which activates transcription by binding to the DNA-

bound octamer transcription factor rather than binding to the DNA directly (T. Gerster *et al.*, *Proc. Natl. Acad. Sci. USA* 85:6347-6351 (1988)).

5 The nuclear receptor family, which includes receptors for steroid hormones, thyroid hormones, vitamin D, and the vitamin A derivative retinoic acid, are also transcriptional enhancer factors which bind DNA directly in the presence of their cognate ligand by recognition of specific enhancer elements, *i.e.*, hormone- or ligand-responsive elements (R.M. Evans, *Cell* 240:889-895 (1988)). These cognate ligands tend to be small, hydrophobic molecules, including steroid hormones such as estrogen and progesterone, thyroid hormone, vitamin D, and various retinoids (S. Halachmi *et al.*, *Science* 264:1455-1458 (1994); Gronemeyer, H. and Laudet, V., *Protein Profile* 2:1173-1308 (1995)).

10 Despite their small size and apparently simple structure, however, the cognate ligands associated with NRs are known to elicit a wide range of physiological responses. Adrenal steroids for example, such as cortisol and aldosterone, widely influence body homeostasis, controlling glycogen and mineral metabolism, have widespread effects on the immune and nervous systems, and influence the growth and differentiation of cultured cells. The sex hormones (progesterone, estrogen and testosterone) provoke the development and determination of the embryonic reproductive system, masculinize/feminize the brain at birth, control reproduction and related behavior in adults and are responsible for development of secondary sex characteristics. Vitamin D is necessary for proper bone development and plays a critical role in calcium metabolism and bone differentiation. Significantly, aberrant production of these hormones has been associated with a broad spectrum of clinical disease, including cancer and similar pathologic conditions.

20 All NRs display a modular structure, with five to six distinct regions, termed A-F. The N-terminal A/B region contains the activation function AF-1, which can activate transcription constitutively. Region C encompasses the DNA binding domain (DBD), which recognizes cognate *cis*-acting elements. Region E contains the ligand-binding domain (LBD), a dimerization surface and the ligand-

25

30

dependent transcriptional activation function AF-2 (reviewed in Mangelsdorff, D.J. *et al.*, *Cell* 83:835-839 (1995a); Mangelsdorff & Evans, *Cell* 83:841-850 (1995b); Beato, M. *et al.*, *Cell* 83:851-857 (1995); Gronemeyer & Laudet, "Transcription Factors 3: Nuclear Receptors", in *Protein Profile*, vol. 2, Academic Press (1995); Kastner, P. *et al.*, *EMBO J.* 11:629-642 (1992); Chambon, P., *FASEB J* 10:940-954 (1996)).

Several classes of domains in activators are capable of mediating transcriptional activation. Yeast activators GAL4 and GCN4 and herpes simplex VP16 all contain activation domains that are composed of acidic stretches of amino acids, which may act by forming amphipathic  $\alpha$  helices (I.A. Hope *et al.*, *Cell* 46:885-894 (1986); J. Ma *et al.*, *Cell* 48:847-853 (1987); E. Giniger *et al.*, *Nature* 330:670-672 (1987); S.J. Triezenberg *et al.*, *Genes Dev.* 2:718-729 (1988)). The activation functions of human Sp1 and CTF/NFI proteins contain glutamine- and proline-rich areas, respectively (A.J. Courey *et al.*, *Cell* 55:887-898 (1988); N. Mermod *et al.*, *Cell* 58:741-753 (1989)). Studies with steroid hormone receptors have shown that both the N-terminal A/B domain and the C-terminal hormone binding domain (HBD) contain transcription activation functions (AFs) (M.T. Bocquel *et al.*, *Nucl. Acids Res.*, 17:2581-2595 (1989); L. Tora *et al.*, *Cell* 59:477-487 (1989)). The AFs of the human estrogen receptor (hER) do not contain stretches of acidic amino acids (S. Halachmi *et al.*, *Science* 264:1455-1458 (1994)). Conversely, however, the human glucocorticoid receptor (hGR) contains two activation functions,  $\tau$ -1 (located in the A/B domain) and  $\tau$ -2 (located in the N-terminal region of the HBD), both of which are acidic (S.M. Hollenberg *et al.*, *Cell* 55:899-906 (1988)).

From the results of studies on transcriptional interference/squelching between nuclear receptors and on homo- and heterosynergistic stimulation of initiation of transcription from minimal promoters by the activation functions present in hER (AF-1 and AF-2) and the acidic activator VP16, it has been proposed that AFs may activate transcription by interacting with different components of the basic initiation complex (Bocquel *et al.*, *Nucl. Acids. Res.*

17:2581-2595 (1989); Meyer *et al.*, *Cell* 57:433-442 (1989); L. Tora *et al.*, *Cell* 59:477-487 (1989)). Studies of the transcriptional interference/squelching properties of AADs, hER AF-1 and hER AF-2, however, showed that both hER AF-1 and AF-2 can squelch acidic activators, such as VP16, but that the converse was not true, *i.e.*, AADs do not squelch hER AF-1 or AF-2. Moreover, hER AF-1 and AF-2, which are clearly distinguished by their synergistic properties, nevertheless squelch each other (D. Tasset *et al.*, *Cell* 62:1177-1187 (1990)).

Based on these results, it was proposed that a string of transcriptional intermediary factors (TIFs) exists, interposed between enhancer factors and the basic transcriptional factors. For example, AF-1 and AF-2 have been suggested to contact the string of TIFs at functionally equivalent points, while AADs are believed to interact at an earlier point in the series (D. Tasset *et al.*, *Cell* 62:1177-1187 (1990)).

Several putative coactivator TIFs for NR AF-2s have been characterized (see Chambon, P., *FASEB J* 10:940-954 (1996); Glass, C.K. *et al.*, *Current Opin. Cell Biol.* 9:222-232 (1997); Horwitz, K.B. *et al.*, *Mol. Endocrinol.* 10:1167-1177 (1996) for recent reviews). In particular, LeDouarin, B. *et al.*, *EMBO J.* 15:6701-6715 (1996) have demonstrated that a 10-amino acid fragment of TIF1 $\alpha$  is necessary and sufficient to mediate interaction with RXR in a ligand- and AF-2 integrity-dependent manner. Notably, within this TIF1 $\alpha$  fragment, they identified a LxxLLL (SEQ ID NO:13) motif, termed NR box, whose integrity is required for interaction with nuclear receptors, and pointed out that this motif is conserved in several other putative coactivators (LeDouarin, B. *et al.*, *EMBO J.* 15:6701-6715 (1996)) Whereas TIF1 $\alpha$  and several other putative coactivators do not, or only very poorly, stimulate transactivation by NRs in transiently transfected mammalian cells, the TIF2/SRC-1 family (Oñate, S.A. *et al.*, *Science* 270:1354-1357 (1995); Voegel, J.J. *et al.*, *EMBO J.* 15:3667-3675 (1996)), the CBP/p300 family (Kamei, Y. *et al.*, *Cell* 85:403-414 (1996); Chakravarti, D. *et al.*, *Nature* 378:99-103 (1996); Hanstein, B., *et al.*, *Proc. Natl. Acad. Sci USA* 93:11540-11545 (1996); Smith, C.L. *et al.*, *Proc. Natl. Acad. Sci. USA* 93:8884-8888 (1996); for recent reviews

see Eckner, R., *Biol. Chem.* 377:685-688 (1996); Janknecht & Hunter, *Current Biol.* 6:951-954 (1996b); Shikama, N. *et al.*, *Trends in Cell Biol.* 7:230-236 (1997)) and the androgen receptor coactivator ARA70 (Yeh & Chang, *Proc. Natl. Acad. Sci. USA* 93:5517-5521 (1996)) have been unequivocally shown to enhance AF-2 activity.

In addition to binding NRs, CBP/p300 can also interact directly with SRC-1 (Kamei, Y. *et al.*, *Cell* 85:403-414 (1996); Yao, T.P. *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10626-10631 (1996)) and both factors have been shown to exert histone acetyltransferase activity (Bannister & Kouzarides, *Nature* 384:641-643 (1996); Ogryzko, V.V. *et al.*, *Cell* 87:953-959 (1996)). Moreover, CBP/p300 can recruit p/CAF which is itself a nuclear histone acetyltransferase (Yang, X.J. *et al.*, *Nature* 382:319-324 (1996)). However, apart from interacting with coactivators in a ligand-dependent manner, NRs have also been shown to interact, often in a ligand-independent fashion, directly or indirectly with components of the transcriptional machinery, such as TFIIB, TBP, TAFs, or TFIIF (Baniahmad *et al.*, (1993)); Jacq, X. *et al.*, *Cell* 79:107-117 (1994); Schulman, I.G. *et al.*, *Mol. Cell. Biol.* 16:3807-3813 (1996); May, M. *et al.*, *EMBO J.* 15:3093-3104 (1996); Mengus, G. *et al.*, *Genes & Dev.* 11:1381-1395 (1997)).

Hong, H. *et al.*, *Proc. Natl. Acad. Sci. USA* 93:4948-4952 (1996) originally described a partial cDNA of the mouse homologue of TIF2, named GRIP1, and recently reported the isolation of a full length GRIP1 cDNA (Hong, H. *et al.*, *Mol. Cell. Biol.* 17:2735-2744 (1997)). Using the yeast *Saccharomyces cerevisiae* as a model system, they have shown that transcriptional activation by TR, RAR and RXR, could also be stimulated by GRIP1 coexpression, which suggests that TIF2/GRIP1 could be a general coactivator for NRs (Hong, H. *et al.*, *Mol. Cell. Biol.* 17:2735-2744 (1997)).

The overall picture emerging from multiple recent studies on the mechanisms by which nuclear receptors modulate target gene transcription involves three subsequent steps, (i) the ligand-induced transconformation of the NR LBD, which results in (ii) the dissociation of corepressors and formation of

5 TIFs/coactivator complexes, which themselves (iii) through interaction with additional downstream factors (e.g., CBP, p300) modulate the acetylation status of core histones and, thus, chromatin condensation/decondensation. Histone acetylation on its own is, however, insufficient for transcription activation (Wong  
10 *et al.*, (1997)), and a simultaneous or subsequent fourth event comprises the direct and/or indirect recruitment of elements of the transcription machinery (e.g., TFIB, TBP, TAFs, TFIIF; Jacq, X. *et al.*, *Cell* 79:107-117 (1994); Schulman, IG. *et al.*, *Mol. Cell. Biol.* 16:3807-3813 (1996); May, M. *et al.*, *EMBO J.* 15:3093-3104 (1996); Mengus, G. *et al.*, *Genes & Dev.* 11:1381-1395 (1997)). Note that such interactions do not need to be ligand-dependent, if the primary function of the liganded LBD (AF-2) is to regulate DNA accessibility through chromatin remodeling. Indeed, several of the reported interactions between NRs and general transcription factors occur in a ligand-independent manner. Accordingly, there is a need in the art for the isolation and characterization of transcriptional  
15 intermediary factors.

### *Summary of the Invention*

By screening 340,000 clones of a human placenta cDNA expression library with an estradiol-bound estrogen receptor probe, the present inventors have identified a cDNA clone containing the gene encoding transcriptional intermediary factor 2 (TIF2). By the invention, TIF2 has been shown to exhibit all the  
20 properties expected for a TIF/mediator of AF-2: it interacts directly with the LBDs of several NRs in an agonist- and AF-2-integrity-dependent manner *in vitro* and *in vivo*, harbours an autonomous AF, relieves NR autosquelching, and enhances the activity of NR AF-2s when overexpressed in mammalian cells.

25 Thus, in one aspect, the present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding TIF2 whose amino acid sequence is shown in Figure 1 (SEQ ID NO:2) or a fragment thereof. In another aspect, the

invention provides isolated nucleic acid molecules encoding TIF2 having an amino acid sequence as encoded by the cDNA deposited as ATCC Deposit No. 97612.

5 The invention further provides an isolated nucleic acid molecule that hybridizes under stringent conditions to the above-described nucleic acid molecules. The present invention also relates to variants of the nucleic acid molecules of the present invention, which encode fragments, analogs or derivatives of the TIF2 protein, *e.g.*, polypeptides having at least one biological activity that is substantially similar to at least one biological activity of the TIF2 protein.

10 The present invention is further directed to isolated nucleic acid molecules that encode a cytoplasmic TIF2 polypeptide. Methods for generating nucleic acid molecules that encode a cytoplasmic TIF2 polypeptide include mutating or deleting the NLSs-coding N-terminal region of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1). Preferably, nucleic acid molecules encoding a  
15 cytoplasmic TIF2 polypeptide will be fragments having a deletion in all or part of the N-terminal NLSs coding region. By the invention, the cytoplasmic TIF2 polypeptides described herein display at least one biological activity that is substantially similar to at least one biological activity of TIF2.

20 Further embodiments of the invention include isolated nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 90% identical, and more preferably at least 95%, 96%, 97%, 98%, or 99% identical to the above described nucleic acid molecules.

25 The present invention also relates to vectors which contain the above-described isolated nucleic acid molecules, host cells transformed with the vectors and the production of TIF2 polypeptides by recombinant methods.

The present invention further provides isolated TIF2 polypeptides having the amino acid sequence shown in Figure 1 (SEQ ID NO:2). In a further aspect, isolated TIF polypeptides are provided having an amino acid sequence as encoded by the cDNA deposited as ATCC Deposit No. 97612.

Screening methods are also provided for identifying agonists and antagonists of nuclear receptor AF-2 function, for identifying agonists and antagonists of TIF2 AD1 activity, and for identifying agonists and antagonists of TIF2 AD2 activity. Also provided are TIF2 antibodies.

### *Brief Description of the Figures*

**Figure 1(a-b).** The nucleotide (SEQ ID NO:1) and amino acid (SEQ ID NO:2) sequences of the transcriptional intermediary factor-2 (TIF2) protein. This protein has a deduced molecular weight of about 160 kDa. The amino acid sequence of the functional coactivator TIF2.1 protein fragment is shown from amino acid residue 624 to residue 1287.

**Figure 2(a-c).** TIF2 is the 160-kDa nuclear-receptor-interacting factor.

(a) GST pull-down experiments identify a 160-kDa protein interacting with liganded estrogen receptor (ER) and retinoic acid receptor (RAR)- $\alpha$  ligand binding domains (LBDs) (ER(DEF) and RAR $\alpha$ (DEF), respectively). Note that less material was run in lane 5 than in lanes 1-4.

(b) Immunodepletion followed by Far-Western detection demonstrates identity of TIF2 with the biochemically identified 160-kDa protein. Open triangle, TIF2; arrowhead, TIF1; circle, antibody crossreaction to GST-ER(DEF). The  $\alpha$ -TIF2-immunodetected species smaller than TIF2 (lanes 2 and 6) most probably is a degradation product of TIF2, as it is removed by immunodepletion with  $\alpha$ -TIF2 (lanes 4 and 8).

(c) Northern blotting reveals a  $\approx$ 9-kb TIF2 transcript in various human tissues.

**Methods.** (a) *In vivo*  $^{35}$ S-Met-labeled MCF7 whole cell extracts (Cavaillès, V. *et al.*, *Proc. Natl. Acad. Sci. USA* 91:10009-10013 (1994)) twice precleared with GST-loaded glutathione sepharose, were incubated (Le Douarin, B. *et al.*, *EMBO J.* 14:2020-2033 (1995)) with GST, GST-hER (DEF) or GST-

hRAR $\alpha$ (DEF), in presence or absence of  $10^{-6}$  M E2 or T-RA. Bound proteins were recovered with SDS sample buffer and revealed by fluorography (Amplify, Amersham) of SDS-polyacrylamide gels.

5 (b) HeLa whole cell extracts (2 ml in 500 mM NaCl, 250 mM TrisHCl pH 7.5, 20% glycerol, 5 mM DTT), were precleared with protein-G sepharose (400  $\mu$ l) and treated with protein-G sepharose (3 x 400  $\mu$ l) loaded with m $\alpha$ -TIF2 (raised against a synthetic peptide encompassing amino acids E624-Q643 coupled to ovalbumin) or non-specific mouse IgG serum. After further clearing with protein-G sepharose (400  $\mu$ l), the supernatant was incubated (Le Douarin, B. *et al.*, *EMBO J.* 14:2020-2033 (1995)) with GST-hER(DEF) in presence or absence of E2( $10^{-6}$ M). Retained proteins were recovered with SDS sample buffer, separated by SDS-PAGE and electroblotted on nitrocellulose membranes. Far Western blotting was as described (Cavaillès, V. *et al.*, *Proc. Natl. Acad. Sci. USA* 91:10009-10013 (1994)). For immunoblotting rabbit polyclonal antiserum (p $\alpha$ -TIF2), raised against purified (Chen, Z-P. *et al.*, *J. Biol. Chem.* 269:25770-25776 (1994)) recombinant *E. coli*-expressed His-tagged TIF2.1, was used. p $\alpha$ -TIF2 and rabbit polyclonal p $\alpha$ -TIF1 were diluted 1:2000 for ECL-based Western blotting (Amersham). All constructs used in this study were verified by DNA sequencing.

20 (c) Human Northern blot (Clontech, No 7760-1; Lot 5x332) was revealed with  $^{32}$ P-labeled TIF2.1. To confirm proportionate loading, the membrane was rehybridized with  $^{32}$ P-labeled  $\beta$ -actin cDNA (Clontech).

25 **Figure 3(a-b).** Amino acid sequence of TIF2: homology with SRC-1 indicates the existence of a novel family of NR mediators.

30 (a) Alignment and amino acid sequences of TIF-2 (SEQ ID NO:2) and the steroid receptor coactivator SRC-1 (SEQ ID NO:3) (Onate, S.A. *et al.*, *Science* 270:1354-1357 (1995)). Two charged clusters rich in acidic and basic amino acid residues, three serine/threonine (S/T)-rich regions and one glutamine-rich region are highlighted. The N-terminal charged cluster contains putative bipartite nuclear

localization signals (NLSs) (overlined). The regions encoding TIF2.1 (amino acids 624 to 1287; functional coactivator fragment) and dnSRC-1 (amino acids 865 to 1061; dominant negative fragment) are indicated. An asterisk identifies the TIF2 stop codon. Note that TIF2.1 and dnSRC-1 do not overlap, indicating that dnSRC-1 may possibly contain a NR-interacting region distinct from that of TIF2.1.

(b) Schematic comparison of TIF2 and SRC-1. Percent identities (similarities in parentheses) of homologous regions are indicated. The N-terminal charged cluster harbouring the putative NLS and the C-terminal S/T-rich region of TIF2 are not, or only weakly, conserved in SRC-1.

**Methods.** 340,000 clones of a human placenta cDNA  $\lambda$ EXlox expression library were screened with a  $^{32}$ P-labeled GST-hER(DEF) probe in presence of  $10^{-6}$ M E2 using the Far-Western technique (Cavaillès, V. *et al.*, *Proc. Natl. Acad. Sci. USA* 91:10009-10013 (1994)). The 1992-bp insert corresponding to the initial clone (TIF2.1) was used to rescreen the same library. Five highly overlapping cDNA inserts covered a region of 6 kb containing a 1,464-amino acid ORF. All inserts were sequenced on both strands. Transient expression of the assembled cDNA inserts encompassing the predicted ORF yielded a 160-kDa protein.

**Figure 4(a-n).** *In vivo* and *in vitro* interactions of TIF2 with nuclear receptors.

(a) Overexpressed TIF2 protein is mostly localized in discrete nuclear bodies and excluded from nucleoli. A superposed image of Hoechst DNA staining and TIF2 immunostaining is shown.

(b-i) Cytoplasmic TIF2.1 interacts in an agonist-dependent manner with nuclear receptors in mammalian cells. Light staining indicates TIF2.1-NO colocalization.

(k-n) TIF2.1 directly interacts *in vitro* in an agonist-dependent manner with nuclear receptors, and point mutations within the AF-2 activation domain

(AD) core abolish this interaction. WT, wild-type. Ligand concentrations for *n*: 9C-RA, T-RA and T3,  $10^{-6}$  M; E2,  $5 \times 10^{-8}$  M; OHT,  $5 \times 10^{-6}$  M. The smaller immunodetected polypeptide is a degradation product of TIF2.1. Note that the anti-TIF2 serum weakly crossreacts with GST-hER(DEF).

5       **Methods. (a-i)** Cos-1 cells were transiently transfected with TIF2.1 (10  $\mu$ g) either (a) alone or (b-i) in addition with the indicated NR expression vectors (10  $\mu$ g, except RAR $\alpha$ , 1  $\mu$ g) in absence or presence of the cognate ligand ( $10^{-6}$  M, except R5020,  $10^{-8}$  M). In d-fHE0 (Webster, N.J. *et al.*, *Cell* 54:199-207 (1988)) was used. Immunocytofluorescence assays were as described (Kastner, P. *et al.*,  
10    *EMBO J.* 11: 629-642 (1992)). Images were recorded by confocal laser microscopy.

15       **(k-n)** GST interaction assays with *E. coli*-expressed recombinant TIF2.1 (Fig. 2b) were performed as described (Le Douarin, B. *et al.*, *EMBO J.* 14:2020-2033 (1995)). Bound proteins were revealed by Western blotting with  $\alpha$ -TIF2 antiserum (dilution 1:30,000), equal loading of affinity matrices was verified by SDS-PAGE and Coomassie staining. 'Input' lanes contain one third of TIF2.1 input.

20       **Figure 5 (a-e).** TIF2 contains an autonomous AF, "antisquelches", and stimulates NO-AF2 activity in an agonist-, promoter- and cell-dependent manner.

**(a)** Increasing amounts of GAL-TIF2.1 fusion protein (lanes 2-4) activates transcription of a cognate reporter in transfected cells. Fold-induction is given below the CAT assays.

25       **(b)** TIF2.1 partially reverses transcriptional autointerference of ER. Normalized CAT expression (mean  $\pm$  s.e. of 4 independent experiments) is shown. Open circles, +E2, +TIF2; squares, +E2, -TIF2; crosses, +OHT, +TIF2.

**(c)** TIF2 enhances transactivation mediated by some NR AF-2s, but not that mediated by other transcription factors. Mean TIF2 stimulations of 3 independent experiments are given (variation  $\leq$  13%). Ligands: lanes 3-4, E2; lanes 7-8, DHT (dihydrotestosterone); lanes 11-12, R5020; lanes 15-16, T-RA.

(d) TIF2 enhances PR-mediated transcriptional activation from both a minimal (GRE-TATA) and a complex (MMTV) promoter; this stimulation is significantly greater in Cos-1 than in HeLa cells.

5 (e) TIF2 greatly enhances agonist-induced activation by ER in Cos-1 and more weakly in HeLa cells. Note that the weak, seemingly ligand-independent, TIF2-induction of ER (compare lanes 1 with 2 and 7 with 8) is due to residual estradiol in the culture medium. In *d* and *e*, TIF2 inductions of  $\geq 3$  experiments are shown (variation  $\leq 10\%$ ).

10 **Methods.** With the exception of GAL-TIF2.1, TIF2.1 and TIF2, the construction of reporter plasmids and expression vectors has been described (Meyer, M-E. *et al.*, *Cell* 57:433-442 (1989); Bocquel, M-T. *et al.*, *Nucl. acids Res.* 17:2581-2595 (1989); Tasset, D. *et al.*, *Cell* 62:1177-1187 (1990); Gronemeyer, H. and Laudet, V., *Protein Profile* 2:1173-1308 (1995); Webster, N. J. *et al.*, *Cell* 54:199-207 (1988); Strähle, U. *et al.*, *EMBO J.* 7:3389-3395 (1988); Seipel, K. *et al.*, *EMBO J.* 11:4961-4968 (1992); Nagpal, S. *et al.*, *EMBO J.* 12:2349-2360 (1993); Chen, J-Y. *et al.*, *EMBO J.* 14:1187-1197 (1995)). CAT assays were performed as described (Bocquel, M-T. *et al.*, *Nucl. Acids Res.* 17:2581-2595 (1989)).

20 (a) HeLa cells were cotransfected with 1  $\mu\text{g}$  (17m)<sub>5</sub>- $\beta$ G-CAT and 10  $\mu\text{g}$  GAL(1-147) or 1,3 and 10  $\mu\text{g}$  GAL(1-147)-TIF2.1, respectively.

(b) HeLa cells were cotransfected with 5  $\mu\text{g}$  Vit-tk-CAT and the indicated amount of HEG0, with or without 5  $\mu\text{g}$  TIF2.1 in the presence of  $10^{-6}$  M E2 or OHT. CAT activity is given relative to that induced by 100 ng HEG0 in presence of E2.

25 (c) HeLa cells were cotransfected with 1  $\mu\text{g}$  17m-tk-CAT and 1  $\mu\text{g}$  of the indicated GAL-fusion vectors with or without the addition of 3  $\mu\text{g}$  TIF2 expression vector in presence or absence of  $10^{-6}$ M ligand.

(d) HeLa (lanes 1-12) or Cos-1 (lanes 13-18) cells were transfected with 5  $\mu\text{g}$  GRE-TATA-CAT (lanes 1-6) or 1  $\mu\text{g}$  MMTV-CAT (lanes 7-18)

together with 1  $\mu$ g hPR with or without 3  $\mu$ g TIF 2 in presence or absence of  $10^{-6}$  M of the indicated ligand.

(e) Cos-1 cells were cotransfected with 1  $\mu$ g Vit-tk-CAT and 1  $\mu$ g HEG0 with or without 3  $\mu$ g TIF2 in presence or absence of  $10^{-6}$  M of the indicated ligands.

**Figure 6 (a-b).** Schematic representation of reporter genes (A) and receptor expression vectors (B) (see the Materials and Methods section of Nagpal *et al.*, *EMBO J* 12(6):2349-2360 (1993) for a detailed description of construction). Sequences of mCRBP11 (SEQ ID NO:11) and mCRBP11(17m-ERE)/CAT (SEQ ID NO:11) are indicated. Minus and plus numbers are with respect to the RNA start site (+1). In (B), the various regions (A-F) of wild-type RARs and RXRs, as well as their truncation mutants, substitution mutants and chimeric receptor constructs are schematically represented (not to scale) (see Zelent *et al.*, *Nature* 339:714-717 (1989); Leid *et al.*, *Trends Biochem. Sci.* 17:427-433 (1992); Leid *et al.*, *Cell* 68:377-395 (1992); Nagpal *et al.*, *Cell* 70:1007-1019 (1992); and Allenby *et al.*, *Proc. Natl. Acad. Sci. USA* 90:30-34 (1993)). Numbers indicate the amino acid positions in the wild-type receptor. The positions of the amino acid substitutions are indicated with an arrow.

**Figure 7(a-e).** Mapping of TIF2 domains.

(a) Schematic representation of functional domains identified in TIF2. The various TIF2 constructs are denoted; expressed residues are given in parentheses. Bold lines indicate expressed sequences. Constructs that score positive or negative for NR interaction, transactivation or CBP binding are identified on the right by "+" and "-" signs respectively; nd, not determined.

(b) Mapping of the nuclear receptor-interacting domain of TIF2. Glutathione-S-transferase (GST) pull-down experiments were performed with  $^{35}$ S-labeled *in-vitro*-translated TIF2 polypeptides and bacterially produced GST, GST-hER $\alpha$ (DEF) and GST-hRAR $\alpha$ (DEF) in the presence or absence of  $10^{-6}$  M of the

cognate ligand (E2, estradiol for ER; RA, all-*trans-retinoic* acid for RAR).

(c) Analysis of the transcriptional activity of GAL-TIF2 fusion proteins. Cos-1 and HeLa cells were transfected with 3 µg of plasmids expressing different regions of TIF2 fused to the DNA-binding domain of the yeast transcription factor GAL4 together with 1 µg of the (17m)<sub>5</sub>-G-CAT reporter plasmid. CAT assays were performed as described (Bocquel, M.T. *et al.*, *Nucl. Acids Res.* 17:2581-2595 (1989)). Quantitative data on CAT reporter expression were obtained either by phosphoimager analysis (BAS2000, Fuji) of <sup>14</sup>C-labeled CAT reaction products separated by thin-layer chromatography, or using the CAT ELISA Kit (Boehringer Mannheim). In all cases, CAT activities were normalized to the β-galactosidase concentrations resulting from cotransfection of 1 µg of pCMVβGal (gift from T. Lerouge) as internal control. Fold inductions above the GAL4 DBD value are indicated. The mean and standard deviation of at least three experiments are shown. A representative Western blot, illustrating the expression levels of the GAL4-TIF2 fusion proteins, expressed from 10 µg of the corresponding expression vectors, is shown on the left. The blot was revealed with mouse monoclonal antibodies 2GV3 and 3GV2 specific for GAL4 DBD and 2GV4B7 specific for VP16 activation domain.

(d) Mapping of the CBP-interacting domain of TIF2. GST pull-down experiments were performed with <sup>35</sup>S-labeled *in-vitro*-translated TIF2 polypeptides and bacterially produced GST and GST-CBP (expressing CBP residues 1872 to 2165).

(e) Two hybrid analysis of the CBP-TIF2 interaction in mammalian cells *in vivo*. HeLa cells were transfected with 0.2 µg of the GAL4 or GAL4-CBP (expressing CBP residues 1872 to 2165) expression vectors together with 0.2 µg of the VP16 or VP16-TIF2 expression vectors in the presence of 1 µg of (17m)<sub>5</sub>-TATA-CAT reporter plasmid. Fold induction relative to the GAL-CBP activity is indicated. The mean of three experiments is shown; in each case, values varied by less than ±20%.

**Figure 8(a-e).** Mapping of the TIF2 nuclear receptor interacting domain (NID).

(a) Alignment of the TIF2 NID (SEQ ID NO:2) with the corresponding regions of SRC-1 (SEQ ID NO:3) and P/CIP (SEQ ID NO:5) and description of NID mutations. The three conserved regions are displayed with the corresponding amino acid numbers of hTIF2 or full-length hSRC-1 (F-SRC-1); the leucines pertaining to the three NR box motifs (I, II, III) are boxed. The various deletion and leucine-to-alanine point mutation constructs are denoted.

(b) Alignment of the TIF2 (SEQ ID NO:2) NR boxes with NR boxes identified in several cofactors: TIF1 $\alpha$  (SEQ ID NO:6), RIP140 (SEQ ID NO:7), and TRIP3 (SEQ ID NO:8). The conserved leucines are boxed.

(c-d) Interaction of TIF2 NID mutants with NRs *in vitro*. GST affinity chromatography experiments were carried out with <sup>35</sup>S-labelled *in-vitro*-translated GAL4 DBD fusions of TIF2 deletion mutants (c) or TIF2.1 point mutants (d) and bacterially expressed GST and GST fusions of the ER(DEF) and RAR(DEF) in the absence or presence of 10<sup>-6</sup> M estradiol or all-*trans-retinoic* acid, respectively. For quantification of point mutant interactions, see below.

(e) Effect of TIF2 NID point mutations on stimulation of NR AF-2 activity. Cos-1 cells were cotransfected with 1  $\mu$ g of the (17m)<sub>5</sub>-TATA-CAT reporter, 0.2  $\mu$ g of GAL-hER $\alpha$ (EF) or GAL-mRXR $\alpha$ (DE), and 2.5  $\mu$ g of the TIF2.1 wildtype or mutated fragments, as indicated. The reporter gene activation relative to the TIF2.1 wildtype activity and in presence of 10<sup>-6</sup> M estradiol (E2) or all-*trans-retinoic* acid (RA), respectively, is indicated for each mutant (black bars); for comparison, *in vitro* binding of the respective mutants relative to TIF2.1 wildtype binding in presence of ligand is indicated by the white bars. Each bar represents the mean value obtained from at least three (interaction) or at least four (transactivation) experiments, respectively; standard deviations are indicated. Note that the absolute values for TIF2.1 wildtype activity varied by  $\pm 16\%$  when cotransfected with GAL-hER $\alpha$ (EF) and by  $\pm 34\%$  when cotransfected with GAL-mRXR $\alpha$ (DE). In the *in-vitro*-interaction assays, the affinity of the TIF2.1

wildtype standard varied by less than  $\pm 25\%$ . Expression levels of TIF2 mutants in the cells were verified by Western blot (not shown) with mouse monoclonal antibody 3Ti3F1, which is directed against an epitope outside the mutated area.

**Figure 9(a-c).** Mapping of the TIF2 activation function-1 (AF-1) and interaction of the AF-1 domain with CBP.

(a) Alignment of the TIF2 AF-1 with the corresponding region of SRC-1 (SEQ ID NO:3) and P/CIP (SEQ ID NO:9). Description of TIF2 AF-1 deletion mutants and their properties. The regions of TIF2 and hSRC-1 predicted to fold into  $\alpha$ -helices are boxed (PHD program). GAL-TIF2 constructs that score positive or negative for transactivation of a GAL4 reporter are identified on the right by "+" and "-" signs, respectively; nd, not determined.

(b) Transcriptional activation of TIF2 AF-1 mutants. Cos-1 and HeLa cells were cotransfected with 3  $\mu$ g of plasmids expressing different mutants of the TIF2 AF-1 fused to the DNA-binding domain of the yeast transcription factor GAL4 together with 1  $\mu$ g of the (17m)<sub>5</sub>-G-CAT reporter plasmid. Fold inductions above the activation seen with the GAL4 DBD alone are indicated. The values represent the mean of at least three experiments. Note that all GAL4-TIF2 fusion proteins were expressed to similar levels, as revealed by Western blot with antibodies directed against GAL4 DBD (data not shown).

(c) Interaction of TIF2 AF-1 mutants with CBP *in vitro*. GST pull-down experiments were performed with <sup>35</sup>S-labeled *in-vitro*-translated GAL-TIF2 fusion proteins and bacterially produced GST and GST-CBP. Note, that the GAL4 DBD on its own does not interact with the GST-CBP affinity matrix.

**Figure 10(a-c).** Identification of TIF2 AF-1 mutants which are impaired in both transcriptional activation and interaction with CBP.

(a) Transcriptional activation by TIF2.13 and TIF2.13 mutants. Cos-1 and HeLa cells were cotransfected with 3  $\mu$ g of plasmids expressing the TIF2.13 region and the indicated TIF2.13 mutants fused to the DNA-binding domain of the

yeast transcription factor GAL4 together with 1  $\mu$ g of the (17m)<sub>5</sub>-G-CAT reporter plasmid. Fold inductions above the GAL4 DBD 1-fold value are indicated. The mean and standard deviation obtained from at least four experiments are shown. The expression levels of the GAL4-TIF2.13 fusion proteins were confirmed by western blotting (data not shown).

(b) Interaction of TIF2.13 wildtype and TIF2.13 mutants with CBP in mammalian cells revealed by two hybrid analysis. HeLa cells were transfected with 0.2  $\mu$ g of GAL4 or GAL-CBP expression vectors together with 0.2  $\mu$ g of VP16 or VP16-TIF2.13 expression vectors in the presence of 1  $\mu$ g of (17m)<sub>5</sub>-TATA-CAT reporter plasmid. Data are represented as fold induction of the activity seen with GAL-CBP alone. The mean and standard deviation obtained from ten experiments are shown. The expression levels were confirmed by Western blotting with antibodies directed against GAL4 DBD and VP16 AAD (data not shown).

(c) Interaction of TIF2.13 wildtype and TIF2.13 mutants with CBP *in vitro*. GST pull-down experiments were performed with <sup>35</sup>S-labeled *in-vitro*-translated VP16-TIF2.13 polypeptides and bacterially produced GST and GST-CBP. Note that the VP16 activation domain on its own does not interact with GST-CBP.

**Figure 11.** The TIF2.1 coactivator fragment efficiently stimulates the ligand-dependent AF-2 of ER, RAR and RXR in yeast. No stimulatory effect of TIF2.1 on the isolated AF-1 of ER (HE15) is observable. Plasmids expressing different regions of hER $\alpha$  (white), hRAR $\alpha$  (grey) and mRXR $\alpha$  (black) fused to the ER DBD (hER $\alpha$ (C)) were introduced into the yeast reporter strain PL3( $\alpha$ ) together with TIF2.1 as indicated. White boxes represent sequences of transformants that were grown in the presence or absence of 10<sup>-6</sup> M of the cognate ligand (estradiol for ER, all-*trans*-retinoic acid for RAR, 9-*cis*-retinoic acid for RXR). OMP decase activities determined on each cell-free extract are expressed

in nmol/min/mg protein; the mean and standard deviation of at least four experiments are shown.

*Figure 12(a-d).* The isolated nuclear receptor-interacting domain (NID) of TIF2 acts dominant-negatively on the transcriptional activation by the ER, RXR and RAR LBDs. The mean value of induction obtained from the quantitation of at least three experiments (relative to the respective receptor LBD activity in absence of recombinant TIF2) is indicated below each panel. Expression levels of TIF2, TIF2.1 and TIF2.5 were routinely verified by Western blot with mouse monoclonal antibody 3Ti3C11 directed against a region of TIF2.5 (not shown).

(a) Overexpression of the TIF2.5 fragment containing the isolated NID reverses the stimulatory effect of the potent coactivator fragment TIF2.1. Cos-1 cells were cotransfected with 1  $\mu$ g of the (17m)<sub>5</sub>-TATA-CAT reporter and 0.2  $\mu$ g GAL-ER $\alpha$ (EF) expression vector in the presence or absence of 10<sup>-6</sup> M estradiol. Where indicated, 0.1  $\mu$ g of TIF2.1 and 2.5  $\mu$ g of TIF2.5 expression vectors were cotransfected in addition.

(b-d) Full length TIF2 and the coactivator fragment TIF2.1 enhance, whereas the nuclear receptor interacting domain TIF2.5 blocks the activity of the ER, RXR and RAR LBDs. Cos-1 and HeLa cells were cotransfected with 1  $\mu$ g of the (17m)<sub>5</sub>-TATA-CAT reporter and 0.2  $\mu$ g of the expression vector encoding the respective GAL DBD-fusion of hER $\alpha$ (EF), mRXR $\alpha$ (DE) or mRAR $\alpha$ (DEF). In the presence or absence of 10<sup>-6</sup> M ligand (E2, estradiol; 9C-RA, 9-*cis*-retinoic acid; T-RA, all-*trans*-retinoic acid), together with 0.25  $\mu$ g or 2.5  $\mu$ g of TIF2, TIF2.1 and TIF2.5 expression vectors.

### *Detailed Description of the Preferred Embodiments*

The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding transcriptional intermediary factor-2 (TIF2) whose amino acid sequence is shown in Figure 1 (SEQ ID NO:2). The TIF2 protein of

the present invention shares sequence homology with the human steroid receptor coactivator SRC-1 (SEQ ID NO:3) (Figure 3). The nucleotide sequence shown in Figure 1 (SEQ ID NO:1) was obtained by sequencing a cDNA clone which was deposited on June 14, 1996 at the ATCC and given accession number 97612.

## *Nucleic Acid Molecules*

In one embodiment of the present invention, isolated nucleic acid molecules are provided which encode the TIF2 protein. Sequence similarities between TIF2 and SRC-1 (Onate *et al.*, *Science* 270:1354 (1995)) indicate the existence of a novel gene family of NR transcriptional mediators. Using information provided herein, such as the nucleotide sequence in Figure 1 (SEQ ID NO:1) or the above-described deposited clone, a nucleic acid molecule of the present invention encoding a TIF2 polypeptide may be obtained using standard cloning and screening procedures. Illustrative of the invention, the nucleic acid molecule described in Figure 1 (SEQ ID NO:1) was discovered in a cDNA expression library from human placenta tissue. The TIF2 cDNA of the present invention encodes a protein of about 159 kDa (1,464 amino acids), which includes N-terminal nuclear localization signals (NLSs), one Gln- and three Ser/Thr-rich regions, and two charged clusters (Figure 3). TIF2 is widely expressed, since the corresponding transcript was found in several human tissues, including pancreas, kidney, muscle, liver, lung, placenta, brain and heart (Figure 2c).

Isolated nucleic acids of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double-stranded or single-stranded. Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

By "isolated" nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For

example, recombinant DNA molecules contained in a vector are considered isolated for purposes of the present invention. Additional illustrative examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells and purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vitro* RNA transcripts of the DNA molecules of the present invention as well as partially or substantially purified mRNA molecules. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Isolated nucleic acid molecules of the present invention include DNA molecules comprising an open reading frame (ORF) with an initiation codon at position 163-165 of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1); and DNA molecules which comprise a sequence substantially different than that described above but which, due to the degeneracy of the genetic code, still encode the TIF2 protein. Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate the degenerate variants described above.

In another aspect, the invention provides isolated nucleic acid molecules encoding the TIF2 polypeptide having an amino acid sequence as encoded by the cDNA clone deposited as ATCC Deposit No. 97612 on June 14, 1996 (American Type Culture Collection, (ATCC) Rockville, MD). The invention further provides an isolated nucleic acid molecule having the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) or the nucleotide sequence of the TIF2 cDNA contained in the above-described clone, or a nucleic acid molecule having a sequence complementary to one of the above sequences. Such isolated nucleic acid molecules, preferably DNA molecules, are useful as probes for gene mapping by *in situ* hybridization with chromosomes and for detecting expression of the TIF2 gene in human tissue, for instance, by Northern blot analysis.

In another aspect, the invention provides an isolated nucleic acid molecule that hybridizes under stringent conditions to the above-described nucleic acid molecules. As used herein "stringent conditions" is intended to mean, as a non-

limiting example, overnight incubation at 42°C in a solution comprising 50% formamide, 5xSSC (150 mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1xSSC at about 65°C. Preferably, such "an isolated nucleic acid molecule that hybridizes under stringent conditions" will be at least 15 bp, preferably at least 20 bp, more preferably at least 30 bp, and most preferably, at least 50 bp in length.

As used herein, "fragments" of an isolated DNA molecule having the nucleotide sequence of the deposited cDNA or the nucleotide sequence as shown in Figure 1 (SEQ ID NO:1) is intended to mean DNA fragments at least 15 bp, more preferably at least 20 bp, and most more preferably at least 30 bp in length which are useful as diagnostic probes and primers as discussed above and in more detail below. Larger DNA fragments, up to, for example, 500 bp in length, are also useful as probes according to the present invention. A fragment of at least 20 bp in length, for example, is intended to mean fragments which include 20 or more contiguous bases from the nucleotide sequence of the deposited cDNA or the nucleotide sequence as shown in Figure 1 (SEQ ID NO:1). As indicated, such fragments are useful diagnostically either as a probe according to conventional DNA hybridization techniques or as primers for amplification of a target sequence by the polymerase chain reaction (PCR).

Since the gene has been deposited and the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) is provided, generating such DNA fragments would be routine to the skilled worker in the relevant art. Restriction endonuclease cleavage or shearing by sonication, for example, may easily be used to generate fragments of various sizes. Alternatively, the DNA fragments of the present invention can be generated synthetically according to the methods and techniques known and available to those skilled in the art. Ten expressed sequence tags with homology to part of the TIF-2 nucleotide sequence were identified by the inventors in GenBank: GenBank Accession numbers T77249, R77864, T77464, R77770, R08880, T85560, R25318, T85561, R08986 and R26517.

The present invention further relates to variants of the nucleic acid molecules of the present invention, which encode for fragments, analogs or derivatives of the TIF2 protein, *e.g.*, polypeptides having biological activity substantially similar to the TIF2 protein. Variants may occur naturally, such as isoforms and allelic variants. Non-naturally occurring variants may be produced using any of the mutagenesis techniques known and available to those skilled in the art.

Such variants include those produced by nucleotide substitutions, deletions or additions. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the TIF2 protein or fragment thereof. Also especially preferred in this regard are conservative substitutions.

The present invention is further directed to isolated nucleic acid molecules that encode a cytoplasmic TIF2 polypeptide. Full-length TIF2 is a nuclear protein due to the presence of N-terminal nuclear localization signals (NLSs) (Figure 3). By a "cytoplasmic TIF2 polypeptide", is intended a TIF2 polypeptide that is essentially found in the cytoplasm after being recombinantly expressed in mammalian cells. Methods for generating nucleic acid molecules that encode a cytoplasmic TIF2 polypeptide include mutating or deleting the NLSs-coding N-terminal region of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1). Examples of NLS sequences include amino acids 13-20 and 31-39 and nucleotides 199-222 and 253-279 of Figure 1 (*See also*, Figure 3). Suitable mutations to the NLSs-coding N-terminal region include substitutions, deletions and insertions which result in a nucleic acid molecule that encodes a TIF2 polypeptide lacking the nuclear localization function. Methods for generating such mutations will be readily apparent to the skilled artisan and are described, for instance, in *Molecular*

*Cloning, A Laboratory Manual*, 2nd edition, edited by Sambrook, J., Fritsch, E.F. and Maniatis, T., (1989), Cold Spring Harbor Laboratory Press.

Preferably, nucleic acid molecules encoding a cytoplasmic TIF2 polypeptide will be fragments having a deletion in all or part of the N-terminal NLSs coding region. Methods for generating such fragments are described below. According to the present invention, such nucleic acid fragments further include N-terminal deletions extending beyond the NLSs coding region and may also include C-terminal deletions. For example, the present inventors have generated a nucleic acid molecule encoding the cytoplasmic TIF2.1 polypeptide (amino acids 624 to 1287 in Figures 1 and 3 (SEQ ID NO: 2)), which, like the nuclear full-length TIF2, interacts in an agonist-dependent manner with the nuclear receptors and enhances nuclear receptor-mediated transcriptional activation. The present inventors have also generated a nucleic acid molecule encoding the cytoplasmic TIF2.5 polypeptide (amino acids 624-869 in Figures 1 and 3 (SEQ ID NO:2)), which interacts with the NID domain of nuclear receptors, but does not enhance transcription. Also generated were nucleic acids encoding the cytoplasmic TIF2.8 and TIF 2.12 polypeptides (amino acids 1010-1179 and amino acids 940-1131, respectively, in Figures 1 and 3 (SEQ ID NO:2), which enhance transcription, but do not bind to nuclear receptors. Thus, by the invention, nucleic acid molecules are provided encoding cytoplasmic TIF2 polypeptides that interact in an agonist-dependent manner with nuclear receptors and enhance nuclear receptor-mediated transcriptional activation. Also provided are cytoplasmic TIF2 polypeptides that bind to nuclear receptors, but do not enhance transcription as are provided cytoplasmic TIF2 polypeptides that enhance transcription, but do not bind to nuclear receptors. As the skilled artisan will recognize, the length of such nucleic acid molecules can vary.

Further embodiments of the invention include isolated nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 90% identical, and more preferably at least 95%, 96%, 97%, 98%, or 99% identical to: (a) the nucleotide sequence of the cDNA deposited as ATCC 97612; (b) the

nucleotide sequence shown in Figure 1 (SEQ ID NO:1); (c) the nucleotide sequence of the cDNA deposited as ATCC 97612 which encodes the full-length TIF2 protein; (d) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), which encodes the full-length TIF2 protein; (e) the nucleotide sequence of the cDNA deposited as ATCC 97612, which encodes the functional coactivator TIF2.1 protein; (f) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), which encodes the functional coactivator TIF2.1 protein; (g) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) which encodes the TIF2.0 polypeptide; (h) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) which encodes the TIF2.2 polypeptide; (i) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) which encodes the TIF2.3 polypeptide; (j) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) which encodes the TIF2.4 polypeptide; (k) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) which encodes the TIF2.5 polypeptide; (l) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) which encodes the TIF2.6 polypeptide; (m) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) which encodes the TIF2.7 polypeptide; (n) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) which encodes the TIF2.8 polypeptide; (o) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) which encodes the TIF2.9 polypeptide; (p) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) which encodes the TIF2.10 polypeptide; (q) the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) which encodes the TIF2.12 polypeptide; and (r) a nucleotide sequence complementary to any of the nucleotide sequences in (a-q).

Whether any two nucleic acid molecules have nucleotide sequences that are at least 90%, 95%, 96%, 97%, 98%, or 99% "identical" can be determined conventionally using known computer algorithms such as the "fastA" program using, for example, the default parameters (Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 (1988)). The present application is directed to such nucleic acid molecules having a nucleotide sequence at least 90%, 95%, 96%, 97%, 98%, 99%, identical to the nucleotide sequence of the above-recited nucleic

acid molecules irrespective of whether they encode a polypeptide having TIF2 activity. This is because, even where a particular nucleic acid molecule does not encode a polypeptide having TIF2 activity, one of skill in the art would still know how to use the nucleic acid molecule as a probe. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having TIF2 activity include, *inter alia*, (1) isolating the TIF2 gene or allelic variants thereof in a cDNA library; (2) *in situ* hybridization (FISH) to metaphase chromosomal spreads to provide precise chromosomal location of the TIF2 gene as described in Verma *et al.*, *Human Chromosomes: a Manual of Basic Techniques*, Pergamon Press, New York (1988); and Northern Blot analysis for detecting TIF2 mRNA expression in specific tissues, such as placenta tissue.

Preferred, however, are nucleic acid molecules having a nucleotide sequence at least 90%, and preferably at least 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of the above-described nucleic acid molecules which do, in fact, encode a polypeptide having at least one TIF2 protein activity. As used herein, "a polypeptide having a TIF2 protein activity" is intended to mean polypeptides exhibiting similar, but not necessarily identical, activity as at least one biological activity of the TIF2 protein as measured in a particular biological assay. For example, the TIF2 protein of the present invention interacts directly in an agonist-dependent manner with the ligand binding domains of several nuclear receptors. Moreover, when recombinantly expressed in mammalian cells, the TIF2 protein of the present invention enhances transcription via CBP-dependent and CBP-independent routes.

Thus, "a polypeptide having a TIF2 protein activity" includes polypeptides having one or more of the following activities: interaction with the LBD of one or more NRs in an agonist-dependent manner; enhancement of CBP-dependent transcriptional activation; or enhancement of CBP-independent transcriptional activation.

Screening assays for determining whether a candidate polypeptide has TIF2 protein activity are described in detail in Examples 1, 3, 4, and 6 below. For

example, by performing such assays, the present inventors have discovered that the functional coactivator fragment TIF2.1 (amino acids 624 to 1287 in Figures 1 and 3 (SEQ ID NO: 2)) is "a polypeptide having a TIF2 protein activity." The present inventors have also discovered that the fragment TIF2.5 (amino acids 624-869) binds to the LBD of NRs without activating transcription, and is "a polypeptide having a TIF2 protein activity." Also discovered was the fragment TIF2.2 (amino acids 1288-1464 as shown in Figure 1 (SEQ ID NO:2)), which enhances CBP-independent transcription. Thus, TIF2.2 is "a polypeptide having a TIF2 protein activity." Another fragment discovered by the inventors, TIF 2.8 (amino acids 1010-1179 as shown in Figure 1 (SEQ ID NO:2)) is a "polypeptide having a TIF2 protein activity" as it activates CBP-dependent transcription.

Due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a nucleotide sequence at least 90%, preferably at least 95%, 96%, 97%, 98%, 99% identical to the nucleotide sequence of the above-described nucleic acid molecules will encode "a polypeptide having a TIF2 protein activity." In fact, since degenerate variants all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described screening assays. It will be further recognized by those skilled in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having a TIF2 protein activity. This is because the skilled artisan is fully aware of possible amino acid substitutions that are either less likely or not likely to significantly affect protein function (*e.g.*, replacing one aliphatic amino acid with a second aliphatic amino acid).

Guidance concerning how to make phenotypically silent amino acid substitutions is provided, for example, in J.U. Bowie *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990), wherein the authors indicate that there are two main approaches for studying the tolerance of an amino acid sequence to change. The first method relies on the process of evolution, in which mutations are either

accepted or rejected by natural selection. The second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and selections or screens to identify sequences that maintain functionality. As the authors state, these studies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at a certain position of the protein. For example, most buried amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described in Bowie *et al.*, *supra*, and the references cited therein.

### *Vectors and Host Cells*

The present invention also relates to vectors which include the isolated DNA molecules of the present invention, host cells which are genetically engineered with the recombinant vectors, and the production of TIF2 polypeptides or fragments thereof, such as TIF2.1, by recombinant techniques.

Recombinant constructs may be introduced into host cells using well known techniques such infection, transduction, transfection, transvection, electroporation and transformation. The vector may be, for example, a phage, plasmid, viral or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged *in vitro* using an appropriate packaging cell line and then transduced into host cells.

Preferred are vectors comprising cis-acting control regions to the polynucleotide of interest. Appropriate trans-acting factors may be supplied by the

host, supplied by a complementing vector or supplied by the vector itself upon introduction into the host.

In certain preferred embodiments in this regard, the vectors provide for specific expression, which may be inducible and/or cell type-specific. Particularly preferred among such vectors are those inducible by environmental factors that are easy to manipulate, such as temperature and nutrient additives.

Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors, e.g., vectors derived from bacterial plasmids, bacteriophage, yeast episomes, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as cosmids and phagemids.

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiating AUG at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as CHO, Cos and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Illustrative examples of vectors preferred for use in bacteria include, but are not limited to, pA2, pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia. Preferred eukaryotic vectors include, but are not limited to, pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Among known bacterial promoters suitable for use in the present invention include the *E. coli* lacI and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR and PL promoters and the trp promoter. Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus ("RSV"), and metallothionein promoters, such as the mouse metallothionein-I promoter.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis *et al.*, *Basic Methods in Molecular Biology* (1986).

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, generally about 10 to 300 bp in size, that act to increase transcriptional activity of a promoter in a given host cell-type. Illustrative examples of enhancers include, but are not limited to, the SV40 enhancer, which is located on the late side of the replication origin at bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. The signals may be endogenous to the polypeptide or they may be heterologous signals.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions. Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification.

The TIF2 protein or fraction thereof can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention include, but are not limited to, naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be post translationally modified (e.g., glycosylated, phosphorylated, farnesylated, etc.). In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

### *TIF2 Polypeptides and Fragments*

The invention further provides an isolated TIF2 polypeptide having the amino acid sequence encoded by the deposited cDNA, or the amino acid sequence as shown in Figure 1 (SEQ ID NO:2), or a fragment thereof. Preferred polypeptide fragments will have a TIF2 protein activity. In order for a TIF2 polypeptide to interact in an agonist-dependent manner with nuclear receptors and to enhance nuclear receptor-mediated transcriptional activation, such TIF2 polypeptide fragments should at least include amino acid residues 624 to 1131 as shown in Figure 1 (SEQ ID NO:2) or amino acid substitutions, additions or deletions thereof that are not significantly detrimental to the polypeptides' ability to interact in an agonist-dependent manner with nuclear receptors and to enhance nuclear receptor-mediated transcriptional activation. In order for a TIF2 polypeptide fragment to interact with the LBD of an NR without activating transcription, the TIF2 polypeptide fragments should at least include amino acids 624-869 as shown in Figure 1 (SEQ ID NO:2), or amino acid substitutions, additions or deletions thereof that are not significantly detrimental to the polypeptides' ability to interact with the LBD of an NR. In order for a TIF2 polypeptide fragment to activate CBP-dependent transcription, the TIF2 polypeptide should at least include amino acid residues 1010-1131 as shown in Figure 1 (SEQ ID NO:2) or amino acid substitutions, additions or deletions thereof that are not significantly detrimental to the polypeptides' ability to activate CBP-dependent transcription. For a TIF2 polypeptide to activate CBP-independent transcription, the TIF2 polypeptide should at least include amino acid residues 1288-1464 as shown in Figure 1 (SEQ ID NO:2) or amino acid substitutions, additions or deletions thereof that are not significantly detrimental to the polypeptides' ability to activate CBP-independent transcription.

Exemplary TIF2 polypeptide fragments according to the present invention include cytoplasmic TIF2 polypeptides having at least one mutation or deletion in

a N-terminal NLS region that interferes with the nuclear localization function. Methods for generating cytoplasmic TIF2 polypeptides are described above.

As used herein, an "isolated" polypeptide or protein is intended to mean a polypeptide or protein removed from its native environment, such as recombinantly produced polypeptides and proteins expressed in host cells and native or recombinant polypeptides which have been substantially purified by any suitable technique (*e.g.*, the single-step purification method disclosed in Smith and Johnson, *Gene* 67:31-40 (1988), which is incorporated by reference herein). Isolated polypeptides or proteins according to the present invention further include such compounds produced synthetically.

The present inventors have discovered that the full-length TIF2 protein is an about 1464 amino acid residue protein with a deduced molecular weight of about 160 kDa. It will be recognized by those skilled in the art that some amino acid sequence of the TIF2 protein can be varied without significant effect on the structure or function of the protein. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the protein which determine activity, such as the region described above which has been determined by the inventors as being critical to the protein's ability to enhance nuclear receptor-mediated transcriptional activation. In general, it is often possible to replace residues which form the tertiary structure, provided that residues performing a similar function are used. In other instances, the type of residue may be completely unimportant if the alteration occurs at a non-critical region of the protein.

Thus, the present invention further includes variations of the TIF2 polypeptide which show substantial TIF2 polypeptide activity or which include regions of TIF2 protein such as the protein fragments discussed below. Such mutants include deletions, insertions, inversions, repeats, and type substitutions (for example, substituting one hydrophilic residue for another, but not strongly hydrophilic for strongly hydrophobic as a rule). Small changes or such "neutral" amino acid substitutions will generally have little effect on activity.

Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe and Tyr.

As indicated in detail above, further guidance concerning which amino acid changes are likely to be phenotypically silent (*i.e.*, not likely to have a significant deleterious effect on a function) can be found in Bowie *et al.*, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990).

The polypeptides of the present invention include polypeptides having an amino acid sequence as encoded by the deposited cDNA, an amino acid sequence as shown in SEQ ID NO:2, as well as an amino acid sequence at least 80% identical, more preferably at least 90% identical, and most preferably at least 95%, 96%, 97%, 98%, or 99% identical, to the amino acid sequence encoded by the deposited cDNA, to the amino acid sequence as shown in SEQ ID NO:2, or to the amino acid sequence of a polypeptide fragment described above. Whether two polypeptides have an amino acid sequence that is at least 80%, 90% or 95% identical can be determined using a computer algorithm as described above.

As described in detail below, the nucleic acid molecules and polypeptides of the present invention are useful in screening assays for identifying agonist and antagonist of NR AF2-mediated transactivation. For example, in Halachmi, S., *et al.*, *Science* 264: 1455 (1994), the authors show that tamoxifen, which has growth inhibitory effects in breast cancer, disrupts the formation of a complex that includes the estrogen receptor and ERAP160. Accordingly, the nucleic acid molecules and polypeptides of the present invention are useful in assays for identifying drugs capable of enhancing or inhibiting nuclear receptor-mediated pathways.

The nucleic acid molecules and polypeptides of the present invention are useful in screening assays for identifying agonists and antagonists of TIF2 AD1

activity, and in screening assays for identifying agonist and antagonists of TIF2 AD2 activity, as described in detail below.

### *Screening Methods*

5 Nuclear receptors (NRs) are members of a superfamily of ligand-inducible transcriptional regulatory factors that include steroid hormone, thyroid hormone, vitamin D3 and retinoid receptors (Leid, M., *et al.*, *Trends Biochem. Sci.* 17:427-433 (1992); Leid, M., *et al.*, *Cell* 68:377-395 (1992); and Linney, E. *Curr. Top. Dev. Biol.*, 27:309-350 (1992)). NRs exhibit a modular structure which reflects the existence of several autonomous functional domains. Based on amino acid  
10 sequence similarity between the chicken estrogen receptor, the human estrogen and glucocorticoid receptors, and the v-erb-A oncogene, Krust, A., *et al.*, *EMBO J.* 5:891-897 (1986), defined six regions, A, B, C, D, E and F (see Figure 6), which display different degrees of evolutionary conservation amongst various members of the nuclear receptor superfamily. The highly conserved region C  
15 contains two zinc fingers and corresponds to the core of the DNA-binding domain (DBD), which is responsible for specific recognition of the cognate response elements. Region E is functionally complex, since in addition to the ligand-binding domain (LBD), it contains a ligand-dependent activation function (AF-2) and a dimerization interface. An autonomous transcriptional activation function (AF-1)  
20 is present in the non-conserved N-terminal A/B regions of the steroid receptors. Interestingly, both AF-1 and AF-2 of steroid receptors exhibit differential transcriptional activation properties which appear to be both cell type and promoter context specific (Gronemeyer, H. *Annu. Rev. Genet.* 25:89-123 (1991)).

25 The all-*trans* (T-RA) and 9-*cis* (9C-RA) retinoic acid signals are transduced by two families of nuclear receptors, RAR  $\alpha$ ,  $\beta$  and  $\gamma$  (and their isoforms) are activated by both T-RA and 9C-RA, whereas RXR  $\alpha$ ,  $\beta$  and  $\gamma$  are exclusively activated by 9C-RA (Allenby, G. *et al.*, *Proc. Natl. Acad. Sci. USA* 90:30-34 (1993)). The three RAR types differ in their B regions, and their main

isoforms ( $\alpha 1$  and  $\alpha 2$ ,  $\beta 1-4$ , and  $\gamma 1$  and  $\gamma 2$ ) have different N-terminal A regions (Leid, M. *et al.*, *Trends Biochem. Sci.* 17:427-433 (1992)). Similarly, the RXR types differ in their A/B regions (Mangelsdorf, D.J. *et al.*, *Genes Dev.* 6:329-344 (1992)).

5           The E-region of RARs and RXRs has also been shown to contain a dimerization interface (Yu, V.C. *et al.*, *Curr. Opin. Biotechnol.* 3:597-602 (1992)). Most interestingly, it was demonstrated that RAR/RXR heterodimers bind much more efficiently *in vitro* than homodimers of either receptor to a number of RA response elements (RAREs) (Yu, V.C. *et al.*, *Cell* 67:1251-1266  
10 (1991); Berrodin, T. J. *et al.*, *Mol. Endocrinol* 6:1468-1478 (1992); Bugge, T. H. *et al.*, *EMBO J.* 11:1409-1418 (1992); Hall, R. K. *et al.*, *Mol. Cell. Biol.* 12: 5527-5535 (1992); Hallenbeck, P. L. *et al.*, *Proc. Natl. Acad. Sci. USA* 89:5572-5576 (1992); Husmann, M. *et al.*, *Biochem. Biophys. Res. Commun.* 187:1558-1564 (1992); Kliwer, S.A. *et al.*, *Nature* 355:446-449 (1992b); Leid, M. *et al.*,  
15 *Cell* 68:377-395 (1992); Marks, M. S. *et al.*, *EMBO J.* 11:1419-1435 (1992); Zhang, X. K. *et al.*, *Nature* 355:441-446 (1992)). RAR and RXR heterodimers are also preferentially formed in solution *in vitro* (Yu, V.C. *et al.*, *Cell* 67:1251-1266 (1991); Leid, M. *et al.*, *Cell* 68:377-395 (1992); Marks, M. S. *et al.*, *EMBO J.* 11:1419-1435 (1992)), although the addition of 9C-RA appears to enhance the  
20 formation of RXR homodimers *in vitro* (Lehman, J. M. *et al.*, *Science* 258:1944-1946 (1992); Zhang, X. K. *et al.*, *Nature* 358:587-591 (1992b)). That RAR-RXR heterodimers, rather than the corresponding homodimers, preferentially bind to RAREs in cultured cells *in vivo* has been strongly supported by experiments described in Durand, B. *et al.*, *Cell* 71:73-85 (1992).

25           As retinoic acid is known to regulate the proliferative and differentiative capacities of several mammalian cell types (Gudas, L.J. *et al.* (1994) In Sporn, M.B., Roberts, A.B. and Goodman, D.S.(eds), *The Retinoids*. 2nd edition, Raven Press, New York, pp. 443-520), retinoids are used in a variety of chemopreventive and chemotherapeutic settings. The prevention of oral, skin and head and neck  
30 cancers in patients at risk for these tumors has been reported (Hong, W. K. *et al.*,

*N. Engl. J. Med.* 315:1501-1505 (1986); Hong, W. K. *et al.*, *N. Engl. J. Med.* 323:795-801 (1990); Kraemer, K. H. *et al.*, *N. Engl. J. Med.* 318:1633-1637 (1988); Bollag, W. *et al.*, *Ann. Oncol.* 3:513-526 (1992); Chiesa, F. *et al.*, *Eur. J. Cancer B. Oral Oncol.* 28:97-102 (1992); Costa, A. *et al.*, *Cancer Res.* 54:Suppl. 7, 2032-2037 (1994)), and retinoids are used in the therapy of acute promyelocytic leukemia (Huang, M.E. *et al.*, *Blood* 72:567-572 (1988); Castaigne, S. *et al.*, *Blood* 76:1704-1709 (1990); Chomienne, C. *et al.*, *Blood* 76:1710-1717 (1990); Chomienne, C. *et al.*, *J. Clin. Invest.* 88:2150-2154 (1991); Chen Z. *et al.*, *Leukemia* 5:288-292 (1991); Lo Coco, F. *et al.*, *Blood* 77:1657-1659 (1991); Warrell, R. P., Jr. *et al.*, *N. Engl. J. Med.* 324:1385-1393 (1991)), squamous cell carcinoma of the cervix and the skin (Verma, A. K., *Cancer Res.* 47:5097-5101 (1987); Lippman S. M. *et al.*, *J. Natl Cancer Inst.* 84:235-241 (1992); Lippman S. M. *et al.*, *J. Natl Cancer Inst.* 84:241-245 (1992)) and Kaposi sarcoma (Bonhomme, L. *et al.*, *Ann. Oncol.* 2:234-235 (1991)).

For example, in Chen, J-Y *et al.*, *EMBO J.* 14(6):1187-1197 (1995), a number of dissociating synthetic retinoids are characterized that selectively induce AF-2 activation function present in the LBD of RAR $\beta$  ( $\beta$ AF-2). The authors also report that these synthetic retinoids, like RA, can inhibit the anchorage-independent growth of oncogene-transformed 3T3 cells. Further, the promoter of the human interleukin-6 (IL-6) gene, whose product is involved in the regulation of hematopoiesis, immune responses and inflammation (Kishimoto, T. *et al.*, *Science* 258:593-597 (1992)), is induced by RA but not by the 'dissociating' retinoids which repressed its activity.

In addition to the retinoid receptors, compounds with agonistic and antagonistic properties on functions of the steroid receptors have also been reported. For example, in Meyer, M-E. *et al.*, *EMBO J.* 9(12): 3923-3932 (1990), a transient expression/gel retardation system was used to study the effects of RU486 and R5020 on glucocorticoid and progesterone receptor function. Further, in Halachimi, S., *et al.*, *Science* 264:1455-1458 (1994), tamoxifen is

shown to competitively inhibit estradiol-induced ERAP160 binding to the estrogen receptor, suggesting a mechanism for its growth-inhibitory effects in breast cancer. Accordingly, due to their clinical importance, there is great interest in developing screening methods capable of identifying agonist and antagonist of nuclear receptor transactivation.

As indicated, the present inventors have cloned a gene encoding TIF2 and have shown that TIF2 and a cytoplasmic fragment thereof bind, in an agonist-dependent manner, to all nuclear receptors analyzed— RAR, RXR, ER, TR, VDR, GR and AR. Further, the present inventors have shown that TIF2 polypeptides are transcriptional mediators of the nuclear receptor AF-2. Thus, the present invention further provides a screening method for identifying a nuclear receptor (NR) antagonist, which involves: (a) providing a host cell containing recombinant genes which express a polypeptide comprising a NR ligand binding domain (LBD) and a polypeptide comprising transcriptional intermediary factor-2 (TIF-2) or a TIF-2-fragment, wherein, in the presence of an agonist, said TIF-2 and said TIF-2-fragment bind said NR LBD; (b) administering a candidate antagonist to said cell; and (c) determining whether said candidate antagonist reduces either: (1) TIF-2- or TIF-2-fragment-binding to the AF-2 of said NR LBD as compared to said binding in the absence of said candidate antagonist; or (2) TIF-2- or TIF-2-fragment-stimulated NR LBD AF-2-mediated transactivation as compared to said transactivation in the absence of said candidate antagonist.

In a further aspect, a screening method is provided for identifying a nuclear receptor (NR) agonist, which involves: (a) providing a host cell containing recombinant genes which express a polypeptide comprising a NR ligand binding domain (LBD) and a polypeptide comprising transcriptional intermediary factor-2 (TIF-2) or a TIF-2-fragment, wherein, in the presence of an agonist, said TIF-2 and said TIF-2-fragment bind said NR LBD; (b) administering a candidate agonist to said cell; and (c) determining whether said candidate agonist enhances either: (1) TIF-2- or TIF-2-fragment-binding to the AF-2 of said NR LBD as compared to said binding in the absence of said candidate agonist; or (2) TIF-2- or TIF-2-

fragment-stimulated NR LBD AF-2-mediated transactivation as compared to said transactivation in the absence of said candidate agonist.

By "a host cell containing recombinant genes" is intended host cells into which one or more of the recombinant constructs described herein have been introduced or a progeny of such host cells.

Candidate antagonist and agonist according to the present invention include 'dissociating' ligands for nuclear receptors such as those described in Chen *et al.*, *EMBO J.* 14:1187-1197 (1995) and Ostrowski *et al.*, *Proc. Natl. Acad. Sci. USA* 92:1812-1816 (1995). Progesterone and glucocorticoid receptor agonist and antagonist are described in Meyer *et al.*, *EMBO J.* 9 (12): 3923-3932 (1990). An estrogen receptor antagonist is described in Halachmi *et al.*, *Science* 264:1455-1458 (1994). Thus, methods are known in the art for developing candidate nuclear receptor agonist and antagonist for screening according to the present invention. For example, the crystal structure of the ligand binding domains of certain nuclear receptors have been described. In particular, the crystal structure of the RXR LBD is described in Bourguet *et al.*, *Nature* 375:377-382 (1995); the crystal structure of the RAR LBD is described in Renaud *et al.*, *Nature* 378:681-689 (1995); and the crystal structure of a thyroid hormone receptor is described in Wagner *et al.*, *Nature* 378:690-697 (1995). Using information from the crystal structure of a nuclear receptor, computer programs are available for designing the structure of candidate agonist and antagonist which would likely bind to the ligand binding domain. Suitable computer program packages for this purpose include WHAT IF (Vriend, G., *J. Mol. Graphics* 8:52-56 (1990)), and GRID (Goodford, *J. Med. Chem.* 28:849-857 (1985)).

Recombinant genes encoding a polypeptide comprising TIF2 or a TIF2-fragment capable of binding nuclear receptors in an agonist -dependent manner are described above. Recombinant genes encoding a polypeptide comprising a NR LBD have been described in great detail in the art. Methods for determining whether a candidate agonist or antagonist enhances or interferes with TIF-2 or TIF-2-fragment binding to a NR are known in the art. For example, the effect of

a candidate agonist or antagonist on TIF2- or TIF-2-fragment-binding to a NR LBD can be studied using glutathione-S-transferase (GST) interaction assays by tagging NR LBDs with GST as described in detail in the Experimental section below and in Le Douarin *et al.*, *EMBO J* 14:2020-2033 (1995).

5       Where the effect of a candidate agonist or antagonist on NR AF-2 transactivation is to be assayed, preferably, the recombinant genes will encode a chimeric polypeptide comprising a NR LBD fused to a DNA binding domain from a transactivator protein. In a further preferred embodiment, the host cell  
10       expressing the recombinant genes will also express a reporter gene. For example, in Chen *et al.*, *EMBO J.* 14(6):1187-1197 (1995), three 'reporter' cell lines have been established in which RAR $\alpha$ , RAR $\beta$ , or RAR $\gamma$  agonists induce luciferase activity that can be measured in the intact cells using a single-photon-counting camera. These cell lines stably express chimeric proteins containing the DNA  
15       binding domain of the yeast transactivator GAL4 fused to the EF regions (which contain that LBD and the AF-2 activation function) of RAR $\alpha$  (GAL-RAR $\alpha$ ), RAR $\beta$  (GAL-RAR $\beta$ ) or RAR $\gamma$  (GAL-RAR $\gamma$ ), and a luciferase reporter gene driven by a pentamer of the GAL4 recognition sequence ('17m') in front of the  $\beta$ -globin promoter (17mx5-G-Luc). This reporter system is insensitive to  
20       endogenous receptors which cannot recognize the GAL4 binding site. Further examples of reporter genes and reporter expression vectors for use according to the present invention to screen candidate agonist and antagonist of retinoid receptors are provided in Figure 6.

25       The ER expression vectors HEO, HE19 and HE15, the GR expression vectors HG1 and HG3 and the PR expression cPR1 and cPR3 are described in Kumar *et al.*, *Cell* 51:941-951 (1987) and Gronemeyer *et al.*, *EMBO J.* 6:3985-3994 (1987). The GR expression vector HG8 and the PR expression vector cPR5A are described in Bocquel *et al.*, *Nucl. Acids Res.* 17:2581-2595 (1989). Reporter genes for the above described ER, GR and PR expression vectors include MMTV-CAT (in the case of PR and GR; Cato *et al.*, *EMBO J.* 5:2237-

2240 (1986)) and vit-tk-CAT (in the case of ER; Klein-Hitpass *et al.*, *Cell* 41:1055-1061 (1986)).

The TR expression vector LexA-TR is described in Lee *et al.*, *Nature* 374:91-94(1995), which also describes using the yeast two hybrid system to identify compounds that affect TR transactivation.

Still further references disclosing reporter plasmids containing a reporter gene and expression vectors encoding a NR LBD include Meyer *et al.*, *Cell* 57:433-442 (1989); Meyer *et al.*, *EMBO J.* 9(12):3923-3932 (1990); Tasset *et al.*, *Cell* 62:1177-1187 (1990); Gronemeyer, H. and Laudet, V., *Protein Profile* 2:1173-1308 (1995); Webster *et al.*, *Cell* 54:199-207 (1988); Strähle *et al.*, *EMBO J.* 7:3389-3395 (1988); Seipel *et al.*, *EMBO J.* 11:4961-4968 (1992); and Nagpal *et al.*, *EMBO J.* 12:2349-2360 (1993). In a particularly preferred embodiment, the effect of a candidate agonist or antagonist on NR AF-2-mediated transactivation is assayed according to the method described in the legend to Figure 5 above.

The present inventors have identified an activation domain of TIF2, AD1 (amino acids 1010-1131 as shown in Figure 1 (SEQ ID NO:2)), which mediates the CBP-dependent transcriptional activation function of TIF2. Further, the present inventors have shown that polypeptides containing this activation domain, when fused to a DNA-binding domain of a transcriptional activator, is capable of activating transcription via a CBP-dependent pathway. Accordingly, the present invention further provides a screening method of identifying an agonist of TIF2 AD1 activation domain activity, which involves: (a) providing a host cell containing a recombinant gene or genes which express a polypeptide comprising a transcriptional activator DNA-binding domain (DBD) and a TIF-2 AD1 activation domain 1; (b) administering a candidate agonist to said cell; and (c) determining whether said candidate agonist enhances TIF2 AD1 activation domain activity.

The invention further provides for a screening method for identifying an antagonist of TIF2 AD1 activation domain activity, which comprises: (a)

providing a host cell containing a recombinant gene or genes which express a polypeptide comprising a transcriptional activator DNA-binding domain (DBD) and a TIF-2 AD1 activation domain 1; (b) administering a candidate antagonist to said cell; and (c) determining whether said candidate antagonist inhibits TIF2 AD1 activation domain activity.

By "transcriptional activator" it is meant molecules that enhance the initiation of transcription by RNA polymerase B (II). Transcriptional activators include yeast transcriptional activators, such as GAL4 and GCN4; the herpes simplex activator, VP16; and members of the nuclear receptor family, which includes RAR, RXR, ER, TR, VDR, GR, and AR.

Recombinant genes encoding a polypeptide comprising a TIF2 AD1 activation domain are described below. Recombinant genes encoding a polypeptide comprising a transcriptional activator DBD are well known in the art. Methods for determining whether a candidate agonist or antagonist enhances or interferes with transcription are well known in the art. For example, the effect of a candidate agonist or antagonist of TIF2 AD1 activation domain activity can be determined using CAT assays as described below and in Gronemeyer *et al.* (1987) and Bocquel *et al.*, *Nucl. Acids Res.* (1989).

Where the effect of a candidate agonist or antagonist of TIF2 AD1 activation domain activity is to be determined, preferably, recombinant genes will encode a chimeric polypeptide comprising a transcriptional activator DBD fused to a TIF2 polypeptide comprising the AD1 activation domain. In a further embodiment, the host cell expressing the recombinant genes will also express a reporter gene. Examples of reporter genes are described above. In a particularly preferred embodiment, the effect of a candidate agonist or antagonist of TIF2 AD1 activation domain function will be determined as described in the legend to Figure 7(c).

The present inventors have also identified a second activation domain of TIF2, AD2 (amino acids 1288-1464 as shown in Figure 1 (SEQ ID NO:2)), which mediates CBP-independent transcriptional activation. Further, the present

inventors have shown that polypeptides containing this activation domain, when fused to a DNA-binding domain of a transcriptional activator, are capable of activating transcription via a CBP-independent pathway. Accordingly, the present invention further provides a screening method for identifying an agonist of TIF2 AD2 activation domain activity, which comprises: (a) providing a host cell containing a recombinant gene or genes which express a polypeptide comprising a transcriptional activator DNA-binding domain (DBD) and a TIF-2 AD2 activation domain; (b) administering a candidate agonist to said cell; and (c) determining whether said candidate agonist enhances TIF2 AD2 activation domain activity.

The invention further provides for a screening method for identifying an antagonist of TIF2 AD2 activation domain activity, which comprises: (a) providing a host cell containing a recombinant gene or genes which express a polypeptide comprising a transcriptional activator DNA-binding domain (DBD) and a TIF-2 AD2 activation domain; (b) administering a candidate antagonist to said cell; and (c) determining whether said candidate antagonist inhibits TIF2 AD2 activation domain activity.

Recombinant genes encoding a polypeptide comprising a TIF2 AD2 activation domain are described below. Recombinant genes encoding a polypeptide comprising a transcriptional activator DBD are well known in the art. Methods for determining whether a candidate agonist or antagonist enhances or interferes with transcription are known in the art.

Where the effect of a candidate agonist or antagonist of TIF2 AD2 activation domain activity is to be determined, preferably, recombinant genes will encode a chimeric polypeptide comprising a transcriptional activator DBD fused to a TIF2 polypeptide comprising the AD2 activation domain. Transcriptional activators are described above. In a further embodiment, the host cell expressing the recombinant genes will also express a reporter gene. Examples of reporter genes are described above. In a particularly preferred embodiment, the effect of

a candidate agonist or antagonist of TIF2 AD2 activation domain activity will be determined as described in the legend to Figure 7(c).

### ***TIF-2 Antibodies and Methods***

5 TIF2 antibodies are also provided by the present invention, as specific for  
a TIF2 protein, a TIF2 polypeptide, a TIF2 protein fragment or a TIF2  
polypeptide fragment. The term "antibody" is meant to include polyclonal  
antibodies, monoclonal antibodies (mAbs), chimeric antibodies, anti-idiotypic  
10 (anti-Id) antibodies to antibodies that can be labeled in soluble or bound form, as  
well as fragments thereof provided by any known technique, such as, but not  
limited to enzymatic cleavage, peptide synthesis or recombinant techniques.  
Polyclonal antibodies are heterogeneous populations of antibody molecules  
derived from the sera of animals immunized with an antigen. A monoclonal  
antibody contains a substantially homogeneous population of antibodies specific  
15 to antigens, which population contains substantially similar epitope binding sites.  
MAbs may be obtained by methods known to those skilled in the art. See, for  
example Kohler and Milstein, *Nature* 256:495-497 (1975); U.S. Patent No.  
4,376,110; Ausubel et al, eds., *CURRENT PROTOCOLS IN MOLECULAR  
BIOLOGY*, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1987-1996);  
20 and Harlow and Lane *ANTIBODIES: A LABORATORY MANUAL* Cold Spring  
Harbor Laboratory (1988); Colligan et al., eds., *Current Protocols in  
Immunology*, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1992-  
1996), the contents of which references are incorporated entirely herein by  
reference.

25 Such antibodies may be of any immunoglobulin class including IgG, IgM,  
IgE, IgA, GILD and any subclass thereof. A hybridoma producing a mAb of the  
present invention may be cultivated *in vitro*, *in situ* or *in vivo*. Production of high

titers of mAbs *in vivo* or *in situ* makes this the presently preferred method of production.

Chimeric antibodies are molecules different portions of which are derived from different animal species, such as those having variable region derived from a murine mAb and a human immunoglobulin constant region, which are primarily used to reduce immunogenicity in application and to increase yields in production, for example, where murine mAbs have higher yields from hybridomas but higher immunogenicity in humans, such that human/murine chimeric mAbs are used. Chimeric antibodies and methods for their production are known in the art (Cabilly *et al.*, *Proc. Natl. Acad. Sci. USA* 81:3273-3277 (1984); European Patent Application 125023 (published November 14, 1984); Neuberger *et al.*, *Nature* 314:268-270 (1985); Taniguchi *et al.*, European Patent Application 171496 (1985); Morrison *et al.*, European Patent Application 173494 (1986); Neuberger *et al.*, PCT Application WO 86/01533, (1986); Kudo *et al.*, European Patent Application 184187 (1986); Morrison *et al.*, European Patent Application 173494 (1986); Robinson *et al.*, PCT Publication PCT/US86/02269 (1987); Liu *et al.*, *Proc. Natl. Acad. Sci. USA* 84:3439-3443 (1987); Sun *et al.*, *Proc. Natl. Acad. Sci. USA* 84:214-218 (1987); Better *et al.*, *Science* 240:1041- 1043 (1988); and Harlow and Lane, *ANTIBODIES: A LABORATORY MANUAL* Cold Spring Harbor Laboratory (1988)). These references are entirely incorporated herein by reference.

An anti-idiotypic (anti-Id) antibody is an antibody which recognizes unique determinants generally associated with the antigen-binding site of an antibody. An Id antibody can be prepared by immunizing an animal of the same species and genetic type (e.g., mouse strain) as the source of the mAb with the mAb to which an anti-Id is being prepared. The immunized animal will recognize and respond to the idiotypic determinants of the immunizing antibody by producing an antibody to these idiotypic determinants (the anti-Id antibody). See, for example, U.S. patent No. 4,699,880, which is herein entirely incorporated by reference.

5 The anti-Id antibody may also be used as an "immunogen" to induce an immune response in yet another animal, producing a so-called anti-anti-Id antibody. The anti-anti-Id may be epitopically identical to the original mAb which induced the anti-Id. Thus, by using antibodies to the idiotypic determinants of a mAb, it is possible to identify other clones expressing antibodies of identical specificity. The anti-Id mAbs thus have their own idiotypic epitopes, or "idiotopes" structurally similar to the epitope being evaluated, such as GRB protein- $\alpha$ .

10 The term "antibody" is also meant to include both intact immunoglobulin molecules as well as fragments thereof, such as, for example, Fab and F(ab')<sub>2</sub>, which are capable of binding antigen. Fab and F(ab')<sub>2</sub> fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody (Wahl et al., J. Nucl. Med. 24:316-325 (1983)). It will be appreciated that Fab and F(ab')<sub>2</sub> and other  
15 fragments of the antibodies useful in the present invention may be used for the detection and quantitation of a TIF2 according to the methods disclosed herein for intact antibody molecules. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments).

20 An antibody is said to be "capable of binding" a molecule if it is capable of specifically reacting with the molecule to thereby bind the molecule to the antibody. The term "epitope" is meant to refer to that portion of any molecule capable of being bound by an antibody which can also be recognized by that antibody. Epitopes or "antigenic determinants" usually consist of chemically active  
25 surface groupings of molecules such as amino acids or sugar side chains and have specific three dimensional structural characteristics as well as specific charge characteristics.

30 An "antigen" is a molecule or a portion of a molecule capable of being bound by an antibody which is additionally capable of inducing an animal to produce antibody capable of binding to an epitope of that antigen. An antigen

may have one, or more than one epitope. The specific reaction referred to above is meant to indicate that the antigen will react, in a highly selective manner, with its corresponding antibody and not with the multitude of other antibodies which may be evoked by other antigens.

5           The antibodies, or fragments of antibodies, useful in the present invention may be used to quantitatively or qualitatively detect a TIF2 protein, polypeptide, or fragment, in a sample or to detect presence of cells which express a TIF2 of the present invention. This can be accomplished by immunofluorescence techniques  
10           employing a fluorescently labeled antibody (see below) coupled with light microscopic, flow cytometric, or fluorometric detection.

          The antibodies (of fragments thereof) useful in the present invention may be employed histologically, as in immunofluorescence or immunoelectron microscopy, for *in situ* detection of a TIF2 protein, polypeptide, or fragment, of the present invention. In situ detection may be accomplished by removing a  
15           histological specimen from a patient, and providing a labeled antibody of the present invention to such a specimen. The antibody (or fragment) is preferably provided by applying or by overlaying the labeled antibody (or fragment) to a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of a TIF2 protein, polypeptide, or fragment, but  
20           also its distribution on the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of wide variety of histological methods (such as staining procedures) can be modified in order to achieve such in situ detection.

          Such assays for a TIF2 protein, polypeptide, or fragment, of the present  
25           invention typically comprises incubating a biological sample, such as a biological fluid, a tissue extract, freshly harvested cells such as lymphocytes or leukocytes, or cells which have been incubated in tissue culture, in the presence of a detectably labeled antibody capable of identifying a TIF2 protein, polypeptide, or fragment, and detecting the antibody by any of a number of techniques well-known in the  
30           art.

5 The biological sample may be treated with a solid phase support or carrier such as nitrocellulose, or other solid support or carrier which is capable of immobilizing cells, cell particles or soluble proteins. The support or carrier may then be washed with suitable buffers followed by treatment with a detectably labeled TIF2-specific antibody. The solid phase support or carrier may then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on said solid support or carrier may then be detected by conventional means.

10 By "solid phase support", "solid phase carrier", "solid support", "solid carrier", "support" or "carrier" is intended any support or carrier capable of binding antigen or antibodies. Well-known supports or carriers, include glass, polystyrene, polypropylene, polyethylene, dextran, nylon amylases, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support or carrier configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports or carriers include polystyrene beads. Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

20 The binding activity of a given lot of anti-TIF2 antibody may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation. Other such steps as washing, stirring, shaking, filtering and the like may be added to the assays as is customary or necessary for the particular situation.

25 One of the ways in which a TIF2-specific antibody can be detectably labeled is by linking the same to an enzyme and use in an enzyme immunoassay

30

(ELA). This enzyme, in turn, when later exposed to an appropriate substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or by visual means. Enzymes which can be used detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

Detection may be accomplished using any of a variety of other immunoassays. For example, by radioactivity labeling the antibodies or antibody fragments, it is possible to detect R-PTPase through the use of a radioimmunoassay (RIA). A good description of RIA maybe found in Laboratory Techniques and Bio chemistry in Molecular Biology, by Work, T.S. et al., North Holland Publishing Company, NY (1978) with particular reference to the chapter entitled "An Introduction to Radioimmune Assay and Related Techniques" by Chard, T., incorporated by reference herein. The radioactive isotope can be detected by such means as the use of a  $\gamma$  counter or a scintillation counter or by autoradiography.

It is also possible to label an anti-TIF2 antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can be then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

The antibody can also be detectably labeled using fluorescence emitting metals such as  $^{152}\text{Eu}$ , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriamine pentaacetic acid (EDTA).

5       The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, therrromatic  
10       acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is  
15       determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

An antibody molecule of the present invention may be adapted for utilization in a immunometric assay, also known as a "two-site" or "sandwich" assay. In a typical immunometric assay, a quantity of unlabeled antibody (or  
20       fragment of antibody) is bound to a solid support or carrier and a quantity of detectably labeled soluble antibody is added to permit detection and/or quantitation of the ternary complex formed between solid-phase antibody, antigen, and labeled antibody.

25       Typical, and preferred, immunometric assays include "forward" assays in which the antibody bound to the solid phase is first contacted with the sample being tested to extract the antigen from the sample by formation of a binary solid phase antibody-antigen complex. After a suitable incubation period, the solid support or carrier is washed to remove the residue of the fluid sample, including unreacted antigen, if any, and then contacted with the solution containing an  
30       unknown quantity of labeled antibody (which functions as a "reporter molecule").

After a second incubation period to permit the labeled antibody to complex with the antigen bound to the solid support or carrier through the unlabeled antibody, the solid support or carrier is washed a second time to remove the unreacted labeled antibody.

5 In another type of "sandwich" assay, which may also be useful with the antigens of the present invention, the so-called "simultaneous" and "reverse" assays are used. A "simultaneous" and "reverse" assays are used. A simultaneous assay involves a single incubation step as the antibody bound to the solid support or carrier and labeled antibody are both added to the sample being tested at the  
10 same time. After the incubation is completed, the solid support or carrier is washed to remove the residue of fluid sample and uncomplexed labeled antibody. The presence of labeled antibody associated with the solid support or carrier is then determined as it would be in a conventional "forward" sandwich assay.

In the "reverse" assay, stepwise addition first of a solution of labeled  
15 antibody to the fluid sample followed by the addition of unlabeled antibody bound to a solid support or carrier after a suitable incubation period is utilized. After a second incubation, the solid phase is washed in conventional fashion to free it of the residue of the sample being tested and the solution of unreacted labeled antibody. The determination of labeled antibody associated with a solid support or carrier is then determined as in the "simultaneous" and "forward" assays.  
20

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

### ***Example 1: TIF2 Cloning and Expression***

25 In keeping with previous reports (Halachmi, S. *et al.*, *Science* 264:1455-1458 (1994); Cavaillès, V. *et al.*, *Proc. Natl. Acad. Sci. USA* 91:10009-10013 (1994); Kurokawa, R. *et al.*, *Nature* 377:451-454 (1995)), we observed agonist-

dependent binding *in vitro* of a 160-kDa protein from <sup>35</sup>S-labelled whole cell extracts (HeLa, Cos-1, P19.6, MCF-7) to the glutathione-S-transferase (GST)-tagged LBDs of retinoic acid (RAR) and estrogen (ER) receptors (FIG. 2a). One cDNA clone, identified by screening 340,000 clones of a human placenta cDNA expression library with an estradiol (E2)-bound <sup>32</sup>P-labelled ER(DEF) probe, encoded a protein fragment (TIF2.1) that interacted on Far-Western blots with three different <sup>32</sup>P-labelled NR LBDs (ER, RAR, RXR) in an agonist-dependent manner (not shown), and could therefore correspond to the above 160-kDa protein. The TIF2 coding sequence (FIG. 3a), preceded by in-frame stop codons 5' of the initiator AUG, was obtained upon rescreening with a TIF2.1 cDNA probe. Human TIF2 cDNA encodes a 159,160 Da protein (1,464 amino acids), which includes N-terminal putative nuclear localization signals (NLSs), one Gln- and three Ser/Thr-rich regions, and two charged clusters (FIG. 3). Some regions of TIF2 show significant sequence similarities with the recently described (Onate, S.A. *et al.*, *Science* 270:1354-1357 (1995)) steroid receptor coactivator SRC-1 (FIG. 3). TIF2 appears to be widely expressed, since the corresponding transcript was found in several human tissues, albeit at a much lower level in kidney (FIG. 2c and not shown).

Immunodepletion studies strongly support that TIF2 is the 160-kDa protein species which interacts in an agonist-dependent manner with NR LBDs (see above and Halachmi, S. *et al.*, *Science* 264:1455-1458 (1994); Cavaillès, V. *et al.*, *Proc. Natl. Acad. Sci. USA* 91:10009-10013 (1994); and Kurokawa, R. *et al.*, *Nature* 377:451-454 (1995)). Western blotting with a rabbit antiserum (α-TIF2), raised against bacterially expressed TIF2.1, revealed predominantly a 160-kDa HeLa cell protein that interacted with agonist-bound GST-ER(DEF) (FIG. 2b, lanes 1 and 2; see also legend to FIG. 2b). Immunodepletion with a mouse monoclonal TIF2 antibody (mα-TIF2) prior to affinity purification resulted in a specific decrease of TIF2, but not TIF1 (Le Douarin, B. *et al.*, *EMBO J.* 14:2020-2033 (1995)) amounts, retained on E2-bound GST-ER(DEF) (FIG. 2b, compare lanes 2 with 4 and 6 with 8). Importantly, the subsequent Far-Western analysis

with an E2-bound  $^{32}\text{P}$ -GST-ER(DEF) probe revealed the 160-kDa species only in control, but not TIF2-immunodepleted extracts (FIG. 2b, compare lanes 10 and 12).

5 Transiently expressed full-length TIF2 was nuclear and mainly associated with discrete bodies (FIG. 4a). Since the overexpressed TIF2.1 fragment was essentially cytoplasmic (supporting the above assignment of a N-terminal TIF2 NLS), the interaction of TIF2.1 with NRs could be studied in mammalian cells using nuclear cotranslocation assays. In the absence of ligand, TIF2.1 remained cytoplasmic and NRs were nuclear (for RAR $\alpha$ , ER and PR, see FIGs. 4b, d, g).  
10 Agonist exposure, however, resulted in all three cases in nuclear colocalization of TIF2.1 and NR, indicating NR-TIF2 interaction *in vivo* (FIGs. 4c, e, h). Agonist-dependent interaction of TIF2.1 with NRs was observed for all other receptors analyzed (RXR, TR, VDR, GR and AR; not shown). Interestingly, no interaction was detected between ER and TIF2.1 in presence of the ER AF-2 antagonist hydroxytamoxifen (OHT) (FIG. 4f), and the PR AF-2 antagonist RU 486 reversed the R5020-induced PR-TIF2.1 interaction (FIG. 4i).  
15

In agreement with the Far-Western blot experiments NRs and TIF2 directly interacted, as purified TIF2.1 protein bound *in vitro* in the presence of an agonist to GST-ER(DEF), GST-RAR $\alpha$ (DEF), GST-RXR $\alpha$ (DE) and GST-TR(DE) (FIG. 4k, l, m, lanes 3 and 4; FIG. 4n, lanes 5 and 6). As expected, TIF2 binding to GST-RXR $\alpha$ (DE) occurred with 9*cis*-RA (9C-RA) but not all-*trans*-RA (T-RA) (FIG. 4n, lanes 1 and 2), and OHT prevented E2-dependent binding of TIF2 to GST-ER(DEF) (FIG. 4n, lanes 7-9). The integrity of the conserved core of the ER, RAR $\alpha$  and RXR $\alpha$  AF-2 activating domains (AF-2 AD) which was shown to be critical for AF-2 activity (Le Douarin, B. *et al.*, *EMBO J.* 14:2020-2033 (1995); Danielian, P.S. *et al.*, *EMBO J.* 11:1025-1033 (1992); Durand, B. *et al.*, *EMBO J.* 13:5370-5382 (1994); and Gronemeyer, H. and Laudet, V., *Protein Profile* 2:1173-1308 (1995), and therein), was required for TIF2 interaction *in vitro*. Most AF-2 AD core mutants which have lost AF-2 activity (ER, FIG. 4k, lanes 5-8; RAR $\alpha$ , FIG. 4l, lanes 5-10; RXR $\alpha$ , FIG. 4m,  
20  
25  
30

lanes 5-8) did not detectably, or only weakly, associate with TIF2, whereas the GST-LBD fusion of the RXR $\alpha$  mutant E461Q, whose AF-2 is only partially impaired (Le Douarin, B. *et al.*, *EMBO J.* 14:2020-2033 (1995)), still exhibited a significant RA-dependent interaction with TIF2.1 *in vitro* (FIG. 4m, lanes 9 and 10). No significant interaction of TIF2.1 was observed with either GST-VP16 (acidic activation domain), GST-TBP, GST-TFIIB, or a series of GST-TAFs (hTAF<sub>II</sub>18, hTAF<sub>II</sub>20, hTAF<sub>II</sub>28 and hTAF<sub>II</sub>55; see Jacq, X. *et al.*, *Cell* 79:107-117 (1994); Mengus, G. *et al.*, *EMBO J.* 14:1520-1531 (1995)) (not shown).

Conceptually, a TIF capable of mediating the transcriptional activity of a cognate AF to the transcription machinery, could itself be an activator when fused to a heterologous DNA-binding domain. Interestingly, in transiently transfected HeLa cells, TIF2.1 fused to the GAL4 DNA-binding domain strongly transactivated a GAL4 reporter (FIG. 5a). Thus, TIF2 may correspond to one of the hypothetical limiting factor(s) previously proposed to be involved in NR transcriptional interference/squelching (Meyer, M.-E. *et al.*, *Cell* 57:433-442 (1989); Bocquel, M.-T. *et al.*, *Nucl. Acids Res.* 17:2581-2595 (1989); Tasset, D. *et al.*, *Cell* 62:1177-1187 (1990)). Supporting this possibility, "anti-squelching" experiments showed that expression of TIF2.1 in ER-transfected cells could, at least partially, reverse the transcriptional autointerference (Bocquel, M.-T. *et al.*, *Nucl. Acids Res.* 17:2581-2595 (1989)) generated by expressing increased amounts of ER (FIG. 5b; note the marked shift of the bell-shaped activation curve to higher ER concentrations in the presence of TIF2.1). At high ER expression levels, the TIF2.1-stimulated transactivation decreased, possibly due to squelching of other putative mediators (Jacq, X. *et al.*, *Cell* 79:107-117 (1994); Lee, J.W. *et al.*, *Nature* 374:91-94 (1995); Le Douarin, B. *et al.*, *EMBO J.* 14:2020-2033 (1995); vom Baur, E. *et al.*, *EMBO J.* 15:110-124 (1996); Lee, J.W. *et al.*, *Endocrinology* 9:243-254 (1995); Cavaillès, V. *et al.*, *EMBO J.* 14:3741-3751 (1995); Onate, S.A. *et al.*, *Science* 270:1354-1357 (1995)) and/or transcriptional factors.

As expected, coexpression of TIF2.1 with antagonist-bound NR did not lead to any stimulation of the transactivation brought about by AF-1 in the presence of pure AF-2 antagonists (Berry, M. *et al.*, *EMBO J.* 9:2811-2818 (1990); Meyer, M.E. *et al.*, *EMBO J.* 9:3923-3932 (1990)), further supporting that TIF2 is AF-2-specific (FIG. 5b and 5e for ER, OHT; FIG. 5d for PR, RU486). TIF2 expression also increased AF-2/agonist-mediated transactivation by the androgen (AR) and progesterone (PR) receptors, but not transactivation by GAL-VP16 and GAL-AP2 (FIG. 5c). Under similar conditions, transactivation by GAL-RAR, GAL-RXR, GAL-VDR, GAL-TR and GAL-GR were unaffected by TIF2 (FIG. 5c, and not shown), suggesting that for these NRs either TIF2 is not critically involved in mediating their AF-2 activities or endogenous TIF2 amounts are sufficient to optimally support transactivation, for instance, because TIF2 has a higher affinity for these receptors. TIF2-stimulation is to some extent affected by the promoter environment of the responsive gene, as the TIF2 effect on PR/5020-induced transactivation was greater for a complex (MMTV) than for a minimal (GRE-TATA) promoter, although the latter was also reproducibly stimulated (FIG. 5d). As expected from the distinct levels of TIF2 transcripts in different tissues (FIG. 2c), the effect of TIF2 was cell type-dependent, since TIF2 had a much stronger effect on PR- and ER-induced transactivations in Cos-1 than in HeLa cells (FIGs. 5d, e).

Squelching (Meyer, M.-E. *et al.*, *Cell* 57:433-442 (1989); Bocquel, M.-T. *et al.*, *Nucl. Acids Res.* 17:2581-2595 (1989); Tasset, D. *et al.*, *Cell* 62:1177-1187 (1990)) and structural studies (Bourguet, M. *et al.*, *Nature* 375:377-382 (1995); Benaud, J.-P. *et al.*, *Nature* 378:681-689 (1995); Wagner, R.L. *et al.*, *Nature* 378:690-697 (1995); Wurtz, J.-M. *et al.*, *Nature Struct. Biol.* 3:87-94 (1996)) have supported a model in which binding of the ligand to the LBD of NRs results in conformational changes generating the surface(s) required for interaction with transcriptional intermediary factors (TIFs/mediators) which transduce the AF-2 activity to the transcription machinery. Conceptually such mediators should exhibit the following properties: (i) they should bind to agonist-, but not

antagonist-bound NR LBDs, (ii) their binding should be prevented by mutations abolishing AF-2 activity, (iii) they should collectively exhibit a transactivation function(s), (iv) their expression should relieve AF-2 autosquelching, and (v) their overexpression should stimulate the activity of AF-2, whenever they are present in limiting amounts. The present study is the first report of a *bona fide* mediator of NR AF-2s which exhibits all these properties.

### *Example 2: Production of TIF-2 Antibodies*

The following TIF2 antibodies were made using known techniques, unless otherwise specified below. See, e.g., Ausubel et al, eds., *CURRENT PROTOCOLS IN MOLECULAR BIOLOGY*, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1987-1996); Harlow and Lane *ANTIBODIES: A LABORATORY MANUAL* Cold Spring Harbor Laboratory (1988); and Colligan et al., eds., *Current Protocols in Immunology*, Greene Publishing Assoc. and Wiley Interscience, N.Y., (1992-1996), the contents of which references are incorporated entirely herein by reference.

***Polyclonal Antibodies.*** The TIF2.1 coding sequence (amino acids 624-1287) was cloned into pET15b and the resulting plasmid transformed into the *E. coli* strain BL21 (DE3). After overexpression of the (His)<sub>6</sub>-TIF2.1 protein the bacteria were lysed and the protein purified from the crude extract via affinity chromatography on a HiTrap chelating column (Pharmacia) as described (see Bourguet et al., *Prot. Expr. Purif.* 6:604-608 (1995) for technical details). Aliquots of the purified protein (50µg) in emulsion (Freund's Adjuvant) were injected (only once) into a New Zealand rabbit using a multisite intradermal injection protocol. Antisera obtained from serial bleeds revealed a single band of about 160 kDa on Western blots of extracts from Cos-1 cells transformed with a full length TIF2 expression vector.

***Monoclonal Antibodies.*** A 20mer amino-acid peptide of TIF2 (with an added C-terminal cysteine) was selected on the basis of its potential immunogenic

characteristics in terms of hydrophilicity, flexibility, surface probability and the 'antigenic index' according to software programmes Plot and Peptidestructure from the GCG package.

The chosen peptide corresponds to the N terminal fragment encoded by the TIF2 partial cDNA initially isolated (which encodes amino acids 624 to 1287) and corresponds to amino acids 624 to 643 of the total protein (SEQ ID NO:2):

ERADGQSRLHDSKGQTKLLQ(C) (SEQ ID NO:4)  
 624 643

The peptide was coupled to ovalbumin via the additional cysteine using the MBS heterobifunctional crosslinker. Injections were performed in BALB/c mice intraperitoneally and intravenously.

Spleen cells from the immunized mice were fused to the Sp2/0 Ag14 myeloma. Growing hybridomas were first screened by ELISA using the recombinant TIF2.1 protein and the free peptide. Positive cultures were then tested by immunocytofluorescence on Cos cells transfected with TIF2.1 (in the pSG5 vector) as well as by western blot using the transfected Cos cell extracts and HeLa nuclear extract. The positive cultures were also tested for their ability to immunoprecipitate the TIF2.1 protein from Cos transfected cells.

Cultures were cloned twice on soft agar. 5 hybridomas have been established, 4 secreting IgG<sub>1</sub>,  $\kappa$  and 1 IgG<sub>2a</sub>,  $\kappa$  antibodies, as shown in the Table:

Hybridoma	ELISA	Immuno fluoresc. (Cos)	Western blot (Cos)	Immuno precip. (Cos)
1Ti-1B6 (IgG <sub>1</sub> , $\kappa$ )	+	+	+	+
1Ti-1C9 (IgG <sub>1</sub> , $\kappa$ )	+	+	+	-
1Ti-1D8 (IgG <sub>1</sub> , $\kappa$ )	+	+	++	+
1Ti-1D12 (IgG <sub>1</sub> , $\kappa$ )	+	+	++	+
1Ti-1G3 (IgG <sub>2a</sub> , $\kappa$ )	+	+	++	+

### Example 3: Identification of TIF2 NID

All recombinant DNA work was performed according to standard procedures (Ausubel, F.M. *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York (1993)). GST-fusions of nuclear receptors were expressed from the following previously described plasmids: GST (pGEX2T; Pharmacia), GST-ER (pGEX2T-hER $\alpha$ (DEF), also called pGEX2THE14G, amino acids 282-595), GST-RXR (pGEX2T-mRXR $\alpha$ (DE), amino acids 205-467), and GST-RAR (pGEX2T-hRAR $\alpha$ (DEF), amino acids 153-462) (all LeDouarin, B. *et al.*, *EMBO J.* 14:2020-2033 (1995a)).

To further delineate the TIF2 NR interaction domain (NID), we studied the interaction between a series of TIF2 deletion mutants and the ER or RAR $\alpha$  LBDs, using GST-fusion protein-based *in vitro* assays. In both cases, an NID was mapped to the central region of TIF2 (amino acids 624-869 in mutant TIF2.5; see FIGS. 7a and b). No additional NID could be identified in the N- or C-termini of TIF2 (FIGS. 7a and b; mutants TIF2.0, TIF2.2 and TIF2.7). Note that, in contrast, SRC-1, a paralogue of TIF2, apparently harbours two distinct non-contiguous NIDs located in the central and C-terminal regions (Oñate, S.A. *et al.*, *Science* 270:1354-1357 (1995); Yao, T.P. *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10626-10631 (1996); Zhu, Y. *et al.*, *Gene Expression* 6:185-195 (1996)).

To further narrow down the TIF2 NID, TIF2.5 was C-terminally truncated to Pro775, yielding TIF2.34 which also interacted with ER and RAR $\alpha$  LBDs in a ligand-dependent manner (FIGS. 8a and c). Upon further truncation to Ser697, the resulting mutant still interacted with both ER and RAR $\alpha$  LBDs but, surprisingly, a ligand-dependent interaction was also found with TIF2.36 (FIGS. 8a and c), thus indicating that the TIF2 NID is composed of at least two autonomous NO-interacting modules.

An alignment of the TIF2 NID amino acid sequence present in TIF2.34 with the corresponding region of SRC-1 (Oñate, S.A. *et al.*, *Science* 270:1354-1357 (1995)) revealed three highly conserved regions (FIG. 8a). Interestingly, all

three contain the motif LxxLL (SEQ ID NO:12)(FIG. 8b), originally identified in the so-called "nuclear receptor box" (NR box) of TIF1 $\alpha$  as the LxxLLL (SEQ ID NO:13) motif, which was also present in RIP140 (Cavaillès, V. *et al.*, *EMBO J.* 14:3741-3751 (1995)) and TRIP3 (Lee, J.W. *et al.*, (1995)) (see LeDouarin, B. *et al.*, *EMBO J.* 15:6701-6715 (1996) and FIG. 8b). Importantly, 10-amino-acid sequences comprising the TIF1 $\alpha$  or RP140 NR boxes were sufficient for functional interaction with RXR in a ligand- and AF-2 AD-integrity-dependent manner, and mutation of the leucines at position 4 and 5 (LL $\rightarrow$ AA) of the TIF1 $\alpha$  LxxLLL (SEQ ID NO:13) motif abrogated TIF1 $\alpha$ -RXR interaction (LeDouarin, B. *et al.*, *EMBO J.* 15:6701-6715 (1996)). The functionality of the RIP140 NR box was recently confirmed (Heery, D.M. *et al.*, *Nature* 387:733-736 (1997)).

To investigate the functional significance of these three motifs in the TIF2 NID, the above LL $\rightarrow$ AA mutation was introduced in TIF2.1, either into each motif alone or in all possible combinations of the three motifs (TIF2.1m1 to m23 in FIG. 8a; numbers following "m" refer to the mutated motifs). Mutation of all three MR boxes was required to abrogate both the binding to ER, RAR $\alpha$  and RXR $\alpha$  (FIG. 8d, quantitation in FIG. 8e, white bars) and TIF2-dependent stimulation of ligand-induced transactivation by ER and RXR $\alpha$  AF-2s (FIG. 8e, black bars, and data not shown; in the case of RAR $\alpha$  AF-2 the stimulation was weak and was not quantified). TIF2.1 constructs in which two NR box motifs were mutated still exhibited ER binding and stimulation of AF-2 activity, in particular when the NR box motif II was intact, suggesting that the three NR box-containing modules are at least in part, functionally redundant (FIGS. 8d and e; TIF2.1m12, m13, and m23). This redundancy was obvious when only one NR box motif was mutated; in contrast to TIF1 $\alpha$ , which contains only one NR box (LeDouarin, B. *et al.*, *EMBO J.* 15:6701-6715 (1996)), mutation of a single TIF2 NR box did not abrogate ER binding and stimulation of ER AF-2 activity. All three mutants (TIF2.1m1 to m3) bound to ER and stimulated estradiol-dependent transactivation by the ER with similar efficiency as TIF2.1 itself (FIGS. 8d and e). In the case of RAR $\alpha$  and RXR $\alpha$  the mutations had, in general, a more

deleterious effect on receptor LBD binding and stimulation of AF-2 activity than in the case of ER (FIGS. 8d and e). This may possibly reflect a weaker interaction between TIF2 and either RAR $\alpha$  or RXR $\alpha$  than with ER. However, in spite of exhibiting in general a lower activity, the patterns of NR binding and stimulation of AF-2 activity of the NR box mutants were similar for ER and RAR $\alpha$  and RXR $\alpha$ , as mutation of motif II was always more detrimental in double mutants than mutation of motifs I and III (see FIG. 8e). Importantly, for both ER and RXR $\alpha$  there was a good correlation between the effect of any of the various mutations on TIF2.1-receptor binding *in vitro* and TIF2.1-mediated stimulation of AF-2 activity (FIG. 8e), supporting a mechanism whereby the stimulation of AF-2 activity by TIF2 involves TIF2-NO interaction through NR holo-LBD-TIF2 NR box interface(s).

Our present structure-function analysis reveals that TIF2 contains a single nuclear receptor-interaction domain (NID). Note in contrast to the other TIF2 family member, SRC-1, which was reported to contain two NIDs (Oñate, S.A. *et al.*, *Science* 270:1354-1357 (1995); Yao, T.P. *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10626-10631 (1996); Zhu, Y. *et al.*, *Gene Expression* 6:185-195 (1996)). Note, however, that one of the two SRC-1 NID is most probably homologous to the TIF2 NID characterized here (see FIG. 8a). The TIF-2 NID is composed of three modules, and each can bind independently in a ligand-dependent manner to the NRs tested in this study. Interestingly, these modules contain the NR box motif LxxLL (SEQ ID NO:12), which was originally recorded (as the motif LxxLLL (SEQ ID NO:13), FIG. 8b) within a 10 amino acid NR binding module of TIF1 $\alpha$  which was found to be conserved in the NID of RIP140 and also present in TRIP3 (LeDouarin, B. *et al.*, *EMBO J.* 15:6701-6715 (1996) and refs therein). Moreover, the TIF1 $\alpha$  and RIP140 modules were shown to functionally interact with NRs (LeDouarin, B. *et al.*, *EMBO J.* 15:6701-6715 (1996)). The implication of NR box motifs in NO-coactivator binding and their presence in a number of different coactivators was pointed out in recent reports (Heery, D.M. *et al.*, *Nature* 387:733-736 (1997); Torchia, J. *et al.*, *Nature* 387:677-684 (1987);

LeDouarin, B. *et al.*, *EMBO J.* 15:6701-6715 (1996)). Note that all three TIF2 NR box motifs described here are conserved in the recently discovered TIF2 paralogue p/CIP (Torchia, J. *et al.*, *Nature* 387:677-684 (1987)). In contrast to TIF1 $\alpha$ , for which mutation of leucines at positions 4 and 5 to alanine of its single NR box motif (LL $\rightarrow$ AA) abrogates NR binding, mutation of all three motifs are required in the TIF2 NID to abrogate NR binding, indicating that each of these motifs can contribute to a TIF2 surface that interacts with a cognate surface of NR holo-LBDs. That the NR boxes of TIF2 exhibit functional redundancy is supported by the observation that the LL $\rightarrow$ AA mutation in any of the three TIF2 NID motifs apparently did not (in the case of the ER) or only weakly (in the case of RAR $\alpha$ , RXR $\alpha$ ) reduce the efficiency of NR interaction. Moreover, in the TIF2.1 environment, any single intact NR box motif on its own (i.e., when the two other motifs were mutated) was sufficient for interaction with the holo-ER LBD, although only motif II on its own could bring about a nearly wild-type NR binding efficiency. In contrast, for RAR $\alpha$  and RXR $\alpha$  interaction, mutants with single intact NR boxes were 5 (box II) to 20 (box I or III) times less efficient than the wild-type TIF2 containing the three NR boxes. Crystallography studies will be necessary to distinguish between two possible models, in which the three NR box motifs (i) contribute to the formation of a tripartite NID surface that specifically recognizes a cognate holo-NO LBD surface, or (ii) belongs to independent surfaces which each can interact, albeit with different efficiencies, with the same holo-NO surface. Note, however, that the second model could allow TIF2 to interact cooperatively with both partners of NR homo- or heterodimers, thus rendering transactivation by NRs sensitive to small variations in TIF2 levels. Note also that, for both ER and RXR $\alpha$ , the effects of NR box mutations on NR binding and stimulation of AF-2 activity were correlated, further supporting the conclusion that the transcriptional effect of TIF2 involves the formation of a NR box-NO LBD interaction interface.

The motif LxxLL (SEQ ID NO:12) has been found in a number of other NR coactivators (see above), thus suggesting some similarity in the mode of NO-

coactivator interactions. However, this does not exclude NO-specific modulation of these interactions, as the NR box surrounding sequences are highly variable. In this respect, note also that TIF2 NR boxes II and III are predicted to form  $\alpha$ -helices, while NR box I is predicted to fold into a  $\beta$ -sheet structure (structure predictions according to SOPMA; Geourjon and Deleage, 1994).

***Example 4: Identification of the AD1 and AD2 activation domains of TIF2***

Transient transfection assays with a GAL4 reporter plasmid and chimeras containing various TIF2 fragments linked to the GAL4 DNA binding domain (DBD) demonstrated the presence of two autonomous transcriptional activation domains in the C-terminal 460 amino acids of TIF2, termed AD1 and AD2 (delineated by mutants TIF2.8, TIF2.12 and TIF2.2 in FIGS. 7a and c). Transient transfections of HeLa and Cos-1 cells were performed as described (Gronemeyer *et al.*, (1987); Bocquel, M.T. *et al.*, *Nucl. Acids Res.* 17:2581-2595 (1989)).

The N-terminal AD1 (amino acids 1010-1131), which is present in TIF2.1, showed a stronger activity than the C-terminal AD2 (amino acids 1288-1464) (compare TIF2.8 and TIF2.12 with TIF2.2 in FIGS. 7a and c). Note, however, that the weaker activity of AD2 (relative to AD1) could be due to a lower expression level of the GAL-TIF2.2 fusion protein (compare with GAL-TIF2.8 and GAL-TIF2.12 in FIG. 7c). Both TIF2 activation functions were active in Cos-1 and HeLa cells (FIG. 7c). Notably, the minimal AD1 (TIF2.8) and AD2 (TIF2.2) constructs exhibited some cell-specific activities, as GALTIF2.8 was more active in HeLa than in Cos cells, whereas the opposite was observed for GAL-TIF2.2 (FIG. 7c). Interestingly, the glutamine-rich region of TIF2 could neither activate transcription on its own when fused to the GAL4 DBD (FIGS. 7a and c; mutant TIF2.6), nor was it required for transcriptional activation by AD1 or AD2. No activation function could be detected in the N-terminal part of TIF2 (see FIGS. 7a and c; mutant TIF2.0).

We conclude from these data that the nuclear receptor interacting domain (NID) and the two transcriptional activation functions of TIF2 correspond to distinct modular domains, since TIF2.5 can bind to NRs, but cannot activate transcription, whereas TIF2.2 and TIF2.8 cannot bind NRs but are able to activate transcription (FIG. 7a).

***Example 5: Characterization of the TIF2 AD1 and AD2 activation domains***

Recently CBP and p300, originally identified as coactivators of the transcription factor CREB, were shown to act as general integrators of multiple signaling pathways, including activation via agonist-bound RAR $\alpha$  and TR (for reviews and refs see Eckner, R., *Biol. Chem.* 377:685-688 (1996); Janknecht & Hunter, (1996); Glass, C.K. *et al.*, *Current Opin. Cell Biol.* 9:222-232 (1997); Shikama, N. *et al.*, *Trends in Cell Biol.* 7:230-236 (1997)). Furthermore, it was reported that SRC-1, which belongs to the same gene family as TIF2, interacts with CBP and p300 (Kamei, Y. *et al.*, *Cell* 85:403-414 (1996); Yao, T.P. *et al.*, *Proc. Natl. Acad. Sci. USA* 93:10626-10631 (1996); Hanstein, B., *et al.*, *Proc. Natl. Acad. Sci. USA* 93:11540-11545 (1996)). Using GST-fusion protein-based interaction and animal cell-based two hybrid assays, we therefore analyzed whether TIF2 could also interact with CBP. In the two hybrid system only the central TIF2.1 fragment, but not the N-terminal TIF2.0 or the C-terminal TIF2.2 fragments (FIG. 7a), scored positive for interaction with GAL-CBP (containing amino acids 1872-2165 of CBP, which encompass the SRC-1 interacting domain of CBP; FIG. 7e). A GST-CBP fusion protein was expressed in *E. coli* and used for pull-down assays with *in vitro* translated TIF2 polypeptides (FIG. 7d). TIF2 did interact with CBP and, interestingly, the CBP-interacting domain (CID) apparently overlapped the AD1 activation domain of TIF2 (compare FIGS. 7a, c and d; mutants TIF2.8 and TIF2.12). The interaction of TIF2 with CBP was direct, as a purified *E. coli*-expressed TIF2.1 protein also interacted with GST-

CBP (data not shown). Only this region of TIF2 interacted significantly with the GST CBP fusion protein, thus suggesting that the TIF2 AD1 activity may originate from the recruitment of CBP. Purger N-terminal regions (FIGS. 7a and d; mutants TIF2.10 and TIF2.4) or the C-terminal AD2 activation domain (FIGS. 7a and d; mutant TIF2.2) did not show any binding to GST-CBP. Note that TIF2.2 also did not interact with full-length CBP (data not shown), suggesting that the activity of TIF2 AD is mediated by (a) factor(s) distinct from CBP.

To investigate whether the CID of TIF2 could be separated from the AD1 activation domain, the ability of a series of GAL-TIF2 truncation mutants to activate a GAL4-reporter was compared with their ability to interact with the GST-CBP protein *in vitro* (FIG. 9). TIF2.13 (which encompasses Pro<sub>1011</sub> to Ser<sub>1122</sub>) exhibited a potent transcriptional activity, comparable to that of larger TIF2 fragments (compare FIGS. 7 and 9). Removal of 26 C-terminal (TIF2.15) or 20 N-terminal (TIF2.18) amino acid residues reduced transcriptional activity only weakly (FIGS. 9a and b). Note that TIF2.13 also interacted with CBP *in vivo*, as shown by using a two hybrid assay in transfected mammalian cells (FIG. 10b).

While the internal deletion of residues Asp<sub>1061</sub> to Ala<sub>1070</sub> (TIF2.19) had only a minor effect on the ability of TIF2.13 to transactivate, deletion of the Glu<sub>1071</sub> to Leu<sub>1080</sub> segment (mutant TIF2.20) significantly reduced TIF2 AD1 transcriptional activity. Notably, these residues belong to a sequence predicted to fold into an amphipathic  $\alpha$ -helical structure which is highly conserved between TIF2 and SRC-1 (FIG. 9a). The involvement of this region in transactivation was confirmed by analysis of mutants TIF2.21 to TIF2.32 (FIGS. 9a and b). All constructs containing the TIF2 wild-type sequence from Asp<sub>1075</sub> to Leu<sub>1087</sub> stimulated transcription, whereas even a deletion of only some of these residues significantly reduced transcriptional activation. However, on its own this  $\alpha$ -helical peptide transactivated very poorly, and had to be incorporated into additional upstream and/or downstream TIF2 sequences to generate significant transcriptional activity (FIGS. 9a and b; compare mutants TIF2.13, TIF2.21 and TIF2.32). Importantly,

in all cases ADD activity coincided with CBP interaction, since transcriptionally inactive constructs did not interact with CBP (TIF2.24, TIF2.27 and TIF2.29 in FIGS. 9a-c), while transcriptionally active mutants also bound CBP. Moreover, the strength of the *in vitro* interaction with GST-CBP apparently correlated with transactivation efficiency (FIGS. 9a-c; e.g., compare TIF2.21 and TIF2.31).

To investigate whether the integrity of the putative amphipathic  $\alpha$ -helical region is required for both AD1 transcriptional activity and interaction with CBP, we introduced point mutations into TIF2.13; the three conserved hydrophobic Leu or the hydrophilic Asp-Glu residues were converted to alanines [FIG. 9a; TIF2.13(LL) and TIF2.13(DQ)]. Interestingly, mutation of the three leucine residues almost completely abolished AD1 activity, whereas mutation of the Asp-Glu sequence had very little, if any effect (FIG. 10a). Again, AD1 activity and interaction with CBP *in vitro* (FIG. 10c), as well as *in vivo* (FIG. 10b), were strictly correlated, since GAL-TIF2.13(DQ), which transactivated as efficiently as wild type GAL-TIF2.13, interacted strongly with CBP, whereas the transcriptionally inactive GAL-TIF2.13(LL) interacted very weakly with CBP. Together these results indicate that (i) CBP mediates the AD1 activity of TIF2, (ii) a putative amphipathic  $\alpha$ -helix motif located within the AD1 domain is critically involved in, but not sufficient for, efficient CBP binding/transactivation and (iii) the amphiphilicity of this motif is not required for AD1 activity and CBP binding.

The two TIF2 activation functions AD1 and AD2 apparently operate through different transcriptional activation cascades. While the TIF2 AD1 activation domain could not be separated by mutational analysis from the TIF2 domain which interacts *in vitro* and *in vivo* with a region of the CBP surface which also mediates SRC-1 binding (Kamei, Y. *et al.*, *Cell* 85:403-414 (1996)), neither this region, nor full length CBP, interacted with TIF2 AD2. That the two TIF2 activation functions may operate through distinct pathways is also suggested by the differential cell specificity of the minimal fragments exhibiting AD1 activity (e.g., TIF2.8, TIF2.7, TIF2.9, TIF2.12) and AD2 activity (TIF2.2). While TIF2.2

is more active in Cos-1 than in HeLa cells, all of the minimal fragments containing AD1 are more active in HeLa cells. Along the same lines, removal in TIF2.3 of sequences N-terminal of TIF2.8 resulted in a 10-fold and 2-fold increased transactivation in HeLa and Cos-1 cells, respectively, and removal in TIF2.1 of sequences C-terminal of TIF2.3 gave a 9-fold and 3-fold higher transactivation in HeLa and Cos-1 cells, respectively. This suggests that the deleted sequences could exert either intra- or intermolecular repression on TIF2 AD1 activity/CBP interaction. In addition, the coactivator activity of TIF2 may be cell-specifically modulated by the differential efficiency of its two ADs and factors interacting with the sequences N- and C-terminally of the AD1 activation function.

It is worth noting that the core of AD1 (TIF2.32) on its own is a very poor transactivator and CBP binder, and requires additional surrounding sequences to generate a fully active (i.e., efficient CPB binding) surface. However, mutational analysis of the AD1 core in the context of a strong activator fragment (TIF2.13) reveals the critical importance for transactivation and CBP binding *in vivo* and *in vitro* of three leucine residues (FIG. 10). These leucines belong to a conserved LLxxLxxL (SEQ ID NO:14) motif in all three members of the TIF2 coactivator family (FIG. 9a; Torchia, J. *et al.*, *Nature* 387:677-684 (1987)) which is distinct from the LxxLL (SEQ ID NO:12) NR box motif. Notably, although these leucines are embedded in a predicted amphipathic  $\alpha$ -helix, the amphiphilicity is not required for function, since a mutation of the hydrophilic residues (compare TIF2.13 with TIF2.13 (DQ)) does not affect transactivation/CBP binding.

TIF2 can apparently fulfill at least two mediator functions, (i) as a "bridging factor" between the AF-2 function of nuclear receptors and CBP via its AD1 activation domain and (ii) as a transcriptional mediator through as yet unknown CBP binding-independent route(s) via its AD2 function. Presently, we have no evidence that TIF2 could possess an intrinsic enzymatic activity; none of the bacterially-expressed purified TIF2 fragments, in particular TIF2.1 which was shown to be fully competent in NR and CBP interactions *in vitro*, exhibited any

histone acetylase activity under conditions where bacterially-expressed purified yeast GCN5 was highly active (our unpublished results).

***Example 6: TIF2 enhancement of NR AF-2 activity***

5 The observation that animal transcriptional activators, such as the human ER (Metzger, D. *et al.*, *Nature* 334:31-36 (1988)), are also active in the yeast *Saccharomyces cerevisiae* demonstrated that the basic principles of transcriptional enhancement have been conserved from yeast to man. We therefore investigated whether TIF2 could enhance transcriptional activation by various NR constructs expressed in *S. cerevisiae*. Both, NRs and TIF2.1 were expressed from multicopy  
10 plasmids in the yeast strain PL3( $\alpha$ ), which contains a URA3 reporter gene under the control of three estrogen response elements ((ERE)<sub>3</sub>-URA3; Pierrat, B. *et al.*, *Gene* 119:237-245 (1992)).

In yeast, the hER $\alpha$  constructs were expressed from the following YEp90-based plasmids: HEGO (hER $\alpha$ , YEp90-HEG0, amino acids 1-595), HE15  
15 (YEp90-HE15, amino acids 1-282), and HEG19 (YEp90-HEG19, amino acids 179-595) (all Pierrat, B. *et al.*, *Gene* 119:237-245 (1992)), HE179-338 (YEp90-HE179-338; Pierrat, B. *et al.*, *Gene* 143:193-200 (1994)). From the yeast multicopy plasmid pBL1 (LeDouarin, B. *et al.*, *Nucleic Acids Res.* 23:876-878 (1995b)), which codes for ER(F)-epitope-tagged ER(C)-fusions, the following  
20 plasmids were expressed: ER(C)-RAR(DEF) (pBL1-hRAR $\alpha$ (DEF), amino acids 154-462) and ER(C)-RXR(DE) (pBL1-mRXR $\alpha$ (DE), amino acids 205-467) (both vom Baur, E. *et al.*, *EMBO J.* 15:110-124 (1996)). TIF2 was expressed in yeast from the multicopy plasmid pAS3 (gift from B.LeDouann), which is a derivative of YEp90 containing the *LEU2* marker. Yeast PL3( $\alpha$ ) (Pierrat, B. *et al.*, *Gene*  
25 119:237-245 (1992)) transformants were grown exponentially in the presence or absence of ligand for about five generations in selective medium containing uracil. Yeast extracts were prepared and assayed for OMP decase activity as described previously (Pierrat, B. *et al.*, *Gene* 119:237-245 (1992)).

As expected from previous studies (Metzger, *Nucl. Acids Res.* (1992); Pierrat, B. *et al.*, *Gene* 119:237-245 (1992); Pierrat, B. *et al.*, *Gene* 143:193-200 (1994)) the full length ER (HEG0) induced orotidine 5'-monophosphate decarboxylase (OMP Decase) activity in a ligand-dependent manner (FIG. 11, lanes 1 and 3). Interestingly, the transcriptional activity of ER was further enhanced by coexpression of the TIF2.1 fragment (FIG. 11, compare lanes 3 and 4). In the absence of hormone, TIF2.1 had no significant effect on ER-induced transcriptional activation (FIG. 11, compare lanes 1 and 2). Essentially the same results were observed for HEG19 which is devoid of the N-terminal region A/B, indicating that TIF2 exerts its effect on the ligand-dependent ER AF-2 (FIG. 11, lanes 5-8). In contrast, neither the AF-1 activity of HE15, (which encompasses the ER regions A, B and C; Kumar & Chambon, *Cell* 55:145-156 (1988)), nor the AF-2a activity of the HE179-338 construct (Pierrat, B. *et al.*, *Gene* 143:193-200 (1994)) were stimulated by coexpressing TIF2.1 (FIG. 11, lanes 9-12). This is in agreement with the results obtained in mammalian cells, and with the observation that an intact LBD is required for TIF2.1 to interact with the ER (Voegel, J.J. *et al.*, *EMBO J.* 15:3667-3675 (1996)).

TIF2.1 also stimulated the AF-2 activity of the liganded RXR $\alpha$ (DEF) region in yeast (FIG. 11, compare lanes 19 and 20). This enhancement was ligand-dependent; no activation via the RXR $\alpha$ (DEF) region was observed when the ER(C)-RXR $\alpha$ (DEF) chimera was coexpressed with TIF2.1 in the absence of ligand (FIG. 11, compare lanes 18 and 20). Again these observations parallel those made in HeLa and Cos-1 cells (see FIG. 12c).

Surprisingly, even in the absence of ligand, and in contrast with the observations made with ER and RXR $\alpha$ , TIF2.1 very efficiently enhanced transactivation by the RAR $\alpha$  LBD (FIG. 11, lanes 13 and 14). The addition of retinoic acid further increased this transcriptional activation (FIG. 11, lanes 14 and 16). Note that, as previously reported (Heery, D.M. *et al.*, *Nature* 387:733-736 (1997)), both RAR $\alpha$  and RXR $\alpha$  AF-2 on their own poorly activated transcription from the URA3 reporter.

5 The enhancement of AF-2 activity which was particularly strong in yeast cells, has also been recently observed for GRIP1, the mouse homologue of TIF2 (Hong, H. *et al.*, *Mol. Cell. Biol.* 17:2735-2744 (1997)). These observations suggest that yeast cells contain coactivators which only poorly mimic the action of the mammalian NR coactivators. As yeast cells apparently do not contain a CBP homologue, it will be interesting to investigate which yeast factor mediates the activity of TIF2. Note in this respect that GAL-TIF2.1 is a strong transactivator in yeast (our unpublished results).

10 Interestingly, the expression of TIF2 in yeast led to a marked stimulation of transactivation by the unliganded ER(C)-RAR $\alpha$ (DEF), which was not observed with ER or RXR $\alpha$  unliganded LBDs. Structural studies have revealed that binding of the ligand results in a conformational change of the LBD, which generates the surface(s) for coactivator binding (Renaud, J.P. *et al.*, *Nature* 378:681-689 (1995)). Our present result, therefore, suggests that a high level of coactivators might in the absence of ligand drive the LBD of some receptors into a holo-LBD-like conformation, thus giving rise to ligand-independent transcriptional activity. By analogy, one could speculate that high levels of corepressors could "lock" NR LBDs in the apo-LBD conformation. It would therefore be interesting to investigate whether levels of coregulators might lead to constitutive activity (even in the presence of antagonists) or conversely to lack of inducibility of nuclear receptors in some pathological states.

#### ***Example 7: TIF2 NID inhibition of NR AF-2 activity***

25 Overexpression of the TIF2.1 fragment, which contains both the NID and AD1 activation function, stimulates the ER AF-2 activity of the ER LBD transiently in Cos-1 cells (FIG. 12a, lanes 2 and 3; Voegel, J.J. *et al.*, *EMBO J.* 15:3667-3675 (1996)). That this stimulation was due to a direct interaction between the ER LBD and the NID of TIF2, was strongly suggested by the observation that overexpression of the TIF2.5 mutant which contains the isolated

NID, but lacks AD1 (see FIG. 7a) prevented the stimulatory effect of TIF2.1 (FIG. 12a, compare lanes 3 and 4). Note that in the absence of TIF2.1, TIF2.5 overexpression also decreased the transactivation by the ER AF-2 which was presumably mediated through Cos-1 endogenous coactivators (FIG. 12a, compare lane 4 with lane 2), thus suggesting that these Cos-1 mediators either correspond to endogenous TIF2s, or interact with the ER holo-LBD through surfaces which are identical to, or in direct vicinity of, the TIF2 NID interaction surface.

We previously reported an agonist-dependent interaction of TIF2 with RAR and RXR LBDs, which was dependent on the integrity of the NR AF-2 AD core, but failed to observe a stimulatory effect of TIF2 on the transcription activation of a (17m)<sub>5</sub>-Globin-promoter-CAT reporter by GAL-RAR LBD or GAL-RXR LBD fusion proteins (Voegel, J.J. *et al.*, *EMBO J.* 15:3667-3675 (1996)). Since this failure was likely to be due to the presence of sufficient amounts of endogenous mediators for achieving maximal transactivation from this reporter gene, we modified the transfection conditions and used a reporter construct bearing a minimal promoter. A clear TIF2 and TIF2.1 stimulatory activity for RXR $\alpha$  AF2 was observed in HeLa and Cos-1 cells when using the (17m)<sub>5</sub>-TATA-CAT reporter (FIG. 12c, compare lanes 3-6 and 11-14). This stimulatory effect was less marked with RAR $\alpha$  AF-2 and could be observed reproducibly only with the TIF2.1 fragment in Cos-1 cells (FIG. 12d, compare lane 10 with lanes 13 and 14; note that TIF2.1 is expressed at >10 fold higher levels than TIF2; data not shown). The reporter plasmids (17m)<sub>5</sub>-TATA-CAT (May, M. *et al.*, *EMBO J.* 15:3093-3104 (1996)) and 17M5-G/CAT ((17m)<sub>5</sub>- $\beta$ -globin-CAT; Durand, B. *et al.*, *EMBO J.* 13:5370-5382 (1994)) each contain five copies of the GAL4 response element in front of a simple TATA motif or of the  $\beta$ -globin promoter, respectively, upstream from the CAT reporter gene.

Assuming that TIF2 or coactivators recognizing the TIF2 interacting surface on NR LBDs, generally mediate the AF-2 function of NRs, the NID containing TIF2.5 should exert its dominant negative activity not only on ER, but also on other NRs, independently of the cellular context. We therefore analyzed

the effect of TIF2.5 on the AF-2 activity of ER, RXR $\alpha$  and RAR $\alpha$  in HeLa and in Cos-1 cells (FIGS. 12b-d). In all cases, TIF2.5 expression led to a dose-dependent inhibition of the NR AF-2 activity, indicating that the endogenously present mediators were competed out by the isolated overexpressed TIF2 NID, and strongly suggesting that TIF2 or transcriptional intermediary factors recognizing the same or overlapping surfaces mediate NR AF-2 activity in these transfected cells (FIGS. 12b-d, compare lane 2 with lanes 7 and 8; lane 10 with lanes 15 and 16).

It is important to stress that our present data demonstrate that TIF2 interacts with NRs through a surface (NID) that is critical for NR AF-2 activity, as expression of TIF2.5 which encompasses the NID blocked the ligand-induced activity of all tested NR AF-2s. This observation which clearly establishes that, at least in transfected cells, TIF2 or other coactivators which interact with an overlapping, if not identical, holo-LBD surface, are essential to mediate the NR AF-2 activation function. This is in keeping with the presence of three NR box motifs in the TIF2 NID, and of at least one conserved LxxLL (SEQ ID NO:12) NR box motif in all coactivators described to date.

It will be apparent to those skilled in the art that various modifications and variations can be made in the methods of the present invention without departing from the spirit and scope of the invention. Thus, it is intended that the present invention cover all modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.

The disclosures of all patents, patent applications, and publications referred to above are hereby entirely and expressly incorporated herein by reference.

-71-

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

(i) APPLICANT: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE  
101 rue de Tolbiac  
75654 Paris Cedex 13  
France

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE  
3 rue Michel Ange  
75794 Paris Cedex 16  
France

UNIVERSITÉ LOUIS PASTEUR  
4 rue Blaise Pascal, BP 1032F  
67070 Strasbourg Cedex  
France

BRISTOL-MYERS SQUIBB COMPANY  
Route 206 & Provinceline Road  
Princeton, New Jersey 08543-4000  
United State of America

INVENTORS: Chambon, Pierre  
Gronemeyer, Hinrich  
Voegel, Johannes  
Lutz, Yves

(ii) TITLE OF INVENTION: Transcriptional Intermediary Factor-2

(iii) NUMBER OF SEQUENCES: 14

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Sterne, Kessler, Goldstein & Fox P.L.L.C.  
(B) STREET: 1100 New York Avenue, NW, Suite 600  
(C) CITY: Washington  
(D) STATE: DC  
(E) COUNTRY: USA  
(F) ZIP: 20005-3934

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: To be assigned  
(B) FILING DATE: Herewith  
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 60/021,247  
(B) FILING DATE: 12-JUL-1996

-72-

## (viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Steffe, Eric K.
- (B) REGISTRATION NUMBER: 36,688
- (C) REFERENCE/DOCKET NUMBER: 1383.013PC01/EKS

## (ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 202-371-2600
- (B) TELEFAX: 202-371-2540

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6156 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 163..4554

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGCGGCCGCA GCCTCGGCTA CAGCTTCGGC GGCGAAGGTC AGCGCCGACG GCAGCCGGCA	60
CCTGACGGCG TGACCGACCC GAGCCGATTT CTCTTGGATT TGGCTACACA CTTATAGATC	120
TTCTGCACTG TTTACAGGCA CAGTTGCTGA TATGTGTTCA AG ATG AGT GGG ATG	174
Met Ser Gly Met	
1	
GGA GAA AAT ACC TCT GAC CCC TCC AGG GCA GAG ACA AGA AAG CGC AAG	222
Gly Glu Asn Thr Ser Asp Pro Ser Arg Ala Glu Thr Arg Lys Arg Lys	
5 10 15 20	
GAA TGT CCT GAC CAA CTT GGA CCC AGC CCC AAA AGG AAC ACT GAA AAA	270
Glu Cys Pro Asp Gln Leu Gly Pro Ser Pro Lys Arg Asn Thr Glu Lys	
25 30 35	
CGT AAT CGT GAA CAG GAA AAT AAA TAT ATA GAA GAA CTT GCA GAG TTG	318
Arg Asn Arg Glu Gln Glu Asn Lys Tyr Ile Glu Glu Leu Ala Glu Leu	
40 45 50	
ATT TTT GCA AAT TTT AAT GAT ATA GAC AAC TTT AAC TTC AAA CCT GAC	366
Ile Phe Ala Asn Phe Asn Asp Ile Asp Asn Phe Asn Phe Lys Pro Asp	
55 60 65	
AAA TGT GCA ATC TTA AAA GAA ACT GTG AAG CAA ATT CGT CAG ATC AAA	414
Lys Cys Ala Ile Leu Lys Glu Thr Val Lys Gln Ile Arg Gln Ile Lys	
70 75 80	
GAA CAA GAG AAA GCA GCA GCT GCC AAC ATA GAT GAA GTG CAG AAG TCA	462

-73-

Glu	Gln	Glu	Lys	Ala	Ala	Ala	Ala	Asn	Ile	Asp	Glu	Val	Gln	Lys	Ser	
85					90					95					100	
GAT	GTA	TCC	TCT	ACA	GGG	CAG	GGT	GTC	ATC	GAC	AAG	GAT	GCG	CTG	GGG	510
Asp	Val	Ser	Ser	Thr	Gly	Gln	Gly	Val	Ile	Asp	Lys	Asp	Ala	Leu	Gly	
				105					110					115		
CCT	ATG	ATG	CTT	GAG	GCC	CTT	GAT	GGG	TTC	TTC	TTT	GTA	GTG	AAC	CTG	558
Pro	Met	Met	Leu	Glu	Ala	Leu	Asp	Gly	Phe	Phe	Phe	Val	Val	Asn	Leu	
			120					125					130			
GAA	GGC	AAC	GTT	GTG	TTT	GTG	TCA	GAG	AAT	GTG	ACA	CAG	TAT	CTA	AGG	606
Glu	Gly	Asn	Val	Val	Phe	Val	Ser	Glu	Asn	Val	Thr	Gln	Tyr	Leu	Arg	
		135						140					145			
TAT	AAC	CAA	GAA	GAG	CTG	ATG	AAC	AAA	AGT	GTA	TAT	AGC	ATC	TTG	CAT	654
Tyr	Asn	Gln	Glu	Glu	Leu	Met	Asn	Lys	Ser	Val	Tyr	Ser	Ile	Leu	His	
	150					155						160				
GTT	GGG	GAC	CAC	ACG	GAA	TTT	GTC	AAA	AAC	CTG	CTG	CCA	AAG	TCT	ATA	702
Val	Gly	Asp	His	Thr	Glu	Phe	Val	Lys	Asn	Leu	Leu	Pro	Lys	Ser	Ile	
165				170						175					180	
GTA	AAT	GGG	GGA	TCT	TGG	TCT	GGC	GAA	CCT	CCG	AGG	CGG	AAC	AGC	CAT	750
Val	Asn	Gly	Gly	Ser	Trp	Ser	Gly	Glu	Pro	Pro	Arg	Arg	Asn	Ser	His	
				185					190					195		
ACC	TTC	AAT	TGT	CGG	ATG	CTG	GTA	AAA	CCT	TTA	CCT	GAT	TCA	GAA	GAG	798
Thr	Phe	Asn	Cys	Arg	Met	Leu	Val	Lys	Pro	Leu	Pro	Asp	Ser	Glu	Glu	
			200					205					210			
GAG	GGT	CAT	GAT	AAC	CAG	GAA	GCT	CAT	CAG	AAA	TAT	GAA	ACT	ATG	CAG	846
Glu	Gly	His	Asp	Asn	Gln	Glu	Ala	His	Gln	Lys	Tyr	Glu	Thr	Met	Gln	
		215					220					225				
TGC	TTC	GCT	GTC	TCT	CAA	CCA	AAG	TCC	ATC	AAA	GAA	GAA	GGA	GAA	GAT	894
Cys	Phe	Ala	Val	Ser	Gln	Pro	Lys	Ser	Ile	Lys	Glu	Glu	Gly	Glu	Asp	
	230					235					240					
TTG	CAG	TCC	TGC	TTG	ATT	TGC	GTG	GCA	AGA	AGA	GTT	CCC	ATG	AAG	GAA	942
Leu	Gln	Ser	Cys	Leu	Ile	Cys	Val	Ala	Arg	Arg	Val	Pro	Met	Lys	Glu	
245					250					255					260	
AGA	CCA	GTT	CTT	CCC	TCA	TCA	GAA	AGT	TTT	ACT	ACT	CGC	CAG	GAT	CTC	990
Arg	Pro	Val	Leu	Pro	Ser	Ser	Glu	Ser	Phe	Thr	Thr	Arg	Gln	Asp	Leu	
				265					270					275		
CAA	GGC	AAG	ATC	ACG	TCT	CTG	GAT	ACC	AGC	ACC	ATG	AGA	GCA	GCC	ATG	1038
Gln	Gly	Lys	Ile	Thr	Ser	Leu	Asp	Thr	Ser	Thr	Met	Arg	Ala	Ala	Met	
			280					285					290			
AAA	CCA	GGC	TGG	GAG	GAC	CTG	GTA	AGA	AGG	TGT	ATT	CAG	AAG	TTC	CAT	1086
Lys	Pro	Gly	Trp	Glu	Asp	Leu	Val	Arg	Arg	Cys	Ile	Gln	Lys	Phe	His	
		295					300					305				
GCG	CAG	CAT	GAA	GGA	GAA	TCT	GTG	TCC	TAT	GCT	AAG	AGG	CAT	CAT	CAT	1134
Ala	Gln	His	Glu	Gly	Glu	Ser	Val	Ser	Tyr	Ala	Lys	Arg	His	His	His	

-74-

310	315	320	
GAA GTA CTG AGA CAA GGA TTG GCA TTC AGT CAA ATC TAT CGT TTT TCC Glu Val Leu Arg Gln Gly Leu Ala Phe Ser Gln Ile Tyr Arg Phe Ser 325 330 335 340			1182
TTG TCT GAT GGC ACT CTT GTT GCT GCA CAA ACG AAG AGC AAA CTC ATC Leu Ser Asp Gly Thr Leu Val Ala Ala Gln Thr Lys Ser Lys Leu Ile 345 350 355			1230
CGT TCT CAG ACT ACT AAT GAA CCT CAA CTT GTA ATA TCT TTA CAT ATG Arg Ser Gln Thr Asn Glu Pro Gln Leu Val Ile Ser Leu His Met 360 365 370			1278
CTT CAC AGA GAG CAG AAT GTG TGT GTG ATG AAT CCG GAT CTG ACT GGA Leu His Arg Glu Gln Asn Val Cys Val Met Asn Pro Asp Leu Thr Gly 375 380 385			1326
CAA ACG ATG GGG AAG CCA CTG AAT CCA ATT AGC TCT AAC AGC CCT GCC Gln Thr Met Gly Lys Pro Leu Asn Pro Ile Ser Ser Asn Ser Pro Ala 390 395 400			1374
CAT CAG GCC CTG TGC AGT GGG AAC CCA GGT CAG GAC ATG ACC CTC AGT His Gln Ala Leu Cys Ser Gly Asn Pro Gly Gln Asp Met Thr Leu Ser 405 410 415 420			1422
AGC AAT ATA AAT TTT CCC ATA AAT GGC CCA AAG GAA CAA ATG GGC ATG Ser Asn Ile Asn Phe Pro Ile Asn Gly Pro Lys Glu Gln Met Gly Met 425 430 435			1470
CCC ATG GGC AGG TTT GGT GGT TCT GGG GGA ATG AAC CAT GTG TCA GGC Pro Met Gly Arg Phe Gly Gly Ser Gly Gly Met Asn His Val Ser Gly 440 445 450			1518
ATG CAA GCA ACC ACT CCT CAG GGT AGT AAC TAT GCA CTC AAA ATG AAC Met Gln Ala Thr Thr Pro Gln Gly Ser Asn Tyr Ala Leu Lys Met Asn 455 460 465			1566
AGC CCC TCA CAA AGC AGC CCT GGC ATG AAT CCA GGA CAG CCC ACC TCC Ser Pro Ser Gln Ser Ser Pro Gly Met Asn Pro Gly Gln Pro Thr Ser 470 475 480			1614
ATG CTT TCA CCA AGG CAT CGC ATG AGC CCT GGA GTG GCT GGC AGC CCT Met Leu Ser Pro Arg His Arg Met Ser Pro Gly Val Ala Gly Ser Pro 485 490 495 500			1662
CGA ATC CCA CCC AGT CAG TTT TCC CCT GCA GGA AGC TTG CAT TCC CCT Arg Ile Pro Pro Ser Gln Phe Ser Pro Ala Gly Ser Leu His Ser Pro 505 510 515			1710
GTG GGA GTT TGC AGC AGC ACA GGA AAT AGC CAT AGT TAT ACC AAC AGC Val Gly Val Cys Ser Ser Thr Gly Asn Ser His Ser Tyr Thr Asn Ser 520 525 530			1758
TCC CTC AAT GCA CTT CAG GCC CTC AGC GAG GGG CAC GGG GTC TCA TTA Ser Leu Asn Ala Leu Gln Ala Leu Ser Glu Gly His Gly Val Ser Leu 535 540 545			1806

-75-

GGG TCA TCG TTG GCT TCA CCA GAC CTA AAA ATG GGC AAT TTG CAA AAC	1854
Gly Ser Ser Leu Ala Ser Pro Asp Leu Lys Met Gly Asn Leu Gln Asn	
550 555 560	
TCC CCA GTT AAT ATG AAT CCT CCC CCA CTC AGC AAG ATG GGA AGC TTG	1902
Ser Pro Val Asn Met Asn Pro Pro Pro Leu Ser Lys Met Gly Ser Leu	
565 570 575 580	
GAC TCA AAA GAC TGT TTT GGA CTA TAT GGG GAG CCC TCT GAA GGT ACA	1950
Asp Ser Lys Asp Cys Phe Gly Leu Tyr Gly Glu Pro Ser Glu Gly Thr	
585 590 595	
ACT GGA CAA GCA GAG AGC AGC TGC CAT CCT GGA GAG CAA AAG GAA ACA	1998
Thr Gly Gln Ala Glu Ser Ser Cys His Pro Gly Glu Gln Lys Glu Thr	
600 605 610	
AAT GAC CCC AAC CTG CCC CCG GCC GTG AGC AGT GAG AGA GCT GAC GGG	2046
Asn Asp Pro Asn Leu Pro Pro Ala Val Ser Ser Glu Arg Ala Asp Gly	
615 620 625	
CAG AGC AGA CTG CAT GAC AGC AAA GGG CAG ACC AAA CTC CTG CAG CTG	2094
Gln Ser Arg Leu His Asp Ser Lys Gly Gln Thr Lys Leu Leu Gln Leu	
630 635 640	
CTG ACC ACC AAA TCT GAT CAG ATG GAG CCC TCG CCC TTA GCC AGC TCT	2142
Leu Thr Thr Lys Ser Asp Gln Met Glu Pro Ser Pro Leu Ala Ser Ser	
645 650 655 660	
TTG TCG GAT ACA AAC AAA GAC TCC ACA GGT AGC TTG CCT GGT TCT GGG	2190
Leu Ser Asp Thr Asn Lys Asp Ser Thr Gly Ser Leu Pro Gly Ser Gly	
665 670 675	
TCT ACA CAT GGA ACC TCG CTC AAG GAG AAG CAT AAA ATT TTG CAC AGA	2238
Ser Thr His Gly Thr Ser Leu Lys Glu Lys His Lys Ile Leu His Arg	
680 685 690	
CTC TTG CAG GAC AGC AGT TCC CCT GTG GAC TTG GCC AAG TTA ACA GCA	2286
Leu Leu Gln Asp Ser Ser Ser Pro Val Asp Leu Ala Lys Leu Thr Ala	
695 700 705	
GAA GCC ACA GGC AAA GAC CTG AGC CAG GAG TCC AGC AGC ACA GCT CCT	2334
Glu Ala Thr Gly Lys Asp Leu Ser Gln Glu Ser Ser Ser Thr Ala Pro	
710 715 720	
GGA TCA GAA GTG ACT ATT AAA CAA GAG CCG GTG AGC CCC AAG AAG AAA	2382
Gly Ser Glu Val Thr Ile Lys Gln Glu Pro Val Ser Pro Lys Lys Lys	
725 730 735 740	
GAG AAT GCA CTA CTT CGC TAT TTG CTA GAT AAA GAT GAT ACT AAA GAT	2430
Glu Asn Ala Leu Leu Arg Tyr Leu Leu Asp Lys Asp Asp Thr Lys Asp	
745 750 755	
ATT GGT TTA CCA GAA ATA ACC CCC AAA CTT GAG AGA CTG GAC AGT AAG	2478
Ile Gly Leu Pro Glu Ile Thr Pro Lys Leu Glu Arg Leu Asp Ser Lys	
760 765 770	
ACA GAT CCT GCC AGT AAC ACA AAA TTA ATA GCA ATG AAA ACT GAG AAG	2526

-76-

Thr	Asp	Pro	Ala	Ser	Asn	Thr	Lys	Leu	Ile	Ala	Met	Lys	Thr	Glu	Lys	
		775					780					785				
GAG	GAG	ATG	AGC	TTT	GAG	CCT	GGT	GAC	CAG	CCT	GGC	AGT	GAG	CTG	GAC	2574
Glu	Glu	Met	Ser	Phe	Glu	Pro	Gly	Asp	Gln	Pro	Gly	Ser	Glu	Leu	Asp	
		790				795					800					
AAC	TTG	GAG	GAG	ATT	TTG	GAT	GAT	TTG	CAG	AAT	AGT	CAA	TTA	CCA	CAG	2622
Asn	Leu	Glu	Glu	Ile	Leu	Asp	Asp	Leu	Gln	Asn	Ser	Gln	Leu	Pro	Gln	
805					810					815					820	
CTT	TTC	CCA	GAC	ACG	AGG	CCA	GGC	GCC	CCT	GCT	GGA	TCA	GTT	GAC	AAG	2670
Leu	Phe	Pro	Asp	Thr	Arg	Pro	Gly	Ala	Pro	Ala	Gly	Ser	Val	Asp	Lys	
				825					830					835		
CAA	GCC	ATC	ATC	AAT	GAC	CTC	ATG	CAA	CTC	ACA	GCT	GAA	AAC	AGC	CCT	2718
Gln	Ala	Ile	Ile	Asn	Asp	Leu	Met	Gln	Leu	Thr	Ala	Glu	Asn	Ser	Pro	
			840					845					850			
GTC	ACA	CCT	GTT	GGA	GCC	CAG	AAA	ACA	GCA	CTG	CGA	ATT	TCA	CAG	AGC	2766
Val	Thr	Pro	Val	Gly	Ala	Gln	Lys	Thr	Ala	Leu	Arg	Ile	Ser	Gln	Ser	
		855					860					865				
ACT	TTT	AAT	AAC	CCA	CGA	CCA	GGG	CAA	CTG	GGC	AGG	TTA	TTG	CCA	AAC	2814
Thr	Phe	Asn	Asn	Pro	Arg	Pro	Gly	Gln	Leu	Gly	Arg	Leu	Leu	Pro	Asn	
		870				875					880					
CAG	AAT	TTA	CCA	CTT	GAC	ATC	ACA	TTG	CAA	AGC	CCA	ACT	GGT	GCT	GGA	2862
Gln	Asn	Leu	Pro	Leu	Asp	Ile	Thr	Leu	Gln	Ser	Pro	Thr	Gly	Ala	Gly	
885					890					895					900	
CCT	TTC	CCA	CCA	ATC	AGA	AAC	AGT	AGT	CCC	TAC	TCA	GTG	ATA	CCT	CAG	2910
Pro	Phe	Pro	Pro	Ile	Arg	Asn	Ser	Ser	Pro	Tyr	Ser	Val	Ile	Pro	Gln	
				905					910					915		
CCA	GGA	ATG	ATG	GGT	AAT	CAA	GGG	ATG	ATA	GGA	AAC	CAA	GGA	AAT	TTA	2958
Pro	Gly	Met	Met	Gly	Asn	Gln	Gly	Met	Ile	Gly	Asn	Gln	Gly	Asn	Leu	
			920					925					930			
GGG	AAC	AGT	AGC	ACA	GGA	ATG	ATT	GGT	AAC	AGT	GCT	TCT	CGG	CCT	ACT	3006
Gly	Asn	Ser	Ser	Thr	Gly	Met	Ile	Gly	Asn	Ser	Ala	Ser	Arg	Pro	Thr	
		935					940					945				
ATG	CCA	TCT	GGA	GAA	TGG	GCA	CCG	CAG	AGT	TCG	GCT	GTG	AGA	GTC	ACC	3054
Met	Pro	Ser	Gly	Glu	Trp	Ala	Pro	Gln	Ser	Ser	Ala	Val	Arg	Val	Thr	
		950				955					960					
TGT	GCT	GCT	ACC	ACC	AGT	GCC	ATG	AAC	CGG	CCA	GTC	CAA	GGA	GGT	ATG	3102
Cys	Ala	Ala	Thr	Thr	Ser	Ala	Met	Asn	Arg	Pro	Val	Gln	Gly	Gly	Met	
965					970				975						980	
ATT	CGG	AAC	CCA	GCA	GCC	AGC	ATC	CCC	ATG	AGG	CCC	AGC	AGC	CAG	CCT	3150
Ile	Arg	Asn	Pro	Ala	Ala	Ser	Ile	Pro	Met	Arg	Pro	Ser	Ser	Gln	Pro	
				985					990					995		
GGC	CAA	AGA	CAG	ACG	CTT	CAG	TCT	CAG	GTC	ATG	AAT	ATA	GGG	CCA	TCT	3198
Gly	Gln	Arg	Gln	Thr	Leu	Gln	Ser	Gln	Val	Met	Asn	Ile	Gly	Pro	Ser	

-77-

1000	1005	1010	
GAA TTA GAG ATG AAC ATG GGG GGA CCT CAG TAT AGC CAA CAA CAA GCT Glu Leu Glu Met Asn Met Gly Gly Pro Gln Tyr Ser Gln Gln Gln Ala 1015 1020 1025			3246
CCT CCA AAT CAG ACT GCC CCA TGG CCT GAA AGC ATC CTG CCT ATA GAC Pro Pro Asn Gln Thr Ala Pro Trp Pro Glu Ser Ile Leu Pro Ile Asp 1030 1035 1040			3294
CAG GCG TCT TTT GCC AGC CAA AAC AGG CAG CCA TTT GGC AGT TCT CCA Gln Ala Ser Phe Ala Ser Gln Asn Arg Gln Pro Phe Gly Ser Ser Pro 1045 1050 1055 1060			3342
GAT GAC TTG CTA TGT CCA CAT CCT GCA GCT GAG TCT CCG AGT GAT GAG Asp Asp Leu Leu Cys Pro His Pro Ala Ala Glu Ser Pro Ser Asp Glu 1065 1070 1075			3390
GGA GCT CTC CTG GAC CAG CTG TAT CTG GCC TTG CGG AAT TTT GAT GGC Gly Ala Leu Leu Asp Gln Leu Tyr Leu Ala Leu Arg Asn Phe Asp Gly 1080 1085 1090			3438
CTG GAG GAG ATT GAT AGA GCC TTA GGA ATA CCC GAA CTG GTC AGC CAG Leu Glu Glu Ile Asp Arg Ala Leu Gly Ile Pro Glu Leu Val Ser Gln 1095 1100 1105			3486
AGC CAA GCA GTA GAT CCA GAA CAG TTC TCA AGT CAG GAT TCC AAC ATC Ser Gln Ala Val Asp Pro Glu Gln Phe Ser Ser Gln Asp Ser Asn Ile 1110 1115 1120			3534
ATG CTG GAG CAG AAG GCG CCC GTT TTC CCA CAG CAG TAT GCA TCT CAG Met Leu Glu Gln Lys Ala Pro Val Phe Pro Gln Gln Tyr Ala Ser Gln 1125 1130 1135 1140			3582
GCA CAA ATG GCC CAG GGT AGC TAT TCT CCC ATG CAA GAT CCA AAC TTT Ala Gln Met Ala Gln Gly Ser Tyr Ser Pro Met Gln Asp Pro Asn Phe 1145 1150 1155			3630
CAC ACC ATG GGA CAG CGG CCT AGT TAT GCC ACA CTC CGT ATG CAG CCC His Thr Met Gly Gln Arg Pro Ser Tyr Ala Thr Leu Arg Met Gln Pro 1160 1165 1170			3678
AGA CCG GGC CTC AGG CCC ACG GGC CTA GTG CAG AAC CAG CCA AAT CAA Arg Pro Gly Leu Arg Pro Thr Gly Leu Val Gln Asn Gln Pro Asn Gln 1175 1180 1185			3726
CTA AGA CTT CAA CTT CAG CAT CGC CTC CAA GCA CAG CAG AAT CGC CAG Leu Arg Leu Gln Leu Gln His Arg Leu Gln Ala Gln Gln Asn Arg Gln 1190 1195 1200			3774
CCA CTT ATG AAT CAA ATC AGC AAT GTT TCC AAT GTG AAC TTG ACT CTG Pro Leu Met Asn Gln Ile Ser Asn Val Ser Asn Val Asn Leu Thr Leu 1205 1210 1215 1220			3822
AGG CCT GGA GTA CCA ACA CAG GCA CCT ATT AAT GCA CAG ATG CTG GCC Arg Pro Gly Val Pro Thr Gln Ala Pro Ile Asn Ala Gln Met Leu Ala 1225 1230 1235			3870

-78-

CAG AGA CAG AGG GAA ATC CTG AAC CAG CAT CTT CGA CAG AGA CAA ATG Gln Arg Gln Arg Glu Ile Leu Asn Gln His Leu Arg Gln Arg Gln Met 1240 1245 1250	3918
CAT CAG CAA CAG CAA GTT CAG CAA CGA ACT TTG ATG ATG AGA GGA CAA His Gln Gln Gln Val Gln Gln Arg Thr Leu Met Met Arg Gly Gln 1255 1260 1265	3966
GGG TTG AAT ATG ACA CCA AGC ATG GTG GCT CCT AGT GGT ATG CCA GCA Gly Leu Asn Met Thr Pro Ser Met Val Ala Pro Ser Gly Met Pro Ala 1270 1275 1280	4014
ACT ATG AGC AAC CCT CGG ATT CCC CAG GCA AAT GCA CAG CAG TTT CCA Thr Met Ser Asn Pro Arg Ile Pro Gln Ala Asn Ala Gln Gln Phe Pro 1285 1290 1295 1300	4062
TTT CCT CCA AAC TAC GGA ATA AGT CAG CAA CCT GAT CCA GGC TTT ACT Phe Pro Pro Asn Tyr Gly Ile Ser Gln Gln Pro Asp Pro Gly Phe Thr 1305 1310 1315	4110
GGG GCT ACG ACT CCC CAG AGC CCA CTT ATG TCA CCC CGA ATG GCA CAT Gly Ala Thr Thr Pro Gln Ser Pro Leu Met Ser Pro Arg Met Ala His 1320 1325 1330	4158
ACA CAG AGT CCC ATG ATG CAA CAG TCT CAG GCC AAC CCA GCC TAT CAG Thr Gln Ser Pro Met Met Gln Gln Ser Gln Ala Asn Pro Ala Tyr Gln 1335 1340 1345	4206
GCC CCC TCC GAC ATA AAT GGA TGG GCG CAG GGG AAC ATG GGC GGA AAC Ala Pro Ser Asp Ile Asn Gly Trp Ala Gln Gly Asn Met Gly Gly Asn 1350 1355 1360	4254
AGC ATG TTT TCC CAG CAG TCC CCA CCA CAC TTT GGG CAG CAA GCA AAC Ser Met Phe Ser Gln Gln Ser Pro Pro His Phe Gly Gln Gln Ala Asn 1365 1370 1375 1380	4302
ACC AGC ATG TAC AGT AAC AAC ATG AAC ATC AAT GTG TCC ATG GCG ACC Thr Ser Met Tyr Ser Asn Asn Met Asn Ile Asn Val Ser Met Ala Thr 1385 1390 1395	4350
AAC ACA GGT GGC ATG AGC AGC ATG AAC CAG ATG ACA GGA CAG ATC AGC Asn Thr Gly Gly Met Ser Ser Met Asn Gln Met Thr Gly Gln Ile Ser 1400 1405 1410	4398
ATG ACC TCA GTG ACC TCC GTG TCT ACG TCA GGG CTG TCC TCC ATG GGT Met Thr Ser Val Thr Ser Val Ser Thr Ser Gly Leu Ser Ser Met Gly 1415 1420 1425	4446
CCC GAG CAG GTT AAT GAT CCT GCT CTG AGG GGA GGC AAC CTG TTC CCA Pro Glu Gln Val Asn Asp Pro Ala Leu Arg Gly Gly Asn Leu Phe Pro 1430 1435 1440	4494
AAC CAG CTG CCT GGA ATG GAT ATG ATT AAG CAG GAG GGA GAC ACA ACA Asn Gln Leu Pro Gly Met Asp Met Ile Lys Gln Glu Gly Asp Thr Thr 1445 1450 1455 1460	4542
CGG AAA TAT TGC TGACACTGCT GAAGCCAGTT GCTTCTTCAG CTGACCGGGC	4594

-79-

Arg Lys Tyr Cys

TCACCTTGCTC AAAACACTTC CAGTCTGGAG AGCTGTGTCT ATTTGTTTCA ACCCAACTGA	4654
CCTGCCAGCC GGTTCCTGCTA GAGCAGACAG GCCTGGCCCT GGTTCCTCAGG GTGGCGTCCA	4714
CTCGGCTGTG GCAGGAGGAG CTGCCTCTTC TCTTGACAGT CTGAAGCTCG CATCCAGACA	4774
GTCGCTCAGT CTGTTCCCTG CATTACCTT AGTGCAACTT AGATCTCTCC TCCCCAAGTA	4834
AATGTTGACA GGCCAATTTC ATACCCATGT CAGATTGAAT GTATTTAAAT GTATGTATTT	4894
AAGGAGAACC ATGCTCTTGT TCTGTTCCCTG TTCGGTTCCA GACACTGGTT TCTTGCTTTG	4954
TTTTCCCTGG CTAACAGTCT AGTGCCAAAG ATTAAGATTT TATCTGGGGG AAAGAAAAGA	5014
ATTTTTTAAA AAATTAAACT AAAGATGTTT TAAGCTAAAG CCTGAATTTG GGATGGAAGC	5074
AGGACAGACA CCGTGGACAG CGCTGTATTT ACAGACACAC CCAGTGCCTG AAGACCAACA	5134
AAGTCACAGT CGTATCTCTA GAAAGCTCTA AAGACCATGT TGGAAAGAGT CTCCAGTTAC	5194
TGAACAGATG AAAAGGAGCC TGTGAGAGGG CTGTTAACAT TAGCAAATAT TTTTTCCTTG	5254
TTTTTCTTT GTTAAAACCA AACTGGTTCA CCTGAATCAT GAATTGAGAA GAAATAATTT	5314
TCATTTCTAA ATTAAGTCCC TTTTAGTTTG ATCAGACAGC TTGAATCAGC ATCTCTTCTT	5374
CCCTGTCAGC CTGACTCTTC CTTTCCCCTC TCTCATTCCC CATACTCCCT ATTTTCATTC	5434
CTTTTTTAAA AAATAATATA AGCTACAGAA ACCAGGTAAG CCCTTTATTT CCTTAAATGT	5494
TTTGCCAGCC ACTTACCAAT TGCTAAGTAT TGAATTTTCA AAAAAAAAAA TGCATTTACT	5554
GGCAAGGAGA AGAGCAAAGT TAAGGCTTGA TACCAATCGA GCTAAGGATA CCTGCTTTGG	5614
AAGCATGTTT ATTCTGTTCC CCAGCAACTC TGGCCTCCAA AATGGGAGAA ACGCCAGTGT	5674
GTTTAAATTG ATAGCAGATA TCACGACAGA TTAACTCTT GCCATGTGTT TTTTATTTTG	5734
TTTTTTAGCA GTGCTGACTA AGCCGAAGTT TTGTAAGGTA CATAAAATCC AATTTATATG	5794
TAAACAAGCA ATAATTTAAG TTGAGAACTT ATGTGTTTTA ATTGTATAAT TTTTGTGAGG	5854
TATACATATT GTGGAATTGA CTCAAAAATG AGGTACTTCA GTATTAAATT AGATATCTTC	5914
ATAGCAATGT CTCCTAAAGG TGTTTTGTAA AGGATATCAA TGCCTTGATT AGACCTAATT	5974
TGTAGACTTA AGACTTTTTA TTTTCTAAAC CTTGTGATTC TGCTTATAAG TCATTTATCT	6034
AATCTATATG ATATGCAGCC GCTGTAGGAA CCAATTCCTG ATTTTTATAT GTTTATATTC	6094
TTTCTTAATG AACCTTAGAA AGACTACATG TTAATAAGCA GGCCACTTTT ATGGTTGTTT	6154
TT	6156

-80-

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1464 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Ser Gly Met Gly Glu Asn Thr Ser Asp Pro Ser Arg Ala Glu Thr
 1             5             10             15
Arg Lys Arg Lys Glu Cys Pro Asp Gln Leu Gly Pro Ser Pro Lys Arg
      20             25             30
Asn Thr Glu Lys Arg Asn Arg Glu Gln Glu Asn Lys Tyr Ile Glu Glu
      35             40             45
Leu Ala Glu Leu Ile Phe Ala Asn Phe Asn Asp Ile Asp Asn Phe Asn
      50             55             60
Phe Lys Pro Asp Lys Cys Ala Ile Leu Lys Glu Thr Val Lys Gln Ile
      65             70             75             80
Arg Gln Ile Lys Glu Gln Glu Lys Ala Ala Ala Asn Ile Asp Glu
      85             90             95
Val Gln Lys Ser Asp Val Ser Ser Thr Gly Gln Gly Val Ile Asp Lys
      100            105            110
Asp Ala Leu Gly Pro Met Met Leu Glu Ala Leu Asp Gly Phe Phe Phe
      115            120            125
Val Val Asn Leu Glu Gly Asn Val Val Phe Val Ser Glu Asn Val Thr
      130            135            140
Gln Tyr Leu Arg Tyr Asn Gln Glu Glu Leu Met Asn Lys Ser Val Tyr
      145            150            155            160
Ser Ile Leu His Val Gly Asp His Thr Glu Phe Val Lys Asn Leu Leu
      165            170            175
Pro Lys Ser Ile Val Asn Gly Gly Ser Trp Ser Gly Glu Pro Pro Arg
      180            185            190
Arg Asn Ser His Thr Phe Asn Cys Arg Met Leu Val Lys Pro Leu Pro
      195            200            205
Asp Ser Glu Glu Glu Gly His Asp Asn Gln Glu Ala His Gln Lys Tyr
      210            215            220
Glu Thr Met Gln Cys Phe Ala Val Ser Gln Pro Lys Ser Ile Lys Glu
      225            230            235            240
Glu Gly Glu Asp Leu Gln Ser Cys Leu Ile Cys Val Ala Arg Arg Val

```

245

255

Gly Val Ser Leu Gly Ser Ser Leu Ala Ser Pro Asp Leu Lys Met Gly

545                      550                      555                      560

Asn Leu Gln Asn Ser Pro Val Asn Met Asn Pro Pro Pro Leu Ser Lys  
565                      570                      575

Met Gly Ser Leu Asp Ser Lys Asp Cys Phe Gly Leu Tyr Gly Glu Pro  
580                      585                      590

Ser Glu Gly Thr Thr Gly Gln Ala Glu Ser Ser Cys His Pro Gly Glu  
595                      600                      605

Gln Lys Glu Thr Asn Asp Pro Asn Leu Pro Pro Ala Val Ser Ser Glu  
610                      615                      620

Arg Ala Asp Gly Gln Ser Arg Leu His Asp Ser Lys Gly Gln Thr Lys  
625                      630                      635                      640

Leu Leu Gln Leu Leu Thr Thr Lys Ser Asp Gln Met Glu Pro Ser Pro  
645                      650                      655

Leu Ala Ser Ser Leu Ser Asp Thr Asn Lys Asp Ser Thr Gly Ser Leu  
660                      665                      670

Pro Gly Ser Gly Ser Thr His Gly Thr Ser Leu Lys Glu Lys His Lys  
675                      680                      685

Ile Leu His Arg Leu Leu Gln Asp Ser Ser Ser Pro Val Asp Leu Ala  
690                      695                      700

Lys Leu Thr Ala Glu Ala Thr Gly Lys Asp Leu Ser Gln Glu Ser Ser  
705                      710                      715                      720

Ser Thr Ala Pro Gly Ser Glu Val Thr Ile Lys Gln Glu Pro Val Ser  
725                      730                      735

Pro Lys Lys Lys Glu Asn Ala Leu Leu Arg Tyr Leu Leu Asp Lys Asp  
740                      745                      750

Asp Thr Lys Asp Ile Gly Leu Pro Glu Ile Thr Pro Lys Leu Glu Arg  
755                      760                      765

Leu Asp Ser Lys Thr Asp Pro Ala Ser Asn Thr Lys Leu Ile Ala Met  
770                      775                      780

Lys Thr Glu Lys Glu Glu Met Ser Phe Glu Pro Gly Asp Gln Pro Gly  
785                      790                      795                      800

Ser Glu Leu Asp Asn Leu Glu Glu Ile Leu Asp Asp Leu Gln Asn Ser  
805                      810                      815

Gln Leu Pro Gln Leu Phe Pro Asp Thr Arg Pro Gly Ala Pro Ala Gly  
820                      825                      830

Ser Val Asp Lys Gln Ala Ile Ile Asn Asp Leu Met Gln Leu Thr Ala  
835                      840                      845

Glu Asn Ser Pro Val Thr Pro Val Gly Ala Gln Lys Thr Ala Leu Arg

-83-

850	855	860
Ile Ser Gln Ser Thr Phe Asn Asn Pro Arg Pro Gly Gln Leu Gly Arg		
865	870	875 880
Leu Leu Pro Asn Gln Asn Leu Pro Leu Asp Ile Thr Leu Gln Ser Pro		
	885	890 895
Thr Gly Ala Gly Pro Phe Pro Pro Ile Arg Asn Ser Ser Pro Tyr Ser		
	900	905 910
Val Ile Pro Gln Pro Gly Met Met Gly Asn Gln Gly Met Ile Gly Asn		
	915	920 925
Gln Gly Asn Leu Gly Asn Ser Ser Thr Gly Met Ile Gly Asn Ser Ala		
	930	935 940
Ser Arg Pro Thr Met Pro Ser Gly Glu Trp Ala Pro Gln Ser Ser Ala		
	945	950 955 960
Val Arg Val Thr Cys Ala Ala Thr Thr Ser Ala Met Asn Arg Pro Val		
	965	970 975
Gln Gly Gly Met Ile Arg Asn Pro Ala Ala Ser Ile Pro Met Arg Pro		
	980	985 990
Ser Ser Gln Pro Gly Gln Arg Gln Thr Leu Gln Ser Gln Val Met Asn		
	995	1000 1005
Ile Gly Pro Ser Glu Leu Glu Met Asn Met Gly Gly Pro Gln Tyr Ser		
	1010	1015 1020
Gln Gln Gln Ala Pro Pro Asn Gln Thr Ala Pro Trp Pro Glu Ser Ile		
	1025	1030 1035 1040
Leu Pro Ile Asp Gln Ala Ser Phe Ala Ser Gln Asn Arg Gln Pro Phe		
	1045	1050 1055
Gly Ser Ser Pro Asp Asp Leu Leu Cys Pro His Pro Ala Ala Glu Ser		
	1060	1065 1070
Pro Ser Asp Glu Gly Ala Leu Leu Asp Gln Leu Tyr Leu Ala Leu Arg		
	1075	1080 1085
Asn Phe Asp Gly Leu Glu Glu Ile Asp Arg Ala Leu Gly Ile Pro Glu		
	1090	1095 1100
Leu Val Ser Gln Ser Gln Ala Val Asp Pro Glu Gln Phe Ser Ser Gln		
	1105	1110 1115 1120
Asp Ser Asn Ile Met Leu Glu Gln Lys Ala Pro Val Phe Pro Gln Gln		
	1125	1130 1135
Tyr Ala Ser Gln Ala Gln Met Ala Gln Gly Ser Tyr Ser Pro Met Gln		
	1140	1145 1150
Asp Pro Asn Phe His Thr Met Gly Gln Arg Pro Ser Tyr Ala Thr Leu		

-84-

1155	1160	1165
Arg Met Gln Pro Arg Pro Gly Leu Arg Pro Thr Gly Leu Val Gln Asn		
1170	1175	1180
Gln Pro Asn Gln Leu Arg Leu Gln Leu Gln His Arg Leu Gln Ala Gln		
1185	1190	1195 1200
Gln Asn Arg Gln Pro Leu Met Asn Gln Ile Ser Asn Val Ser Asn Val		
	1205 1210	1215
Asn Leu Thr Leu Arg Pro Gly Val Pro Thr Gln Ala Pro Ile Asn Ala		
	1220 1225	1230
Gln Met Leu Ala Gln Arg Gln Arg Glu Ile Leu Asn Gln His Leu Arg		
	1235 1240	1245
Gln Arg Gln Met His Gln Gln Gln Gln Val Gln Gln Arg Thr Leu Met		
	1250 1255	1260
Met Arg Gly Gln Gly Leu Asn Met Thr Pro Ser Met Val Ala Pro Ser		
	1265 1270	1275 1280
Gly Met Pro Ala Thr Met Ser Asn Pro Arg Ile Pro Gln Ala Asn Ala		
	1285 1290	1295
Gln Gln Phe Pro Phe Pro Pro Asn Tyr Gly Ile Ser Gln Gln Pro Asp		
	1300 1305	1310
Pro Gly Phe Thr Gly Ala Thr Thr Pro Gln Ser Pro Leu Met Ser Pro		
	1315 1320	1325
Arg Met Ala His Thr Gln Ser Pro Met Met Gln Gln Ser Gln Ala Asn		
	1330 1335	1340
Pro Ala Tyr Gln Ala Pro Ser Asp Ile Asn Gly Trp Ala Gln Gly Asn		
	1345 1350	1355 1360
Met Gly Gly Asn Ser Met Phe Ser Gln Gln Ser Pro Pro His Phe Gly		
	1365 1370	1375
Gln Gln Ala Asn Thr Ser Met Tyr Ser Asn Asn Met Asn Ile Asn Val		
	1380 1385	1390
Ser Met Ala Thr Asn Thr Gly Gly Met Ser Ser Met Asn Gln Met Thr		
	1395 1400	1405
Gly Gln Ile Ser Met Thr Ser Val Thr Ser Val Ser Thr Ser Gly Leu		
	1410 1415	1420
Ser Ser Met Gly Pro Glu Gln Val Asn Asp Pro Ala Leu Arg Gly Gly		
	1425 1430	1435 1440
Asn Leu Phe Pro Asn Gln Leu Pro Gly Met Asp Met Ile Lys Gln Glu		
	1445 1450	1455
Gly Asp Thr Thr Arg Lys Tyr Cys		

-85-

1460

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1036 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: not relevant

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Ser Ile Pro Arg Val Asn Pro Ser Val Asn Pro Ser Ile Ser Pro
1           5           10           15
Ala His Gly Val Ala Arg Ser Ser Thr Leu Pro Pro Ser Asn Ser Asn
20           25           30
Met Val Ser Thr Arg Ile Asn Arg Gln Gln Ser Ser Asp Leu His Ser
35           40           45
Ser Ser His Ser Asn Ser Ser Asn Ser Gln Gly Ser Phe Gly Cys Ser
50           55           60
Pro Gly Ser Gln Ile Val Ala Asn Val Ala Leu Asn Lys Gly Gln Ala
65           70           75           80
Ser Ser Gln Ser Ser Lys Pro Ser Leu Asn Leu Asn Asn Pro Pro Met
85           90           95
Glu Gly Thr Gly Ile Ser Leu Ala Gln Phe Met Ser Pro Arg Arg Gln
100          105          110
Val Thr Ser Gly Leu Ala Thr Arg Pro Arg Met Pro Asn Asn Ser Phe
115          120          125
Pro Pro Asn Ile Ser Thr Leu Ser Ser Pro Val Gly Met Thr Ser Ser
130          135          140
Ala Cys Asn Asn Asn Asn Arg Ser Tyr Ser Asn Ile Pro Val Thr Ser
145          150          155          160
Leu Gln Gly Met Asn Glu Gly Pro Asn Asn Ser Val Gly Phe Ser Ala
165          170          175
Ser Ser Pro Val Leu Arg Gln Met Ser Ser Gln Asn Ser Pro Ser Arg
180          185          190
Leu Asn Ile Gln Pro Ala Lys Ala Glu Ser Lys Asp Asn Lys Glu Ile
195          200          205
Ala Ser Thr Leu Asn Glu Met Ile Gln Ser Asp Asn Ser Ser Ser Asp

```

-86-

210                      215                      220  
 Gly Lys Pro Leu Asp Ser Gly Leu Leu His Asn Asn Asp Arg Leu Ser  
 225                      230                      235                      240  
 Asp Gly Asp Ser Lys Tyr Ser Gln Thr Ser His Lys Leu Val Gln Leu  
                     245                      250                      255  
 Leu Thr Thr Thr Ala Glu Gln Gln Leu Arg His Ala Asp Ile Asp Thr  
                     260                      265                      270  
 Ser Cys Lys Asp Val Leu Ser Cys Thr Gly Thr Ser Asn Ser Ala Ser  
                     275                      280                      285  
 Ala Asn Ser Ser Gly Gly Ser Cys Pro Ser Ser His Ser Ser Leu Thr  
                     290                      295                      300  
 Ala Arg His Lys Ile Leu His Arg Leu Leu Gln Glu Gly Ser Pro Ser  
 305                      310                      315                      320  
 Asp Ile Thr Thr Leu Ser Val Glu Pro Asp Lys Lys Asp Ser Ala Ser  
                     325                      330                      335  
 Thr Ser Val Ser Val Thr Gly Gln Val Gln Gly Asn Ser Ser Ile Lys  
                     340                      345                      350  
 Leu Glu Leu Asp Ala Ser Lys Lys Lys Glu Ser Lys Asp His Gln Leu  
                     355                      360                      365  
 Leu Arg Tyr Leu Leu Asp Lys Asp Glu Lys Asp Leu Arg Ser Thr Pro  
 370                      375                      380  
 Asn Leu Ser Leu Asp Asp Val Lys Val Lys Val Glu Lys Lys Glu Gln  
 385                      390                      395                      400  
 Met Asp Pro Cys Asn Thr Asn Pro Thr Pro Met Thr Lys Ala Thr Pro  
                     405                      410                      415  
 Glu Glu Ile Lys Leu Glu Ala Gln Ser Gln Phe Thr Ala Asp Leu Asp  
                     420                      425                      430  
 Gln Phe Asp Gln Leu Leu Pro Thr Leu Glu Lys Ala Ala Gln Leu Pro  
                     435                      440                      445  
 Gly Leu Cys Glu Thr Asp Arg Met Asp Gly Ala Val Thr Ser Val Thr  
 450                      455                      460  
 Ile Lys Ser Glu Ile Thr Ile Lys Ser Glu Ile Leu Pro Ala Ser Leu  
 465                      470                      475                      480  
 Gln Ser Ala Thr Ala Arg Pro Thr Ser Arg Leu Asn Arg Leu Pro Glu  
                     485                      490                      495  
 Leu Glu Leu Glu Ala Ile Asp Asn Gln Phe Gly Gln Pro Gly Thr Gly  
                     500                      505                      510  
 Asp Gln Ile Pro Trp Thr Asn Asn Thr Val Thr Ala Ile Asn Gln Ser

-87-

515                                      520                                      525  
 Lys Ser Glu Asp Gln Cys Ile Ser Ser Gln Leu Asp Glu Leu Leu Cys  
     530                                      535                                      540  
 Pro Pro Thr Thr Val Glu Gly Arg Asn Asp Glu Lys Ala Leu Leu Glu  
     545                                      550                                      555                                      560  
 Gln Leu Val Ser Phe Leu Ser Gly Lys Asp Glu Thr Glu Leu Ala Glu  
                                     565                                      570                                      575  
 Leu Asp Arg Ala Leu Gly Ile Asp Lys Leu Val Gln Gly Gly Gly Leu  
                                     580                                      585                                      590  
 Asp Val Leu Ser Glu Arg Phe Pro Pro Gln Gln Ala Thr Pro Pro Leu  
                                     595                                      600                                      605  
 Ile Met Glu Glu Arg Pro Asn Leu Tyr Ser Gln Pro Tyr Ser Ser Pro  
                                     610                                      615                                      620  
 Phe Pro Thr Ala Asn Leu Pro Ser Pro Phe Gln Gly Met Val Arg Gln  
     625                                      630                                      635                                      640  
 Lys Pro Ser Leu Gly Thr Met Pro Val Gln Val Thr Pro Pro Arg Gly  
                                     645                                      650                                      655  
 Ala Phe Ser Pro Gly Met Gly Met Gln Pro Arg Gln Thr Leu Asn Arg  
                                     660                                      665                                      670  
 Pro Pro Ala Ala Pro Asn Gln Leu Arg Leu Gln Leu Gln Gln Arg Leu  
                                     675                                      680                                      685  
 Gln Gly Gln Gln Gln Leu Ile His Gln Asn Arg Gln Ala Ile Leu Asn  
     690                                      695                                      700  
 Gln Phe Ala Ala Thr Ala Pro Val Gly Ile Asn Met Arg Ser Gly Met  
     705                                      710                                      715                                      720  
 Gln Gln Gln Ile Thr Pro Gln Pro Pro Leu Asn Ala Gln Met Leu Ala  
                                     725                                      730                                      735  
 Gln Arg Gln Arg Glu Leu Tyr Ser Gln Gln His Arg Gln Arg Gln Leu  
                                     740                                      745                                      750  
 Ile Gln Gln Gln Arg Ala Met Leu Met Arg Gln Gln Ser Phe Gly Asn  
     755                                      760                                      765  
 Asn Leu Pro Pro Ser Ser Gly Leu Pro Val Gln Thr Gly Asn Pro Arg  
     770                                      775                                      780  
 Leu Pro Gln Gly Ala Pro Gln Gln Phe Pro Tyr Pro Pro Asn Tyr Gly  
     785                                      790                                      795                                      800  
 Thr Asn Pro Gly Thr Pro Pro Ala Ser Thr Ser Pro Phe Ser Gln Leu  
                                     805                                      810                                      815  
 Ala Ala Asn Pro Glu Ala Ser Leu Ala Asn Arg Asn Ser Met Val Ser

-88-

820	825	830
Arg Gly Met Thr Gly Asn Ile Gly Gly Gln Phe Gly Thr Gly Ile Asn		
835	840	845
Pro Gln Met Gln Gln Asn Val Phe Gln Tyr Pro Gly Ala Gly Met Val		
850	855	860
Pro Gln Gly Glu Ala Asn Phe Ala Pro Ser Leu Ser Pro Gly Ser Ser		
865	870	875
		880
Met Val Pro Met Pro Ile Pro Pro Pro Gln Ser Ser Leu Leu Gln Gln		
885	890	895
Thr Pro Pro Ala Ser Gly Tyr Gln Ser Pro Asp Met Lys Ala Trp Gln		
900	905	910
Gln Gly Ala Ile Gly Asn Asn Asn Val Phe Ser Gln Ala Val Gln Asn		
915	920	925
Gln Pro Thr Pro Ala Gln Pro Gly Val Tyr Asn Asn Met Ser Ile Thr		
930	935	940
Val Ser Met Ala Gly Gly Asn Thr Asn Val Gln Asn Met Asn Pro Met		
945	950	955
		960
Met Ala Gln Met Gln Met Ser Ser Leu Gln Met Pro Gly Met Asn Thr		
965	970	975
Val Cys Pro Glu Gln Ile Asn Asp Pro Ala Leu Arg His Thr Gly Leu		
980	985	990
Tyr Cys Asn Gln Leu Ser Ser Thr Asp Leu Leu Lys Thr Glu Ala Asp		
995	1000	1005
Gly Thr Gln Gln Val Gln Gln Val Gln Val Phe Ala Asp Val Gln Cys		
1010	1015	1020
Thr Val Asn Leu Val Gly Gly Asp Pro Tyr Leu Asn		
1025	1030	1035

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: not relevant

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Glu Arg Ala Asp Gly Gln Ser Arg Leu His Asp Ser Lys Gly Gln Thr

-89-

1	5	10	15
Lys	Leu	Leu	Gln Cys
	20		

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: not relevant

## (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Gly His Lys Lys Leu Leu Gln Leu Leu Thr Cys Ser Ser His Gly Ser  
1 5 10 15

Leu Leu Gln Glu Lys His Arg Ile Leu His Lys Leu Leu Gln Asn Gly  
20 25 30

Asn Asn Ala Leu Leu Arg Tyr Leu Leu Asp Arg Asp Asp Pro Ser Asp  
35 40 45

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Arg Ser Ile Leu Thr Ser Leu Leu Leu Asn Ser Ser  
1 5 10

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

-90-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Phe	Asn	Val	Leu	Lys	Gln	Leu	Leu	Leu	Ser	Glu	Asn
1				5					10		

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Ser	Ala	Thr	Leu	Arg	Ser	Leu	Leu	Leu	Asn	Pro	His
1				5					10		

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 58 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Leu	Arg	Asn	Ser	Leu	Asp	Asp	Leu	Leu	Gly	Pro	Pro	Ser	Asn	Ala	Glu
1				5					10					15	

Gly	Gln	Ser	Asp	Glu	Arg	Ala	Leu	Leu	Asp	Gln	Leu	His	Thr	Phe	Leu
			20					25					30		

Ser	Asn	Thr	Asp	Ala	Thr	Gly	Leu	Glu	Glu	Ile	Asp	Arg	Ala	Leu	Gly
		35					40					45			

Ile	Pro	Glu	Leu	Val	Asn	Gln	Gly	Gln	Ala
	50					55			

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 64 base pairs

-91-

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AGACCTGTTG AACTTTGCAA AGGCAAGGGC AGTTCCTTTG AGCTGGGCTT ATGACCTTTG 60

ACTC 64

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 38 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CGGAGGACAG TCCTCCGGCG GCCGCGGTCA CAGTGACC 38

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 5 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Leu Xaa Xaa Leu Leu  
1 5

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 6 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: not relevant

-92-

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Leu Xaa Xaa Leu Leu Leu .  
1 5

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Leu Leu Xaa Xaa Leu Xaa Xaa Xaa Leu  
1 5

*What Is Claimed Is:*

1. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:

5 (a) a polynucleotide encoding a polypeptide having an amino acid sequence as shown in Figure 1 (SEQ ID NO:2);

(b) a polynucleotide encoding a polypeptide having an amino acid sequence as encoded by the cDNA contained in ATCC Deposit No. 97612;

(c) a polynucleotide encoding a TIF2 polypeptide fragment comprising amino acids 624-869 as shown in Figure 1 (SEQ ID NO:2);

10 (d) a polynucleotide encoding a TIF2 polypeptide fragment comprising amino acids 624-1131 as shown in Figure 1 (SEQ ID NO:2);

(e) a polynucleotide encoding a TIF2 polypeptide fragment comprising amino acids 1010-1131 as shown in Figure 1 (SEQ ID NO:2);

15 (f) a polynucleotide that encodes a TIF2 polypeptide fragment comprising amino acids 1288-1464 in Figure 1 (SEQ ID NO:2);

(g) a polynucleotide having a nucleotide sequence at least 90% identical to the nucleotide sequence of any of the polynucleotides of (a)-(f);

(h) a polynucleotide that hybridizes under stringent conditions to any of the polynucleotides of (a)-(g) or the complement thereof;

20 (i) a polynucleotide fragment of any of the polynucleotides of (a)-(h), wherein said fragment is at least 15 bp in length; and

(j) a polynucleotide having a nucleotide sequence complementary to the nucleotide sequence of any of the polynucleotides of (a)-(i).

25 2. The isolated nucleic acid molecule of claim 1, wherein said polynucleotide is DNA.

-94-

3. The isolated nucleic acid molecule of claim 1, wherein said polynucleotide is RNA.

4. The isolated nucleic acid molecule of claim 1, wherein said polynucleotide encodes a cytoplasmic TIF2 polypeptide fragment.

5. The isolated nucleic acid molecule of claim 4, wherein said TIF2 polypeptide fragment is selected from the group consisting of TIF2.1, TIF2.2, TIF2.3, TIF2.4, TIF2.5, TIF2.6, TIF2.7, TIF2.8, TIF2.9, and TIF2.12.

6. A method for making a recombinant vector comprising inserting the isolated nucleic acid molecule of claim 1 into a vector.

7. A recombinant vector produced by the method of claim 6.

8. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 7 into a host cell.

9. A recombinant host cell produced by the method of claim 8.

10. A recombinant method for producing a polypeptide, comprising culturing the recombinant host cell of claim 9.

11. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide having an amino acid sequence of the TIF2 polypeptide comprising the complete amino acid sequence as shown in Figure 1 (SEQ ID NO:2);

(b) a polypeptide having an amino acid sequence comprising residues 624 to 869 as shown in Figure 1 (SEQ ID NO:2);

-95-

(c) a polypeptide having an amino acid sequence comprising residues 624-1131 as shown in Figure 1 (SEQ ID NO:2);

(d) a polypeptide having an amino acid sequence comprising residues 1010-1131 as shown in Figure 1 (SEQ ID NO:2);

5 (e) a polypeptide having an amino acid sequence comprising residues 1288-1464 as shown in Figure 1 (SEQ ID NO:2);

(f) a polypeptide which is at least 90% identical to any of the polypeptides of (a-e);

10 (g) a polypeptide having an amino acid sequence comprising residues 641-645 as shown in Figure 1 (SEQ ID NO:2);

(h) a polypeptide having an amino acid sequence comprising residues 690-694 as shown in Figure 1 (SEQ ID NO:2); and

(i) a polypeptide having an amino acid sequence comprising residues 745-749 as shown in Figure 1 (SEQ ID NO:2).

15 12. The isolated polypeptide of claim 11, wherein said polypeptide is a cytoplasmic TIF2 polypeptide fragment.

13. The isolated polypeptide of claim 12, wherein said fragment is selected from the group consisting of TIF2.1, TIF2.2, TIF2.3, TIF2.4, TIF2.5, TIF2.6, TIF2.7, TIF2.8, TIF2.9, and TIF2.12.

20 14. A screening method for identifying a nuclear receptor (NR) antagonist, which comprises:

25 (a) providing a host cell containing recombinant genes which express a polypeptide comprising a NR ligand binding domain (LBD) and a polypeptide comprising transcriptional intermediary factor-2 (TIF-2) or a TIF-2-fragment, wherein, in the presence of an agonist, said TIF-2 and said TIF-2-fragment bind said NR LBD and are capable of activating transcription;

(b) administering a candidate antagonist to said cell; and

(c) determining whether said candidate antagonist reduces either: (1) TIF-2- or TIF-2-fragment-binding to the AF-2 of said NR LBD as compared to said binding in the absence of said candidate antagonist; or (2) TIF-2- or TIF-2-fragment-stimulated NR LBD AF-2-mediated transactivation as compared to said transactivation in the absence of said candidate antagonist.

15. A screening method for identifying a nuclear receptor (NR) agonist, which comprises:

(a) providing a host cell containing recombinant genes which express a polypeptide comprising a NR ligand binding domain (LBD) and a polypeptide comprising transcriptional intermediary factor-2 (TIF-2) or a TIF-2-fragment, wherein, in the presence of an agonist, said TIF-2 and said TIF-2-fragment bind said NR LBD;

(b) administering a candidate agonist to said cell; and

(c) determining whether said candidate agonist enhances either: (1) TIF-2- or TIF-2-fragment-binding to the AF-2 of said NR LBD as compared to said binding in the absence of said candidate agonist; or (2) TIF-2- or TIF-2-fragment-stimulated NR LBD AF-2-mediated transactivation as compared to said transactivation in the absence of said candidate agonist.

16. The method of claim 14, wherein said host cell further expresses a reporter gene.

17. The method of claim 15, wherein said host cell further expresses a reporter gene.

18. The method of claim 14, wherein said host cell expresses a polypeptide comprising a NR LBD and GAL4.




19. The method of claim 15, wherein said host cell expresses a polypeptide comprising a NR LBD and GAL4.

20. An isolated antibody that binds specifically to an isolated polypeptide according to claim 11.

[illegible]

FIG. 1A

FIG. 1 B



4/21

(a)

TIF2 NLS NLS

1 MSGHGE:TSOPSAETRRKKECPDQLGSPKRNTEKRNDEQENKYIEELAEIIFANFNIDNFNFKPKCAILKETVKQIROIKEDQEKAAAAANIDEVQKS  
 101 DVSTGQGVYDKDALGPMLEALDGGFFVNVLEGNVVFVSENVQYLRNQEELANKSVYSILHVGDHTEFVQNLKPSIVNGGSGWSEPPRRNSHTFNC  
 201 RMLVKPLPDSSEEGHDNQEAKQYETMQCPAVSQPKSKEEGEDLQSLICVARRVPMKERPVLPSSSEFTTPQDLQCKITSLDTSIMRAAMKPGWEDLV  
 301 RRCIQKFHAQHEGESVSYAKRHHHEVLROGLAFSQIYRFSLSDGLTVAATKSKLIRSQTITNEPQLVISLHMLHPEQNVCMNPDLTGQTMGKPLNPIS

SRC-1 MSIPRVNPSVNPSIS... PAHGVARSSTLPPS

401 NSPAHQALCSGNGPGDMTSSNINFPINGPKQMCMPMGRFGSGGHNHVSCH... QA...  
 50 NSNMVSTRINRQSSDLHSSSHSN... SSNSQCSFGCSFGSQIVANVALNKQ...  
 497 ...  
 118 ...  
 594 ECTTQQAESSCHPGEQKETNDPNLPPAVSSERADGQSRHDSKQTKLLQLL...  
 217 QSDNSSSDGKPLDGLLHNDNR... LSDGDSKY... SQTSHKLVQLL...  
 686 ...  
 306 ...  
 776 ASNTKLIAMKTEKEEMSFEPGDPGSELDNLEEILDDLN... SOLPOLPFDTRGAPAGSVKQAIINDLMQLTAEENSPVTPVGAQKTALRISQSTFNPP...  
 404 CNTNPTMTKATPEEIKLEAQSQFTADLDQFDQLLPTLEKAAQLPGLCETDRMGAVTSVTKSEI... TIKSEILPASLQSATAR...  
 875 PGQLGRLLPNQNLPLDITLQSPGTGAGFPPIRNSPYSVIPQPGMGNQGMIGNQGNLGNSSSTGMIGNSASRPTMPSGEWAPQSSAVRVTCATTSAMNP...  
 481 ...  
 975 PVQGMIRNPAASIPMRPSSQPGQRTLQSQVMNIGPSELEMMGGPQYSQQQAPPNOTAPWPESILPIDQASFASQNRQPPGSSPDDLCPHPAAEAPS...  
 488 ...  
 1075 DEGALLDQL... YLALRNFDGLEEIDRALGIPELV... SQSQAVDPEQSSQDSN... IMLEQKAPVFPQYASQAQMAQGSYSYPMQDPNFHTMGORPSYATLR...  
 548 DEKALLEQLVSFLSGKDETELAELDRALGIDKLVQGGGLDVLSEFPQATPPLIMEERPILYSQPYSSPPTANLP... SPFG... MVRQKPSLGTHP...  
 1170 MQ... PRPGLRPTGLVQ...  
 643 VQVTPPRGAFSPGCMQPROTLNRPPA...  
 1249 ...  
 743 ...  
 1307 ... ISQQDPGFTGATTPOSPLMSPRMAHTQSPHMQSQANPAYQAPSDINGWAQGNMGCSN...  
 837 FGTGINPQMQQNVFQYFGAGNVPGGEANFAPSLSPGSSHVMPPIPPQSSLLQOTPPASGYQSP... DMKAWQGAIGQNVVFSQAVQNO... PTPAQPGVY...  
 1387 ...  
 934 NMSITVSHAGCNTNVQNMNPMMAQMQM... SSLQMPGNTVCPEQINDPALRHTGLYCNQLSSTDLLKTEADGTQVQVQVADVQCTVNLVGGDPYLN




FIG.3A-B

5/21






FIG. 4A-I

FIG. 4K



1 2 3 4 5 6 7 8


(m)



1 2 3 4 5 6 7 8 9 10


FIG. 4M

FIG. 4L



1 2 3 4 5 6 7 8 9 10

(n)



1 2 3 4 5 6 7 8 9

FIG. 4N

7/21




FIG.5A

8/21




FIG.5B

9/21





FIG. 5C



11/21




FIG.5E

12/21



**(A) REPORTERS****(B) RECEPTORS**

FIG. 6A-B




FIG. 7A

14/21





FIG. 7B - E

FIG. 8A



16/21




FIG. 8B - E



18/21






FIG. 9B - C

(A)



(B)



(C)

INPUT	GST	GST-CBP*
+	-	-
-	+	-
-	-	+
+	-	-
-	+	-
-	-	+
+	-	-
-	+	-
-	-	+
+	-	-
-	+	-
-	-	+



1	2	3	4	5	6	7	8	9	10	11	12
VP16			VP16-TIF2.13			VP16-TIF2.13(LL)			VP16-TIF2.13(DQ)		

Figure 10 A-C

20/21




Figure 11




Figure 12A-D

# PATENT COOPERATION TREATY

WO 98/02455  
PCT/US97/12100

PCT

From the INTERNATIONAL BUREAU

## NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

To:

STEFFE, Eric, K.  
Sterne, Kessler, Goldstein & Fox  
P.L.L.C.  
Suite 600  
1100 New York Avenue, N.W.  
Washington, DC 20005-3033  
ETATS-UNIS D'AMERIQUE

**RECEIVED**  
FEB - 2 1998  
STERNE, KESSLER, GOLDSTEIN & FOX PLLC  
2/4/98  
FF 7/5/98  
JA 2/5/98

Date of mailing (day/month/year) 22 January 1998 (22.01.98)		
Applicant's or agent's file reference 1383.013PC01		IMPORTANT NOTICE
International application No. PCT/US97/12100	International filing date (day/month/year) 11 July 1997 (11.07.97)	Priority date (day/month/year) 12 July 1996 (12.07.96)
Applicant INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE et al		

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:  
CA, EP, JP

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication:  
None

**DOCKETED**  
Chpt II Demand (2/12/98)  
Chpt I N.P. (3/12/98) 2-12-98

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on 22 January 1998 (22.01.98) under No. WO 98/02455

### REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

### REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. (41-22) 740.14.35	Authorized officer J. Zahra Telephone No. (41-22) 338.83.38
--	---